PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3025664-10 1986 This sequence difference resulted in an arginine being coded for in clone p53-H-1 and a proline being coded for at the equivalent position in clone p53-H-19. Arginine 40-48 tumor protein p53 Homo sapiens 74-77 2905688-4 1988 Molecular cloning and sequencing of both the alleles of p53 gene revealed a base-pair change in codon 72 causing arginine----proline substitution in the allele with the additional BglII site. Arginine 113-121 tumor protein p53 Homo sapiens 56-59 33290139-9 2020 Conclusion: The p53 rs1042522 arg allele together with tobacco smoking and alcohol drinking, was associated with an increased risk, for gastric cancer and EC, but not the survival among northwestern Chinese patients. Arginine 30-33 tumor protein p53 Homo sapiens 16-19 33653952-4 2021 We report that the p53 mutant R248Q (R, arginine; Q, glutamine) forms, both in cancer cells and in solutions, a condensate with unique properties, mesoscopic protein-rich clusters. Arginine 40-48 tumor protein p53 Homo sapiens 19-22 32144153-0 2020 Withdrawal: Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-serine-rich motif. Arginine 76-84 tumor protein p53 Homo sapiens 60-63 32727419-8 2020 CONCLUSIONS: This pilot study suggests that both the Arg/Arg and Arg/Pro genotypes of p53 codon 72 polymorphism may have value as independent prognostic or predictive parameters for bevacizumab treatment response and failure. Arginine 53-56 tumor protein p53 Homo sapiens 86-89 32711437-12 2020 Significant increased risk of lung cancer was found with Arg/Pro genotypes of TP53, Lys/Gln and Gln/Gln variants of XPD in individuals with family history of cancer (OR=3.44; 95% CI=1.36-8.72; p=0.011; OR=3.17; 95% CI=1.20-8.39; p=0.024; OR=16.35; 95% CI=0.92-289.5; p=0.007, respectively). Arginine 57-60 tumor protein p53 Homo sapiens 78-82 32424519-5 2020 The results indicate that the TP53 Arg/Pro heterozygosity (adjusted OR 2.32, 95% CI 1.28-4.34, p = 0.01), Pro/Pro mutant homozygosity (adjusted OR 4.15, 95% CI 1.75-9.86, p = 0.001), along with the combined genotype (Arg/Pro + Pro/Pro) (adjusted OR 2.83, 95% CI 1.61-4.97, p < 0.001) significantly increases the risk of cervical cancer. Arginine 35-38 tumor protein p53 Homo sapiens 30-34 32424519-5 2020 The results indicate that the TP53 Arg/Pro heterozygosity (adjusted OR 2.32, 95% CI 1.28-4.34, p = 0.01), Pro/Pro mutant homozygosity (adjusted OR 4.15, 95% CI 1.75-9.86, p = 0.001), along with the combined genotype (Arg/Pro + Pro/Pro) (adjusted OR 2.83, 95% CI 1.61-4.97, p < 0.001) significantly increases the risk of cervical cancer. Arginine 222-225 tumor protein p53 Homo sapiens 30-34 32592343-1 2020 BACKGROUND: A transversion missense polymorphism of the TP53 tumor suppressor gene at the codon 72 codes proline instead of arginine causes an altered p53 protein expression and has been found to be associated with an elevated risk of various cancer; especially breast and lung cancer. Arginine 124-132 tumor protein p53 Homo sapiens 56-60 32592343-1 2020 BACKGROUND: A transversion missense polymorphism of the TP53 tumor suppressor gene at the codon 72 codes proline instead of arginine causes an altered p53 protein expression and has been found to be associated with an elevated risk of various cancer; especially breast and lung cancer. Arginine 124-132 tumor protein p53 Homo sapiens 151-154 31088907-1 2019 We discovered that 90.3% of patients with angiomyolipomas, lymphangioleiomyomatosis (LAM), and tuberous sclerosis complex (TSC) carry the arginine variant of codon 72 (R72) of TP53 and that R72 increases the risk for angiomyolipoma. Arginine 138-146 tumor protein p53 Homo sapiens 176-180 31642121-5 2020 Using this tool, we have identified a putative domain enriched in hydrophilic and disorder-promoting residues (Pro, Ser, and Thr) and depleted in positive charges (Arg and Lys) bordering the folded DNA-binding domains of several transcription factors (p53, GCR, NAC46, MYB28, and MYB29). Arginine 164-167 tumor protein p53 Homo sapiens 252-255 31492752-5 2019 A p53 mutant with arginine substitutions of its 18 lysine residues was not ubiquitinated. Arginine 18-26 tumor protein p53 Homo sapiens 2-5 31369573-5 2019 RESULTS: The allele frequency of TP53 codon 72 in our cohort was 37, 42, and 21% for Arg/Arg, Arg/Pro, and Pro/Pro, respectively. Arginine 85-88 tumor protein p53 Homo sapiens 33-37 31369573-5 2019 RESULTS: The allele frequency of TP53 codon 72 in our cohort was 37, 42, and 21% for Arg/Arg, Arg/Pro, and Pro/Pro, respectively. Arginine 89-92 tumor protein p53 Homo sapiens 33-37 31369573-5 2019 RESULTS: The allele frequency of TP53 codon 72 in our cohort was 37, 42, and 21% for Arg/Arg, Arg/Pro, and Pro/Pro, respectively. Arginine 89-92 tumor protein p53 Homo sapiens 33-37 30865893-0 2019 p53 Promotes Cancer Cell Adaptation to Glutamine Deprivation by Upregulating Slc7a3 to Increase Arginine Uptake. Arginine 96-104 tumor protein p53 Homo sapiens 0-3 31128065-0 2019 TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population Objective: This study aimed at exploring the association of TP53 72Arg/Pro polymorphism and Risk of ChronicLymphocytic Leukemia and to assess the correlation between TP53 72Arg/Pro polymorphism and clinical parameter,hematological profile and some biological prognostic markers among Sudanese patients with chronic lymphocyticleukemia. Arginine 13-16 tumor protein p53 Homo sapiens 0-4 31128065-0 2019 TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population Objective: This study aimed at exploring the association of TP53 72Arg/Pro polymorphism and Risk of ChronicLymphocytic Leukemia and to assess the correlation between TP53 72Arg/Pro polymorphism and clinical parameter,hematological profile and some biological prognostic markers among Sudanese patients with chronic lymphocyticleukemia. Arginine 13-16 tumor protein p53 Homo sapiens 217-221 31128065-0 2019 TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population Objective: This study aimed at exploring the association of TP53 72Arg/Pro polymorphism and Risk of ChronicLymphocytic Leukemia and to assess the correlation between TP53 72Arg/Pro polymorphism and clinical parameter,hematological profile and some biological prognostic markers among Sudanese patients with chronic lymphocyticleukemia. Arginine 13-16 tumor protein p53 Homo sapiens 217-221 30651598-2 2019 Human epidemiological studies reveal that a p53 single-nucleotide polymorphism (SNP) at codon 72, encoding proline (P72) or arginine (R72), is associated with differential risk of several cancers, including BrCa. Arginine 124-132 tumor protein p53 Homo sapiens 44-47 30861422-5 2019 To antagonize intracellular MDM2/MDMX for p53 activation, we extended this protein, PMIBcr/Abl, by a C-terminal Arg-repeating hexapeptide to facilitate its cellular uptake. Arginine 112-115 tumor protein p53 Homo sapiens 42-45 30865893-6 2019 We also show that increased intracellular arginine levels following glutamine deprivation are dependent on p53. Arginine 42-50 tumor protein p53 Homo sapiens 107-110 30467244-9 2019 CONCLUSIONS: The TP53 codon 72 Arg allele and XRCC1 codon 399 Gln allele are likely to have a protective effect against lung adenocarcinoma, especially in individuals older than 50 years of age. Arginine 31-34 tumor protein p53 Homo sapiens 17-21 30655613-5 2019 The Arg variant of TP53 is more efficient at inducing apoptosis, whereas the Pro variant is a more potent inductor of cell cycle arrest and DNA repair. Arginine 4-7 tumor protein p53 Homo sapiens 19-23 30375398-7 2018 Further investigation revealed that PANDAR-reduced cisplatin sensitivity was likely or partly due to the PANDAR-binding protein SFRS2 (arginine/serine-rich 2), a splicing factor with the ability to negative regulate p53 and its phosphorylation at Serine 15 (Ser15). Arginine 135-143 tumor protein p53 Homo sapiens 216-219 30607176-8 2018 The genotypic distribution at codon 72 of TP53 in control group was 20%, 62.4% and 16.6% for Arg (wildtype), Arg/Pro (heterozygous) and Pro (homozygous variant) respectively. Arginine 93-96 tumor protein p53 Homo sapiens 42-46 30607176-8 2018 The genotypic distribution at codon 72 of TP53 in control group was 20%, 62.4% and 16.6% for Arg (wildtype), Arg/Pro (heterozygous) and Pro (homozygous variant) respectively. Arginine 109-112 tumor protein p53 Homo sapiens 42-46 30607176-10 2018 The absence of Arg at codon 72 of TP53 is relevant with age higher than 40 years and metastasis to other organs. Arginine 15-18 tumor protein p53 Homo sapiens 34-38 29482350-7 2018 Knowing that TP53 is an antioncogene protein that acts as a tumor suppressor and regulator of apoptosis, the lowest frequency of Arg/Arg genotype observed in these high-risk patients may indicate lower protection from the atherosclerosis process. Arginine 129-132 tumor protein p53 Homo sapiens 13-17 30774789-2 2018 Our research was aimed to study p53 protein codon 72 polymorphism, a single base pair change of either arginine (Arg; CGC) or proline (Pro; CCC) that creates 3 distinct genotypes in reticular oral lichen planus (OLP) in comparison to oral SCC which is the most common oral mucosal malignancy as positive control and inflammatory fibrous hyperplasia (IFH) lesion as negative control. Arginine 103-111 tumor protein p53 Homo sapiens 32-35 30774789-2 2018 Our research was aimed to study p53 protein codon 72 polymorphism, a single base pair change of either arginine (Arg; CGC) or proline (Pro; CCC) that creates 3 distinct genotypes in reticular oral lichen planus (OLP) in comparison to oral SCC which is the most common oral mucosal malignancy as positive control and inflammatory fibrous hyperplasia (IFH) lesion as negative control. Arginine 113-116 tumor protein p53 Homo sapiens 32-35 29482350-7 2018 Knowing that TP53 is an antioncogene protein that acts as a tumor suppressor and regulator of apoptosis, the lowest frequency of Arg/Arg genotype observed in these high-risk patients may indicate lower protection from the atherosclerosis process. Arginine 133-136 tumor protein p53 Homo sapiens 13-17 30065615-3 2018 Results: p53 heterozygous arginine variant was associated with decreased risk of breast cancer in total cohort. Arginine 26-34 tumor protein p53 Homo sapiens 9-12 30288482-4 2018 Objective: This study was designed to examine associations of TP53 72 Arg>Pro (rs1042522), and MDM2 309 T>G (rs937283) polymorphisms with spermatogenetic failure in Iranian population. Arginine 70-73 tumor protein p53 Homo sapiens 62-66 29261364-1 2018 BACKGROUND: The TP53 codon 72 Proline-Arginine polymorphism (TP53 P72R) is the most widely studied candidate among those evaluated for a putative association between impaired apoptosis and glaucoma. Arginine 38-46 tumor protein p53 Homo sapiens 16-20 29743236-0 2018 IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. Arginine 5-8 tumor protein p53 Homo sapiens 69-72 29261364-1 2018 BACKGROUND: The TP53 codon 72 Proline-Arginine polymorphism (TP53 P72R) is the most widely studied candidate among those evaluated for a putative association between impaired apoptosis and glaucoma. Arginine 38-46 tumor protein p53 Homo sapiens 61-65 29261364-2 2018 Considering the earlier findings about enhanced apoptotic potential by the Arg variant of TP53 P72R and the conflicting results about its association with glaucoma, we initiated a hospital-based case-control association study in a north Indian cohort to investigate the association of TP53 P72R with glaucoma. Arginine 75-78 tumor protein p53 Homo sapiens 90-94 29568320-3 2018 The enzymes responsible for arginine methylation, protein arginine methyltransferases (PRMTs), have been shown to methylate or associate with important regulatory proteins of the cell cycle and DNA damage repair pathways, such as cyclin D1, p53, p21 and the retinoblastoma protein. Arginine 28-36 tumor protein p53 Homo sapiens 241-244 28436014-3 2017 We assessed the extent to which the pharmacokinetic characteristics are a function of the staple for a peptide inhibiting the interaction of p53 with the human double minute 2 (Hdm2) protein and differ from those of the standard cationic cell-penetrating peptide nona-arginine. Arginine 268-276 tumor protein p53 Homo sapiens 141-144 29479097-9 2018 CONCLUSIONS: In Pakistani women the association of TP53 gene codon 72 arginine/proline polymorphism was present.. Arginine 70-78 tumor protein p53 Homo sapiens 51-55 29307398-6 2018 TP53 codon 72 (arginine) exhibits higher rates of apoptosis and leukemia inhibitory factor expression, whereas the C allele (proline) reduces leukemia inhibitory factor expression. Arginine 15-23 tumor protein p53 Homo sapiens 0-4 29302583-3 2017 The HPV oncoprotein E6 binds to the tumor suppressor gene product p53, promoting its degradation; the Arg allele of TP53 R72P polymorphism binds more ardently with HPV E6 than the Pro variant. Arginine 102-105 tumor protein p53 Homo sapiens 66-69 29302583-3 2017 The HPV oncoprotein E6 binds to the tumor suppressor gene product p53, promoting its degradation; the Arg allele of TP53 R72P polymorphism binds more ardently with HPV E6 than the Pro variant. Arginine 102-105 tumor protein p53 Homo sapiens 116-120 28874603-6 2017 An Arg-to-His, but not Arg-to-Lys, mutation in the transcription factor p53 (p53-R273H) decreased its transcriptional activity and attenuated the DNA damage response in fibroblasts and breast cancer cells with high pHi. Arginine 3-6 tumor protein p53 Homo sapiens 72-75 28874603-6 2017 An Arg-to-His, but not Arg-to-Lys, mutation in the transcription factor p53 (p53-R273H) decreased its transcriptional activity and attenuated the DNA damage response in fibroblasts and breast cancer cells with high pHi. Arginine 3-6 tumor protein p53 Homo sapiens 77-80 28857739-7 2017 Moreover, p53 arg/arg patients infected by an HPV16 prototype strain were associated with an increased risk of more severe lesions, while a significant relationship between the p53 arg/arg genotype in patients with T350G sequence variation and the risk of high-grade squamous intraepithelial lesions (HSILs) was revealed. Arginine 14-17 tumor protein p53 Homo sapiens 10-13 28857739-7 2017 Moreover, p53 arg/arg patients infected by an HPV16 prototype strain were associated with an increased risk of more severe lesions, while a significant relationship between the p53 arg/arg genotype in patients with T350G sequence variation and the risk of high-grade squamous intraepithelial lesions (HSILs) was revealed. Arginine 18-21 tumor protein p53 Homo sapiens 10-13 28857739-7 2017 Moreover, p53 arg/arg patients infected by an HPV16 prototype strain were associated with an increased risk of more severe lesions, while a significant relationship between the p53 arg/arg genotype in patients with T350G sequence variation and the risk of high-grade squamous intraepithelial lesions (HSILs) was revealed. Arginine 18-21 tumor protein p53 Homo sapiens 10-13 28857739-7 2017 Moreover, p53 arg/arg patients infected by an HPV16 prototype strain were associated with an increased risk of more severe lesions, while a significant relationship between the p53 arg/arg genotype in patients with T350G sequence variation and the risk of high-grade squamous intraepithelial lesions (HSILs) was revealed. Arginine 18-21 tumor protein p53 Homo sapiens 10-13 28857739-8 2017 CONCLUSION: The oncogenic potential of the virus is increased by the presence of the p53 arg/arg genotype in the Greek population in such a way that the specific protein interaction E6 (L83V)-p53 (Arg-72) can modify an individual"s susceptibility to cervical disease. Arginine 89-92 tumor protein p53 Homo sapiens 85-88 28857739-8 2017 CONCLUSION: The oncogenic potential of the virus is increased by the presence of the p53 arg/arg genotype in the Greek population in such a way that the specific protein interaction E6 (L83V)-p53 (Arg-72) can modify an individual"s susceptibility to cervical disease. Arginine 89-92 tumor protein p53 Homo sapiens 192-195 28857739-8 2017 CONCLUSION: The oncogenic potential of the virus is increased by the presence of the p53 arg/arg genotype in the Greek population in such a way that the specific protein interaction E6 (L83V)-p53 (Arg-72) can modify an individual"s susceptibility to cervical disease. Arginine 93-96 tumor protein p53 Homo sapiens 85-88 29557783-3 2018 In humans, single nucleotide polymorphism (SNP) with either arginine (R72) or proline (P72) at codon 72 influences p53 activity; the P72 allele has a weaker p53 activity and function in tumor suppression. Arginine 60-68 tumor protein p53 Homo sapiens 115-118 29557783-3 2018 In humans, single nucleotide polymorphism (SNP) with either arginine (R72) or proline (P72) at codon 72 influences p53 activity; the P72 allele has a weaker p53 activity and function in tumor suppression. Arginine 60-68 tumor protein p53 Homo sapiens 157-160 29951436-0 2017 Association of p53 codon 72 Arg>Pro polymorphism and risk of cancer in Iranian population: A systematic review and meta-analysis. Arginine 28-31 tumor protein p53 Homo sapiens 15-18 29951436-1 2017 Background: Different studies have investigated the association between p53 codon 72 Arg>Pro polymorphism and cancer risk. Arginine 85-88 tumor protein p53 Homo sapiens 72-75 29951436-12 2017 Conclusion: Our study revealed that p53 codon 72 Arg>Pro polymorphism was not associated with overall cancer odds in Iranian population. Arginine 49-52 tumor protein p53 Homo sapiens 36-39 29126407-7 2017 RESULTS: Patients with Arg/Arg and Arg/Pro at codon 72 of TP53 had a higher complete response rate (61% vs. 44%, P = 0.007) than those with Pro/Pro. Arginine 23-26 tumor protein p53 Homo sapiens 58-62 29308362-6 2017 Molecular analysis of p53 codon 72 gene polymorphism was performed by polymerase chain reaction - restriction fragment length polymorphism for Arg/Arg, Arg/Pro, and Pro/Pro. Arginine 143-146 tumor protein p53 Homo sapiens 22-25 29308362-6 2017 Molecular analysis of p53 codon 72 gene polymorphism was performed by polymerase chain reaction - restriction fragment length polymorphism for Arg/Arg, Arg/Pro, and Pro/Pro. Arginine 147-150 tumor protein p53 Homo sapiens 22-25 29308362-6 2017 Molecular analysis of p53 codon 72 gene polymorphism was performed by polymerase chain reaction - restriction fragment length polymorphism for Arg/Arg, Arg/Pro, and Pro/Pro. Arginine 147-150 tumor protein p53 Homo sapiens 22-25 29308362-8 2017 Results: Genotype frequencies of 35 carcinoma cases of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 23%, 57%, and 20%, respectively, and six leukoplakia cases of p53 Arg/Arg and Arg/Pro genotype were 50% and 50%, respectively. Arginine 59-62 tumor protein p53 Homo sapiens 55-58 28857739-8 2017 CONCLUSION: The oncogenic potential of the virus is increased by the presence of the p53 arg/arg genotype in the Greek population in such a way that the specific protein interaction E6 (L83V)-p53 (Arg-72) can modify an individual"s susceptibility to cervical disease. Arginine 93-96 tumor protein p53 Homo sapiens 192-195 28857739-8 2017 CONCLUSION: The oncogenic potential of the virus is increased by the presence of the p53 arg/arg genotype in the Greek population in such a way that the specific protein interaction E6 (L83V)-p53 (Arg-72) can modify an individual"s susceptibility to cervical disease. Arginine 197-200 tumor protein p53 Homo sapiens 85-88 28857739-8 2017 CONCLUSION: The oncogenic potential of the virus is increased by the presence of the p53 arg/arg genotype in the Greek population in such a way that the specific protein interaction E6 (L83V)-p53 (Arg-72) can modify an individual"s susceptibility to cervical disease. Arginine 197-200 tumor protein p53 Homo sapiens 192-195 28475405-3 2017 A common coding region variant at amino acid 72 of p53 encodes either proline (P72) or arginine (R72). Arginine 87-95 tumor protein p53 Homo sapiens 51-54 28789369-5 2017 Notably, the Pro72 allele was significantly enriched in patients with ESCC compared with its abundance in the healthy control group, and the genotype of Pro/Arg on p53 codon 72 was confirmed to exhibit a significant correlation with ESCC in Mongolian patients. Arginine 157-160 tumor protein p53 Homo sapiens 164-167 28789369-7 2017 Mongolian patients who carry the partocular genotype of Arg/Pro or Pro/Pro on p53 codon 72 may be more likely to develop ESCC. Arginine 56-59 tumor protein p53 Homo sapiens 78-81 28671612-6 2017 The extraordinary loss of arginine may be attributed to some extent to composition of its codons as well as to the importance of arginine in the functioning of prominent tumor suppressor proteins like p53. Arginine 26-34 tumor protein p53 Homo sapiens 201-204 28671612-6 2017 The extraordinary loss of arginine may be attributed to some extent to composition of its codons as well as to the importance of arginine in the functioning of prominent tumor suppressor proteins like p53. Arginine 129-137 tumor protein p53 Homo sapiens 201-204 28053964-7 2016 p53 gene polymorphism at codon 72 is statistically significant in Arg/Arg and Pro/Pro genotypes. Arginine 66-69 tumor protein p53 Homo sapiens 0-3 28214592-4 2017 We found that the polymorphism rs1042522:C > G in codon 72 of exon 4 of the TP53 gene, whose C variant produces a proline and is more common in most ethnicities, has a G variant producing an arginine in 79.8% of NFPAs (n = 42; p < 1.411 x 10-18 vs. 1000 Genomes database), causing patients to present a decade earlier with symptomatic NFPAs. Arginine 194-202 tumor protein p53 Homo sapiens 79-83 28347732-0 2017 Association between the p53 arginine/arginine homozygous genotype at codon 72 and human papillomavirus E6/E7 mRNA expression. Arginine 28-36 tumor protein p53 Homo sapiens 24-27 28347732-0 2017 Association between the p53 arginine/arginine homozygous genotype at codon 72 and human papillomavirus E6/E7 mRNA expression. Arginine 37-45 tumor protein p53 Homo sapiens 24-27 28347732-9 2017 CONCLUSION: The presence of the p53 arginine/arginine homozygous genotype at codon 72 was significantly associated with the positive HPV E6/E7 mRNA expression. Arginine 36-44 tumor protein p53 Homo sapiens 32-35 28347732-9 2017 CONCLUSION: The presence of the p53 arginine/arginine homozygous genotype at codon 72 was significantly associated with the positive HPV E6/E7 mRNA expression. Arginine 45-53 tumor protein p53 Homo sapiens 32-35 27768124-5 2017 The human Tp53 gene harbors a common single-nucleotide polymorphism (SNP) at codon 72, which yields an arginine-to-proline amino-acidic substitution (Arg72Pro) that modulates the apoptotic activity of the p53 protein. Arginine 103-111 tumor protein p53 Homo sapiens 10-14 27768124-5 2017 The human Tp53 gene harbors a common single-nucleotide polymorphism (SNP) at codon 72, which yields an arginine-to-proline amino-acidic substitution (Arg72Pro) that modulates the apoptotic activity of the p53 protein. Arginine 103-111 tumor protein p53 Homo sapiens 11-14 27768124-9 2017 Patients harboring the Pro allele of the Tp53 Arg72Pro SNP showed higher levels of circulating EPC-containing CD34+ cells, EPC-mobilizing cytokines - vascular endothelial growth factor and stromal cell-derived factor-1alpha - and good functional outcome following ICH, when compared with the homozygous Arg allele patients, which is compatible with increased neovascularization. Arginine 46-49 tumor protein p53 Homo sapiens 41-45 29333597-2 2017 TP53 codon 72 polymorphism (P72R) results in proline (P) or arginine (R) at 72 amino acid position, which causes synthesis of proteins with distinct functions. Arginine 60-68 tumor protein p53 Homo sapiens 0-4 28033105-6 2016 Multivariate analysis showed a significant association with NSCLC for the combination between the TP53 codon72 Arg/Pro and the Pro/Pro genotypes (OR 2.21, 95 % CI 1.390-3.51; p=0.001). Arginine 111-114 tumor protein p53 Homo sapiens 98-102 28611978-6 2017 KEY MESSAGE: High rates of tumor suppressor gene p53 mutations, particularly p53 arginine mutations, were detected in pancreatic cancer patients. Arginine 81-89 tumor protein p53 Homo sapiens 49-52 28611978-6 2017 KEY MESSAGE: High rates of tumor suppressor gene p53 mutations, particularly p53 arginine mutations, were detected in pancreatic cancer patients. Arginine 81-89 tumor protein p53 Homo sapiens 77-80 28611978-8 2017 Oral bacteria peptidylarginine deiminases might lead to the p53 and K-ras point mutations by degrading arginine. Arginine 22-30 tumor protein p53 Homo sapiens 60-63 28357076-5 2017 The distribution frequency of p53 sites of arginine (Arg)/Arg, Arg/proline (Pro), Pro/Pro were 18.4, 48.8 and 32.8% in the control group, as compared with 18.7, 49.9 and 31.4% in the case group, which indicated that there was no difference between two groups (chi2=0.14; P=0.93). Arginine 43-51 tumor protein p53 Homo sapiens 30-33 28357076-5 2017 The distribution frequency of p53 sites of arginine (Arg)/Arg, Arg/proline (Pro), Pro/Pro were 18.4, 48.8 and 32.8% in the control group, as compared with 18.7, 49.9 and 31.4% in the case group, which indicated that there was no difference between two groups (chi2=0.14; P=0.93). Arginine 53-56 tumor protein p53 Homo sapiens 30-33 28357076-5 2017 The distribution frequency of p53 sites of arginine (Arg)/Arg, Arg/proline (Pro), Pro/Pro were 18.4, 48.8 and 32.8% in the control group, as compared with 18.7, 49.9 and 31.4% in the case group, which indicated that there was no difference between two groups (chi2=0.14; P=0.93). Arginine 58-61 tumor protein p53 Homo sapiens 30-33 28357076-5 2017 The distribution frequency of p53 sites of arginine (Arg)/Arg, Arg/proline (Pro), Pro/Pro were 18.4, 48.8 and 32.8% in the control group, as compared with 18.7, 49.9 and 31.4% in the case group, which indicated that there was no difference between two groups (chi2=0.14; P=0.93). Arginine 58-61 tumor protein p53 Homo sapiens 30-33 28053964-7 2016 p53 gene polymorphism at codon 72 is statistically significant in Arg/Arg and Pro/Pro genotypes. Arginine 70-73 tumor protein p53 Homo sapiens 0-3 27376811-2 2016 The change from an arginine (Arg) to a proline (Pro) at codon 72 can influence the biological activity of p53, which predisposes to an increased risk of recurrent spontaneous abortion (RSA). Arginine 19-27 tumor protein p53 Homo sapiens 106-109 28139534-1 2016 BACKGROUND & OBJECTIVES: The Arg>Pro polymorphism in codon 72 of p53 gene is known to affect the susceptibility of cervical cancer differently in different population worldwide although information regarding its role in determining survival status and disease outcome in patients is lacking. Arginine 33-36 tumor protein p53 Homo sapiens 72-75 28139534-2 2016 The present study was conducted to determine the genotype frequency and prognostic role of p53 codon 72 Arg>Pro polymorphism in patients with advanced stage cervical cancer in India. Arginine 104-107 tumor protein p53 Homo sapiens 91-94 27210019-4 2016 By changing lysines 351 and 357 to arginine, thereby blocking all post-translational modifications of these residues, DNA binding and transcriptional regulation by p53 remain virtually unchanged. Arginine 35-43 tumor protein p53 Homo sapiens 164-167 29894073-12 2016 They may therefore, conclude that detection of allelic polymorphisms of codon 72 of the p53 gene including arginine/arginine could be a risk factor predisposition for breast cancer and valuable tool for determining prognosis, progress, and treatment purposes. Arginine 107-115 tumor protein p53 Homo sapiens 88-91 29894073-12 2016 They may therefore, conclude that detection of allelic polymorphisms of codon 72 of the p53 gene including arginine/arginine could be a risk factor predisposition for breast cancer and valuable tool for determining prognosis, progress, and treatment purposes. Arginine 116-124 tumor protein p53 Homo sapiens 88-91 27304453-10 2016 The results revealed that (1) homozygosity of the Pro72 variant of p53 was present in 26 laryngeal carcinoma patients (65%), (2) heterozygosity for the Pro/Arg genotype was present in 13 patients (32.5%), and (3) the Arg72 variant of the p53 allele was present in 1 patient (2.5%) before treatment. Arginine 156-159 tumor protein p53 Homo sapiens 67-70 27376811-2 2016 The change from an arginine (Arg) to a proline (Pro) at codon 72 can influence the biological activity of p53, which predisposes to an increased risk of recurrent spontaneous abortion (RSA). Arginine 29-32 tumor protein p53 Homo sapiens 106-109 27376811-7 2016 There was a significant association between p53 polymorphism at codon 72 and RSA in recessive model (Pro/Pro vs. Pro/Arg+Arg/Arg; OR=1.60, 95% CI: 1.14-2.24) and co-dominant model (Pro/Pro vs. Arg/Arg; OR=1.47, 95% CI: 1.02-2.12) whether the study that was deviated from HWE was eliminated or not. Arginine 117-120 tumor protein p53 Homo sapiens 44-47 27376811-7 2016 There was a significant association between p53 polymorphism at codon 72 and RSA in recessive model (Pro/Pro vs. Pro/Arg+Arg/Arg; OR=1.60, 95% CI: 1.14-2.24) and co-dominant model (Pro/Pro vs. Arg/Arg; OR=1.47, 95% CI: 1.02-2.12) whether the study that was deviated from HWE was eliminated or not. Arginine 121-124 tumor protein p53 Homo sapiens 44-47 27376811-7 2016 There was a significant association between p53 polymorphism at codon 72 and RSA in recessive model (Pro/Pro vs. Pro/Arg+Arg/Arg; OR=1.60, 95% CI: 1.14-2.24) and co-dominant model (Pro/Pro vs. Arg/Arg; OR=1.47, 95% CI: 1.02-2.12) whether the study that was deviated from HWE was eliminated or not. Arginine 121-124 tumor protein p53 Homo sapiens 44-47 27376811-7 2016 There was a significant association between p53 polymorphism at codon 72 and RSA in recessive model (Pro/Pro vs. Pro/Arg+Arg/Arg; OR=1.60, 95% CI: 1.14-2.24) and co-dominant model (Pro/Pro vs. Arg/Arg; OR=1.47, 95% CI: 1.02-2.12) whether the study that was deviated from HWE was eliminated or not. Arginine 121-124 tumor protein p53 Homo sapiens 44-47 27376811-7 2016 There was a significant association between p53 polymorphism at codon 72 and RSA in recessive model (Pro/Pro vs. Pro/Arg+Arg/Arg; OR=1.60, 95% CI: 1.14-2.24) and co-dominant model (Pro/Pro vs. Arg/Arg; OR=1.47, 95% CI: 1.02-2.12) whether the study that was deviated from HWE was eliminated or not. Arginine 121-124 tumor protein p53 Homo sapiens 44-47 27159678-0 2016 Association of p53 codon72 Arg>Pro polymorphism with susceptibility to nasopharyngeal carcinoma: evidence from a case-control study and meta-analysis. Arginine 27-30 tumor protein p53 Homo sapiens 15-18 27159678-3 2016 Single-nucleotide polymorphism of p53 at codon72 leading to substitution of proline (Pro) in place of arginine (Arg) has been identified as a risk factor for development of many cancers, including nasopharyngeal carcinoma (NPC). Arginine 102-110 tumor protein p53 Homo sapiens 34-37 27159678-3 2016 Single-nucleotide polymorphism of p53 at codon72 leading to substitution of proline (Pro) in place of arginine (Arg) has been identified as a risk factor for development of many cancers, including nasopharyngeal carcinoma (NPC). Arginine 112-115 tumor protein p53 Homo sapiens 34-37 27159678-5 2016 We aimed to conduct a case-control study for a possible relation of p53 codon72 Arg>Pro polymorphism with NPC risk in underdeveloped states of India, combine the result with previously available records from different databases and perform a meta-analysis to draw a more definitive conclusion. Arginine 80-83 tumor protein p53 Homo sapiens 68-71 27159678-7 2016 The p53 codon72 Arg>Pro polymorphism was typed by polymerase chain reaction, which showed an association with NPC risk. Arginine 16-19 tumor protein p53 Homo sapiens 4-7 27159678-11 2016 The outcome of the study indicated that both allele frequency and genotype distribution of p53 codon72 Arg>Pro polymorphism were significantly associated with NPC risk. Arginine 103-106 tumor protein p53 Homo sapiens 91-94 26909997-6 2016 TP53*72 showed genotypic distribution: in the control group, there was 16.10% homozygous Pro, and 42.44% heterozygous and 41.46% homozygous Arg; in the BC group, there was 15.43% homozygous Pro, and 42.55% heterozygous and 42.02% homozygous Arg. Arginine 140-143 tumor protein p53 Homo sapiens 0-4 26909997-6 2016 TP53*72 showed genotypic distribution: in the control group, there was 16.10% homozygous Pro, and 42.44% heterozygous and 41.46% homozygous Arg; in the BC group, there was 15.43% homozygous Pro, and 42.55% heterozygous and 42.02% homozygous Arg. Arginine 241-244 tumor protein p53 Homo sapiens 0-4 26909997-10 2016 In TP53*248, there was 100% homozygous Arg distribution in both groups. Arginine 39-42 tumor protein p53 Homo sapiens 3-7 26209050-10 2016 The gene-gene interaction of these polymorphisms increased EOC risk in a more than additive manner (ORs for the presence of both BAX AA and TP53 Arg/Pro genotypes = 8.7, 95 % CI = 1.66-45.48). Arginine 145-148 tumor protein p53 Homo sapiens 140-144 26751966-4 2016 Tumor suppressor protein p53 activation and G1/G0 cell cycle arrest support cell survival upon prolonged arginine starvation. Arginine 105-113 tumor protein p53 Homo sapiens 25-28 26751966-5 2016 Cells with the mutant or deleted TP53 fail to stop cell cycle progression at defined cell cycle checkpoints which appears to be associated with reduced recovery after durable metabolic stress triggered by arginine withdrawal. Arginine 205-213 tumor protein p53 Homo sapiens 33-37 26718886-9 2016 The patients with a proline (Pro) polymorphism in SNP72 of TP53 showed significantly higher PrP-positive rates than those with arginine (Arg). Arginine 137-140 tumor protein p53 Homo sapiens 59-63 26696550-5 2016 RESULTS: The Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to capecitabine plus paclitaxel chemotherapy in patients with gastric cancer when compared to the Arg/Arg genotype (30.6 vs. 63.2%, p value 0.000). Arginine 203-206 tumor protein p53 Homo sapiens 34-38 26696550-5 2016 RESULTS: The Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to capecitabine plus paclitaxel chemotherapy in patients with gastric cancer when compared to the Arg/Arg genotype (30.6 vs. 63.2%, p value 0.000). Arginine 207-210 tumor protein p53 Homo sapiens 34-38 28203651-6 2016 SNP analysis of p53 codon 72 demonstrated the highest prevalence of the Arg/Arg (56%) phenotype, followed by Arg/Pro (33%) and Pro/Pro (11%). Arginine 72-75 tumor protein p53 Homo sapiens 16-19 26738694-7 2016 Moreover, genotype analysis revealed a statistically significant association between Pro/Pro genotype of p53 Arg72Pro polymorphism and increased frequencies of MN both spontaneous and AFB1-induced cultures when compared Arg/Arg genotype (0.69 +- 0.19 versus 0.46 +- 0.13, p < 0.001; 1.59 +- 0.65 versus 1.01 +- 0.41 p < 0.001; respectively). Arginine 109-112 tumor protein p53 Homo sapiens 105-108 26738694-7 2016 Moreover, genotype analysis revealed a statistically significant association between Pro/Pro genotype of p53 Arg72Pro polymorphism and increased frequencies of MN both spontaneous and AFB1-induced cultures when compared Arg/Arg genotype (0.69 +- 0.19 versus 0.46 +- 0.13, p < 0.001; 1.59 +- 0.65 versus 1.01 +- 0.41 p < 0.001; respectively). Arginine 220-223 tumor protein p53 Homo sapiens 105-108 28203651-6 2016 SNP analysis of p53 codon 72 demonstrated the highest prevalence of the Arg/Arg (56%) phenotype, followed by Arg/Pro (33%) and Pro/Pro (11%). Arginine 76-79 tumor protein p53 Homo sapiens 16-19 28203651-6 2016 SNP analysis of p53 codon 72 demonstrated the highest prevalence of the Arg/Arg (56%) phenotype, followed by Arg/Pro (33%) and Pro/Pro (11%). Arginine 76-79 tumor protein p53 Homo sapiens 16-19 25232917-8 2015 Patients with homozygous Arg/arg at codon 72 of P53 had a better median OS months than Arg/Pro and Pro/Pro (13.4 vs. 8.4 vs. 1.5 months, respectively; P = 0.045). Arginine 25-28 tumor protein p53 Homo sapiens 48-51 26420962-0 2015 TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. Arginine 14-17 tumor protein p53 Homo sapiens 0-4 26420962-0 2015 TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. Arginine 18-21 tumor protein p53 Homo sapiens 0-4 26420962-4 2015 A single nucleotide polymorphism (SNP) in the TP53 gene resulting in the presence of either arginine (Arg) or proline (Pro) or both at codon 72 was shown to alter TP53 tumor-suppressor properties. Arginine 92-100 tumor protein p53 Homo sapiens 46-50 26420962-4 2015 A single nucleotide polymorphism (SNP) in the TP53 gene resulting in the presence of either arginine (Arg) or proline (Pro) or both at codon 72 was shown to alter TP53 tumor-suppressor properties. Arginine 92-100 tumor protein p53 Homo sapiens 163-167 26420962-4 2015 A single nucleotide polymorphism (SNP) in the TP53 gene resulting in the presence of either arginine (Arg) or proline (Pro) or both at codon 72 was shown to alter TP53 tumor-suppressor properties. Arginine 102-105 tumor protein p53 Homo sapiens 46-50 26420962-4 2015 A single nucleotide polymorphism (SNP) in the TP53 gene resulting in the presence of either arginine (Arg) or proline (Pro) or both at codon 72 was shown to alter TP53 tumor-suppressor properties. Arginine 102-105 tumor protein p53 Homo sapiens 163-167 26420962-8 2015 RESULTS: The most frequent TP53 genotype in IBD patients was Arg/Arg occurring in 54%-64% of cases (and in only 32% of controls). Arginine 61-64 tumor protein p53 Homo sapiens 27-31 26420962-8 2015 RESULTS: The most frequent TP53 genotype in IBD patients was Arg/Arg occurring in 54%-64% of cases (and in only 32% of controls). Arginine 65-68 tumor protein p53 Homo sapiens 27-31 26420962-11 2015 CONCLUSION: The data suggests that the TP53 codon 72 Arg/Arg genotype is associated with increased risk for IBD development. Arginine 53-56 tumor protein p53 Homo sapiens 39-43 26420962-11 2015 CONCLUSION: The data suggests that the TP53 codon 72 Arg/Arg genotype is associated with increased risk for IBD development. Arginine 57-60 tumor protein p53 Homo sapiens 39-43 26405550-6 2015 Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Arginine 368-371 tumor protein p53 Homo sapiens 40-43 26405550-6 2015 Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Arginine 368-371 tumor protein p53 Homo sapiens 40-43 26617937-6 2015 Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythia, and Treponema denticola possess the PAD enzyme, and p53 arginine mutations have been detected in patients with pancreatic cancer. Arginine 127-135 tumor protein p53 Homo sapiens 123-126 26617937-9 2015 The hypothesis in question can be tested if the DNA of P. gingivalis or the antibodies against P. gingivalis can be detected in patients with the p53 arginine mutation.If this hypothesis is true, it could reveal the real cause of pancreatic cancer, which is a fatal disease. Arginine 150-158 tumor protein p53 Homo sapiens 146-149 26425661-3 2015 Recent studies suggest that PRMT5, which is frequently elevated in human cancers, cooperates with oncogenic cyclin D1 and leaves marks on p53 by way of arginine methylation, promoting the bypass of wild-type p53, and in doing so, evade apoptosis. Arginine 152-160 tumor protein p53 Homo sapiens 138-141 26785263-1 2016 BACKGROUND: In human papillomavirus (HPV)-induced carcinogenesis, the arginine (Arg) allele of the TP53 codon 72 polymorphism binds more efficiently to the HPV E6 oncoprotein than the proline (Pro) allele. Arginine 70-78 tumor protein p53 Homo sapiens 99-103 26785263-1 2016 BACKGROUND: In human papillomavirus (HPV)-induced carcinogenesis, the arginine (Arg) allele of the TP53 codon 72 polymorphism binds more efficiently to the HPV E6 oncoprotein than the proline (Pro) allele. Arginine 80-83 tumor protein p53 Homo sapiens 99-103 26785263-8 2016 Most OPSCC patients had the TP53 Arg/Arg or Arg/Pro genotype. Arginine 33-36 tumor protein p53 Homo sapiens 28-32 26782376-10 2015 Analysis of p53 gene polymorphisms showed a higher frequency for the genotype Arg/Pro (66%) and a lower frequency for the Arg/Arg (23%) and Pro/Pro (11%) genotypes. Arginine 78-81 tumor protein p53 Homo sapiens 12-15 26782376-10 2015 Analysis of p53 gene polymorphisms showed a higher frequency for the genotype Arg/Pro (66%) and a lower frequency for the Arg/Arg (23%) and Pro/Pro (11%) genotypes. Arginine 122-125 tumor protein p53 Homo sapiens 12-15 26782376-10 2015 Analysis of p53 gene polymorphisms showed a higher frequency for the genotype Arg/Pro (66%) and a lower frequency for the Arg/Arg (23%) and Pro/Pro (11%) genotypes. Arginine 122-125 tumor protein p53 Homo sapiens 12-15 26405550-6 2015 Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Arginine 247-255 tumor protein p53 Homo sapiens 40-43 26405550-6 2015 Conversely, the interaction between the p53 and p21 polymorphisms significantly decreased the risk of prostate cancer, with the odds ratio (OR) being 0.49 [95% confidence interval (CI), 0.27-0.86; P<0.05] for subjects carrying the p53 codon 72 arginine (Arg)/proline (Pro)+Pro/Pro and p21 C98A CA genotypes compared to the combined reference genotypes p53 codon 72 Arg/Arg and p21 C98A CC. Arginine 257-260 tumor protein p53 Homo sapiens 40-43 25232917-8 2015 Patients with homozygous Arg/arg at codon 72 of P53 had a better median OS months than Arg/Pro and Pro/Pro (13.4 vs. 8.4 vs. 1.5 months, respectively; P = 0.045). Arginine 29-32 tumor protein p53 Homo sapiens 48-51 25232917-8 2015 Patients with homozygous Arg/arg at codon 72 of P53 had a better median OS months than Arg/Pro and Pro/Pro (13.4 vs. 8.4 vs. 1.5 months, respectively; P = 0.045). Arginine 87-90 tumor protein p53 Homo sapiens 48-51 25232917-9 2015 P53/p21 combination had a better median OS and disease-free survival (DFS) of 12.1 and 13.7 months for wild type cases (GG + Ser/ser) and 20.3 and 20.7 months for patients with either variant genes (GC + Ser/arg) compared with 1.1 and 1.9 months for patients with both variant genes (CC + arg/arg), (P = 0.037 and 0.004). Arginine 208-211 tumor protein p53 Homo sapiens 0-3 25232917-9 2015 P53/p21 combination had a better median OS and disease-free survival (DFS) of 12.1 and 13.7 months for wild type cases (GG + Ser/ser) and 20.3 and 20.7 months for patients with either variant genes (GC + Ser/arg) compared with 1.1 and 1.9 months for patients with both variant genes (CC + arg/arg), (P = 0.037 and 0.004). Arginine 289-292 tumor protein p53 Homo sapiens 0-3 25232917-9 2015 P53/p21 combination had a better median OS and disease-free survival (DFS) of 12.1 and 13.7 months for wild type cases (GG + Ser/ser) and 20.3 and 20.7 months for patients with either variant genes (GC + Ser/arg) compared with 1.1 and 1.9 months for patients with both variant genes (CC + arg/arg), (P = 0.037 and 0.004). Arginine 289-292 tumor protein p53 Homo sapiens 0-3 26123760-10 2015 However, a significant association between p53 Arg72Pro polymorphism and the risk of oral cancer with HPV infection was detected in the Arg/Arg vs. Arg/Pro + Pro/Pro model. Arginine 47-50 tumor protein p53 Homo sapiens 43-46 26123760-10 2015 However, a significant association between p53 Arg72Pro polymorphism and the risk of oral cancer with HPV infection was detected in the Arg/Arg vs. Arg/Pro + Pro/Pro model. Arginine 136-139 tumor protein p53 Homo sapiens 43-46 26123760-10 2015 However, a significant association between p53 Arg72Pro polymorphism and the risk of oral cancer with HPV infection was detected in the Arg/Arg vs. Arg/Pro + Pro/Pro model. Arginine 136-139 tumor protein p53 Homo sapiens 43-46 25774791-4 2015 RESULTS: The pooled data by a fixed-effects model suggested an increased risk of CM associated with p53 Arg72Pro polymorphism under the genetic model of Arg/Pro vs. Pro/Pro without heterogeneity (ORArg/Pro vs. Pro/Pro = 1.76, 95% CI = 1.55-1.99, Pheterogeneity = 0.075). Arginine 104-107 tumor protein p53 Homo sapiens 100-103 26131172-10 2015 Interestingly, in the subgroup analysis regarding P53 codon 72 polymorphism, increased HCC risk could be observed in the Pro/Pro+Pro/Arg subgroup under a recessive model (OR=1.78; 95% CI=1.29-2.44). Arginine 133-136 tumor protein p53 Homo sapiens 50-53 25889455-8 2015 In vitro experiments in cell lines indicated that enzymes controlling DNA methylation were differentially regulated by codon 72 Arg or Pro isoforms of p53. Arginine 128-131 tumor protein p53 Homo sapiens 151-154 26064201-1 2015 BACKGROUND: The polymorphism of TP53 codon 72, a transversion of G to C (Arg to Pro), has been demonstrated to be associated with the risk for lung cancer. Arginine 73-76 tumor protein p53 Homo sapiens 32-36 26064201-3 2015 Thus, we performed a meta-analysis by pooling all currently available case-control studies to estimate the effect of TP53 codon 72 Arg/Pro polymorphism on the development of lung cancer in the Chinese population. Arginine 131-134 tumor protein p53 Homo sapiens 117-121 25226867-7 2015 TP53 sequence analysis of the index patient revealed the germline mutation c.1025G > C in a heterozygous state, resulting in an amino acid exchange from arginine to proline (p.Arg342Pro) in the tetramerization domain of p53. Arginine 156-164 tumor protein p53 Homo sapiens 0-4 25582697-5 2015 Molecular analysis of lymphomas revealed that arginine methylation of p53 selectively suppresses expression of crucial proapoptotic and antiproliferative target genes, thereby sustaining tumor cell self-renewal and proliferation and bypassing the need for the acquisition of inactivating p53 mutations. Arginine 46-54 tumor protein p53 Homo sapiens 70-73 25582697-5 2015 Molecular analysis of lymphomas revealed that arginine methylation of p53 selectively suppresses expression of crucial proapoptotic and antiproliferative target genes, thereby sustaining tumor cell self-renewal and proliferation and bypassing the need for the acquisition of inactivating p53 mutations. Arginine 46-54 tumor protein p53 Homo sapiens 288-291 25226867-7 2015 TP53 sequence analysis of the index patient revealed the germline mutation c.1025G > C in a heterozygous state, resulting in an amino acid exchange from arginine to proline (p.Arg342Pro) in the tetramerization domain of p53. Arginine 156-164 tumor protein p53 Homo sapiens 223-226 25256710-2 2015 Several genetic polymorphisms exist in TP53, including a proline to arginine variant at amino acid 72 (P72 and R72, respectively); this polymorphism alters p53 function. Arginine 68-76 tumor protein p53 Homo sapiens 39-43 26005978-9 2015 Indians compared to control population presented: - TP53 super representation of Arg/Arg haplotype, 74.5% versus 42.5%, p<0.0001. Arginine 81-84 tumor protein p53 Homo sapiens 52-56 26005978-9 2015 Indians compared to control population presented: - TP53 super representation of Arg/Arg haplotype, 74.5% versus 42.5%, p<0.0001. Arginine 85-88 tumor protein p53 Homo sapiens 52-56 25256710-2 2015 Several genetic polymorphisms exist in TP53, including a proline to arginine variant at amino acid 72 (P72 and R72, respectively); this polymorphism alters p53 function. Arginine 68-76 tumor protein p53 Homo sapiens 156-159 26320432-1 2015 BACKGROUND: Earlier studies on the association between p53 codon 72 Arg>Pro polymorphism and cancer risk were inconclusive and conflicting for the Saudi population. Arginine 68-71 tumor protein p53 Homo sapiens 55-58 25921167-1 2015 OBJECTIVE: To assess associations between codon 72 polymorphisms (Pro or B and Arg or b alleles) of the TP53 gene and lung cancer risk among Bangladeshis. Arginine 79-82 tumor protein p53 Homo sapiens 104-108 26320432-9 2015 CONCLUSIONS: The current meta-analysis suggests that the codon 72 Arg>Pro polymorphism of the p53 gene might not contribute to cancer susceptibility in Saudi population. Arginine 66-69 tumor protein p53 Homo sapiens 97-100 25502079-3 2015 A common polymorphism of the p53 codon 72 in exon 4 with two alleles encoding arginine or proline is known at this locus. Arginine 78-86 tumor protein p53 Homo sapiens 29-32 25153662-8 2014 Moreover, this association was enhanced when combined with HPV-16 seropositivity and p53 Arg/Arg or Arg/Pro genotypes. Arginine 89-92 tumor protein p53 Homo sapiens 85-88 25526208-6 2014 The p53 codon 72 Pro/Pro genotype was associated with a longer median PFS time of 30.3 months compared with 18.2 months for patients with Arg/Arg variants. Arginine 138-141 tumor protein p53 Homo sapiens 4-7 25526208-6 2014 The p53 codon 72 Pro/Pro genotype was associated with a longer median PFS time of 30.3 months compared with 18.2 months for patients with Arg/Arg variants. Arginine 142-145 tumor protein p53 Homo sapiens 4-7 25526208-7 2014 Moreover, the p53 codon 72 Pro/ Pro genotype was associated with a longer median OS time of 31.6 months compared with 25.8 months for those with Arg/Arg variants; the P value was marginally significant. Arginine 145-148 tumor protein p53 Homo sapiens 14-17 25526208-7 2014 Moreover, the p53 codon 72 Pro/ Pro genotype was associated with a longer median OS time of 31.6 months compared with 25.8 months for those with Arg/Arg variants; the P value was marginally significant. Arginine 149-152 tumor protein p53 Homo sapiens 14-17 24115240-1 2014 BACKGROUND: The TP53 single nucleotide polymorphism (SNP) rs1042522 encodes arginine (Arg) or proline (Pro). Arginine 76-84 tumor protein p53 Homo sapiens 16-20 24115240-1 2014 BACKGROUND: The TP53 single nucleotide polymorphism (SNP) rs1042522 encodes arginine (Arg) or proline (Pro). Arginine 86-89 tumor protein p53 Homo sapiens 16-20 25316267-4 2014 There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Arginine 170-173 tumor protein p53 Homo sapiens 55-59 25316267-4 2014 There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Arginine 170-173 tumor protein p53 Homo sapiens 165-169 25316267-4 2014 There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Arginine 170-173 tumor protein p53 Homo sapiens 165-169 25316267-4 2014 There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Arginine 174-177 tumor protein p53 Homo sapiens 55-59 25316267-4 2014 There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Arginine 174-177 tumor protein p53 Homo sapiens 165-169 25316267-4 2014 There were significant differences in the frequency of TP53 and MDM2 genotypes in EC patients-increased EC occurrence was observed with the presence of MDM2 G/G and TP53 Arg/Arg genotypes, while allele Pro of TP53 decreased cancer risk. Arginine 174-177 tumor protein p53 Homo sapiens 165-169 25316267-5 2014 Analysis of combined MDM2/TP53 polymorphisms revealed that T/T-Pro/Arg genotype decreased EC risk, whereas G/G-Arg/Arg genotype increased it. Arginine 67-70 tumor protein p53 Homo sapiens 26-30 25316267-6 2014 Association of these genetic polymorphisms with histological grading showed increased MDM2 G/G homozygote and TP53 Arg/Arg homozygote frequencies in grading 2 as well as allele G overrepresentation in G1 and G3 EC patients. Arginine 115-118 tumor protein p53 Homo sapiens 110-114 25316267-6 2014 Association of these genetic polymorphisms with histological grading showed increased MDM2 G/G homozygote and TP53 Arg/Arg homozygote frequencies in grading 2 as well as allele G overrepresentation in G1 and G3 EC patients. Arginine 119-122 tumor protein p53 Homo sapiens 110-114 25316267-7 2014 Finally, with clinical FIGO staging under evaluation, an increase in MDM2 G/G and TP53 Arg/Arg homozygote frequencies in staging I and TP53 Arg/Arg homozygote frequencies in staging II were observed. Arginine 87-90 tumor protein p53 Homo sapiens 82-86 25316267-7 2014 Finally, with clinical FIGO staging under evaluation, an increase in MDM2 G/G and TP53 Arg/Arg homozygote frequencies in staging I and TP53 Arg/Arg homozygote frequencies in staging II were observed. Arginine 91-94 tumor protein p53 Homo sapiens 82-86 25316267-7 2014 Finally, with clinical FIGO staging under evaluation, an increase in MDM2 G/G and TP53 Arg/Arg homozygote frequencies in staging I and TP53 Arg/Arg homozygote frequencies in staging II were observed. Arginine 91-94 tumor protein p53 Homo sapiens 82-86 25316267-7 2014 Finally, with clinical FIGO staging under evaluation, an increase in MDM2 G/G and TP53 Arg/Arg homozygote frequencies in staging I and TP53 Arg/Arg homozygote frequencies in staging II were observed. Arginine 91-94 tumor protein p53 Homo sapiens 82-86 25429397-5 2014 Accordingly, more mucous cells are present in primary human airway cultures with p53(Arg) compared with p53(Pro). Arginine 85-88 tumor protein p53 Homo sapiens 81-84 25153662-8 2014 Moreover, this association was enhanced when combined with HPV-16 seropositivity and p53 Arg/Arg or Arg/Pro genotypes. Arginine 93-96 tumor protein p53 Homo sapiens 85-88 25153662-8 2014 Moreover, this association was enhanced when combined with HPV-16 seropositivity and p53 Arg/Arg or Arg/Pro genotypes. Arginine 93-96 tumor protein p53 Homo sapiens 85-88 24561640-8 2014 By contrast, expression of p53 was upregulated by L-Arg. Arginine 50-55 tumor protein p53 Homo sapiens 27-30 25034526-6 2014 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in lung cancer were 25.5, 37.7, and 36.8 %, respectively; frequencies in the controls were 53.4, 30.2, and 16.4 %, respectively (p < 0.01). Arginine 47-50 tumor protein p53 Homo sapiens 19-22 25034526-6 2014 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in lung cancer were 25.5, 37.7, and 36.8 %, respectively; frequencies in the controls were 53.4, 30.2, and 16.4 %, respectively (p < 0.01). Arginine 51-54 tumor protein p53 Homo sapiens 19-22 25034526-6 2014 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in lung cancer were 25.5, 37.7, and 36.8 %, respectively; frequencies in the controls were 53.4, 30.2, and 16.4 %, respectively (p < 0.01). Arginine 51-54 tumor protein p53 Homo sapiens 19-22 25025520-2 2014 The arginine allele at codon 72 in p53 tumor suppressor gene has been reported to be a risk-factor in different ethnic groups. Arginine 4-12 tumor protein p53 Homo sapiens 35-38 25536560-2 2014 To set of p53-mediated apoptosis gene polymorphisms (TP53 codon 72 Arg/Pro, r21 codon 31 Ser/Arg, MDM2 SNP309) for the occurrence of CLL in patients who were exposed to ionizing radiation (IR) from the Chornobyl accident. Arginine 67-70 tumor protein p53 Homo sapiens 10-13 25536560-2 2014 To set of p53-mediated apoptosis gene polymorphisms (TP53 codon 72 Arg/Pro, r21 codon 31 Ser/Arg, MDM2 SNP309) for the occurrence of CLL in patients who were exposed to ionizing radiation (IR) from the Chornobyl accident. Arginine 93-96 tumor protein p53 Homo sapiens 10-13 25536560-7 2014 The distribution of genotypes in patients with CLL did not differ from controls, except for reduced the frequency of homozygotes Arg/Arg TP53 among patients with CLL (p = 0.01). Arginine 129-132 tumor protein p53 Homo sapiens 137-141 25536560-7 2014 The distribution of genotypes in patients with CLL did not differ from controls, except for reduced the frequency of homozygotes Arg/Arg TP53 among patients with CLL (p = 0.01). Arginine 133-136 tumor protein p53 Homo sapiens 137-141 25177931-6 2014 TP53 72 showed the following genotypic distribution: the control group was 29.75% homozygous wild-type (Arg), 47.11% heterozygous (Arg-Pro), and 23.14% homozygous variant (Pro). Arginine 104-107 tumor protein p53 Homo sapiens 0-4 25177931-6 2014 TP53 72 showed the following genotypic distribution: the control group was 29.75% homozygous wild-type (Arg), 47.11% heterozygous (Arg-Pro), and 23.14% homozygous variant (Pro). Arginine 131-134 tumor protein p53 Homo sapiens 0-4 25177931-8 2014 Only one patient had the homozygous TP53 248 genotype (Arg-Trp/Gln); all other patients were homozygous wild-type in both the control and endometriosis groups (P = 0.51; NS). Arginine 55-58 tumor protein p53 Homo sapiens 36-40 24782034-9 2014 The most frequent genotype in both CIN(+) and CIN(-) patients was Arg/Pro TP53 codon 72 and A1A1 for 16-bp Del in intron 3. Arginine 66-69 tumor protein p53 Homo sapiens 74-78 23475592-2 2014 This SNP encodes either an arginine or proline at position 72 (R72P) of the p53 protein, which can alter the apoptotic activity of p53 via transcriptional and non-transcriptional mechanisms. Arginine 27-35 tumor protein p53 Homo sapiens 76-79 23475592-2 2014 This SNP encodes either an arginine or proline at position 72 (R72P) of the p53 protein, which can alter the apoptotic activity of p53 via transcriptional and non-transcriptional mechanisms. Arginine 27-35 tumor protein p53 Homo sapiens 131-134 29259398-9 2015 Conclusions: We conclude: the p53 codon 72*Arg/*Arg genotype, with its strong apoptotic effects, negatively influences spermatozoa motility and male fertility. Arginine 43-46 tumor protein p53 Homo sapiens 30-33 29259398-9 2015 Conclusions: We conclude: the p53 codon 72*Arg/*Arg genotype, with its strong apoptotic effects, negatively influences spermatozoa motility and male fertility. Arginine 48-51 tumor protein p53 Homo sapiens 30-33 24710610-2 2014 A common polymorphism of the encoding TP53 gene (codon 72, Pro > Arg, rs1042522) is associated with susceptibility to virus-related and other cancers. Arginine 68-71 tumor protein p53 Homo sapiens 38-42 24743655-7 2014 Several novel RNAi suppressors of Tp53 were identified, one of which, PRDM1beta (BLIMP-1), was confirmed to be an Arg-specific transcript. Arginine 114-117 tumor protein p53 Homo sapiens 34-38 24691905-5 2014 By employing homologous recombination, we introduced various combinations of missense mutations (lysine to arginine) into eight acetylation sites of the endogenous p53 gene in human embryonic stem cells (hESCs). Arginine 107-115 tumor protein p53 Homo sapiens 164-167 24474455-8 2014 The Arg72Pro-p53 polymorphism showed for the genotypes Arg/Pro and Pro/Pro, and for the Pro allele, a significant association only to the risk for CIN (p<0.03). Arginine 4-7 tumor protein p53 Homo sapiens 13-16 24710610-5 2014 The allele frequency of TP53 codon 72 Arg was 0.30 among 314 Ghanaian primiparae and 0.31 among 545 Rwandan children, respectively, and it was not associated with infection prevalence or parasite density. Arginine 38-41 tumor protein p53 Homo sapiens 24-28 26005655-3 2014 Although some studies have indicated an association between the TP53 Arg/Arg variant and an increased risk for prostate cancer, other studies have shown a positive correlation between the TP53 Pro/Pro genotype instead. Arginine 69-72 tumor protein p53 Homo sapiens 64-68 24625390-6 2014 In the event of pairwise combinations of the single nucleotide polymorphisms, a risk elevation was shown for MDM2 GG homozygotes/p53 wild-type Arg in hereditary melanoma (P=0.01). Arginine 143-146 tumor protein p53 Homo sapiens 129-132 24384472-8 2014 Through this study, we have provided the first evidence on the pivotal role of arginine 213 that determines the p53 mediated functions of p21 in human cancer cells. Arginine 79-87 tumor protein p53 Homo sapiens 112-115 24657665-3 2014 The G to T transversion at the third position of codon 249 (AGG) of the TP53 gene, substituting arginine to serine, is the most common aflatoxin-induced mutation linked to HCC. Arginine 96-104 tumor protein p53 Homo sapiens 72-76 24843801-7 2014 There is a statistically significant association between p53 codon 72 polymorphism and allergic asthma: Arg/Arg genotype is more represented in asthmatic patients than in controls (P=0.018). Arginine 104-107 tumor protein p53 Homo sapiens 57-60 24843801-7 2014 There is a statistically significant association between p53 codon 72 polymorphism and allergic asthma: Arg/Arg genotype is more represented in asthmatic patients than in controls (P=0.018). Arginine 108-111 tumor protein p53 Homo sapiens 57-60 24747975-0 2014 Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis. Arginine 48-51 tumor protein p53 Homo sapiens 35-38 24747975-3 2014 Therefore, we performed this meta-analysis to investigate the relation between p53 codon 72 Arg>Pro polymorphism and overall OC susceptibility. Arginine 92-95 tumor protein p53 Homo sapiens 79-82 24747975-4 2014 METHODS: We searched all eligible published studies based on the association between codon 72 of the p53 Arg>Pro polymorphism and risk of OC. Arginine 105-108 tumor protein p53 Homo sapiens 101-104 24747975-10 2014 CONCLUSIONS: This meta-analysis suggested that codon 72 of the p53 Arg>Pro polymorphism may not significantly contribute in ovary cancer susceptibility. Arginine 67-70 tumor protein p53 Homo sapiens 63-66 26005655-3 2014 Although some studies have indicated an association between the TP53 Arg/Arg variant and an increased risk for prostate cancer, other studies have shown a positive correlation between the TP53 Pro/Pro genotype instead. Arginine 73-76 tumor protein p53 Homo sapiens 64-68 24615009-7 2014 Notably, patients with TP53 mutation and the Pro72 allele experienced a 23.7-fold increase in hazard ratio (95% CI 3.38-165.9; P = 0.001) for OS compared with patients with wild-type p53 and those with the Arg/Arg genotype. Arginine 206-209 tumor protein p53 Homo sapiens 23-27 24615009-7 2014 Notably, patients with TP53 mutation and the Pro72 allele experienced a 23.7-fold increase in hazard ratio (95% CI 3.38-165.9; P = 0.001) for OS compared with patients with wild-type p53 and those with the Arg/Arg genotype. Arginine 210-213 tumor protein p53 Homo sapiens 23-27 24435975-7 2014 However, in a multivariate analysis adjusted for alcohol consumption, smoking, ethnicity, and number of pregnancies, the interaction between the genotypes TP53 Arg/Arg (rs1042522) and MDM2 TT (rs2279744) showed to be associated to RPL, increasing the risk for this condition (OR = 2.58, 95% CI: 1.31-5.07, p = 0.006). Arginine 160-163 tumor protein p53 Homo sapiens 155-159 24326769-0 2014 The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Arginine 52-55 tumor protein p53 Homo sapiens 40-43 24326769-2 2014 Polymorphism of p53 gene codon72 arginine (Arg)/proline (Pro) (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. Arginine 33-41 tumor protein p53 Homo sapiens 16-19 24326769-2 2014 Polymorphism of p53 gene codon72 arginine (Arg)/proline (Pro) (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. Arginine 33-41 tumor protein p53 Homo sapiens 104-107 24326769-2 2014 Polymorphism of p53 gene codon72 arginine (Arg)/proline (Pro) (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. Arginine 43-46 tumor protein p53 Homo sapiens 16-19 24326769-2 2014 Polymorphism of p53 gene codon72 arginine (Arg)/proline (Pro) (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. Arginine 43-46 tumor protein p53 Homo sapiens 104-107 24326769-3 2014 It has been suggested that p53 codon72 Arg/Pro polymorphism is associated with susceptibility to hepatocellular carcinoma (HCC). Arginine 39-42 tumor protein p53 Homo sapiens 27-30 24326769-10 2014 This meta-analysis suggests that p53 codon72 Arg/Pro polymorphism may be associated with the risk of HCC, especially in subgroup analysis of Asian and Caucasian population, hospital-based population, the female, and the individuals infected with hepatitis virus. Arginine 45-48 tumor protein p53 Homo sapiens 33-36 24435975-7 2014 However, in a multivariate analysis adjusted for alcohol consumption, smoking, ethnicity, and number of pregnancies, the interaction between the genotypes TP53 Arg/Arg (rs1042522) and MDM2 TT (rs2279744) showed to be associated to RPL, increasing the risk for this condition (OR = 2.58, 95% CI: 1.31-5.07, p = 0.006). Arginine 164-167 tumor protein p53 Homo sapiens 155-159 24435975-8 2014 In conclusion, our study indicates that the combination of TP53 Arg/Arg (rs1042522) and MDM2 TT (rs2279744) genotypes may be a risk factor for RPL. Arginine 64-67 tumor protein p53 Homo sapiens 59-63 24435975-8 2014 In conclusion, our study indicates that the combination of TP53 Arg/Arg (rs1042522) and MDM2 TT (rs2279744) genotypes may be a risk factor for RPL. Arginine 68-71 tumor protein p53 Homo sapiens 59-63 24761888-6 2014 Further, significant differences were observed in the p53 exon 8 mutations for the genetic polymorphisms of Lys/Arg for AhR (p=0.02, 95%CI: 0.70-15.86), Val/Val for CYP1A1 (p=0.04, 95%CI: 0.98-19.09) and null for GSTM1 (p=0.02, 95%CI: 1.19-6.26), respectively. Arginine 112-115 tumor protein p53 Homo sapiens 54-57 24366026-2 2014 The polymorphism in the p53 72nd codon involves a proline to arginine substitution, leading to changes in gene transcription activity, interaction with other proteins and modulation of apoptosis. Arginine 61-69 tumor protein p53 Homo sapiens 24-27 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 46-49 tumor protein p53 Homo sapiens 16-19 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 46-49 tumor protein p53 Homo sapiens 41-44 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 46-49 tumor protein p53 Homo sapiens 41-44 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 50-53 tumor protein p53 Homo sapiens 16-19 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 50-53 tumor protein p53 Homo sapiens 41-44 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 50-53 tumor protein p53 Homo sapiens 41-44 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 50-53 tumor protein p53 Homo sapiens 16-19 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 50-53 tumor protein p53 Homo sapiens 41-44 25422197-11 2014 The analysis of p53 72 SNP revealed that p53 (Arg/Arg), (Pro /Arg) variant are higher (40.59% and 33.66%) as compared to p53 pro/pro variant (25.74%) in the healthy population. Arginine 50-53 tumor protein p53 Homo sapiens 41-44 24587255-8 2014 We also demonstrated that cell lines bearing Pro/Pro homozygosity in codon72 of p53 exon4, which is important for NF-kappaB binding to p53, are more resistant to 5-FU than those with Arg/Arg homozygosity. Arginine 183-186 tumor protein p53 Homo sapiens 80-83 24587255-8 2014 We also demonstrated that cell lines bearing Pro/Pro homozygosity in codon72 of p53 exon4, which is important for NF-kappaB binding to p53, are more resistant to 5-FU than those with Arg/Arg homozygosity. Arginine 187-190 tumor protein p53 Homo sapiens 80-83 24333670-7 2014 Serine/arginine-rich splicing factor 3 was a promising candidate for the serine/arginine-rich splicing factors responsible for the alternative splicing of p53 in response to caffeine treatment. Arginine 7-15 tumor protein p53 Homo sapiens 155-158 25215298-6 2014 Moreover, we conducted p53 mutation analysis and revealed a mutation at codon 273 which led to the replacement of arginine by histidine. Arginine 114-122 tumor protein p53 Homo sapiens 23-26 25070816-0 2014 L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro. Arginine 0-10 tumor protein p53 Homo sapiens 106-109 25070816-6 2014 RESULTS AND CONCLUSIONS: L-arginine enhanced ADI-induced inhibited cell growth through expression of NF-kappaBp65 and p53 in a dose-dependent manner. Arginine 25-35 tumor protein p53 Homo sapiens 118-121 23860773-0 2013 P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis. Arginine 13-16 tumor protein p53 Homo sapiens 0-3 24376578-10 2013 In the MDM2 SNP309-TP53 R72P interaction analysis, we found that subjects with MDM2 309TT and TP53 Pro/Pro genotype, MDM2 309 TG and TP53 Arg/Pro genotype, and MDM2 309 GG and TP53 Pro/Pro genotype were associated with significantly increased risk of developing HCC as compared with the reference MDM2 309TT and TP53 Arg/Arg genotype. Arginine 138-141 tumor protein p53 Homo sapiens 19-23 25606382-0 2013 The association between polymorphism of P53 codon 72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3704 cases. Arginine 53-56 tumor protein p53 Homo sapiens 40-43 25606382-2 2013 Polymorphism of p53 gene codon 72 Arg/Pro (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. Arginine 34-37 tumor protein p53 Homo sapiens 16-19 25606382-2 2013 Polymorphism of p53 gene codon 72 Arg/Pro (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. Arginine 34-37 tumor protein p53 Homo sapiens 84-87 25606382-3 2013 It has been suggested that p53 codon 72 Arg/Pro polymorphism is associated with susceptibility to hepatocellular carcinoma (HCC). Arginine 40-43 tumor protein p53 Homo sapiens 27-30 25606382-10 2013 CONCLUSIONS/SIGNIFICANCE: This meta-analysis suggests that p53 codon 72 Arg/Pro polymorphism may be associated with the risk of HCC, especially in subgroup analysis of Asian and Caucasian population, hospital-based population, the female, and the individuals infected with hepatitis virus. Arginine 72-75 tumor protein p53 Homo sapiens 59-62 23812725-0 2013 P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis. Arginine 13-16 tumor protein p53 Homo sapiens 0-3 23812725-1 2013 The polymorphism of p53 codon 72, a transversion of G to C (Arg to Pro), has been demonstrated to be associated with the risk for lung cancer. Arginine 60-63 tumor protein p53 Homo sapiens 20-23 23837945-8 2013 RESULTS: Patients carrying p53 Arg/Arg or Arg/Pro had a higher risk of esophageal SCC (P<0.001, Odds ratio [OR] 4.98, 95% confidential interval [CI] 3.46-7.17), however, not found in MDM2 rs937283. Arginine 31-34 tumor protein p53 Homo sapiens 27-30 23837945-8 2013 RESULTS: Patients carrying p53 Arg/Arg or Arg/Pro had a higher risk of esophageal SCC (P<0.001, Odds ratio [OR] 4.98, 95% confidential interval [CI] 3.46-7.17), however, not found in MDM2 rs937283. Arginine 35-38 tumor protein p53 Homo sapiens 27-30 23837945-8 2013 RESULTS: Patients carrying p53 Arg/Arg or Arg/Pro had a higher risk of esophageal SCC (P<0.001, Odds ratio [OR] 4.98, 95% confidential interval [CI] 3.46-7.17), however, not found in MDM2 rs937283. Arginine 35-38 tumor protein p53 Homo sapiens 27-30 23837945-9 2013 The risk of esophageal SCC increased significantly among patients carrying p53 Arg/Arg, or Arg/Pro and HPV16-seropositivity (P<0.001, OR 9.33, 95% CI 5.44-16.0), but not for MDM2 rs937283. Arginine 79-82 tumor protein p53 Homo sapiens 75-78 23837945-11 2013 CONCLUSION: HPV16 seropositivity synergized with p53 Arg/Arg or Arg/Pro and increased ESCC risk, especially in smokers or drinkers. Arginine 53-56 tumor protein p53 Homo sapiens 49-52 23715779-9 2013 Concerning the histological types of lung cancer, the p53 codon 72 variant exerts risk effect on the lung carcinogenesis in patients with adenocarcinoma (OR Arg/Pro vs. Arg/Arg = 1.10, 95 % CI = 1.00-1.22, P OR = 0.048). Arginine 157-160 tumor protein p53 Homo sapiens 54-57 23715779-9 2013 Concerning the histological types of lung cancer, the p53 codon 72 variant exerts risk effect on the lung carcinogenesis in patients with adenocarcinoma (OR Arg/Pro vs. Arg/Arg = 1.10, 95 % CI = 1.00-1.22, P OR = 0.048). Arginine 169-172 tumor protein p53 Homo sapiens 54-57 23715779-9 2013 Concerning the histological types of lung cancer, the p53 codon 72 variant exerts risk effect on the lung carcinogenesis in patients with adenocarcinoma (OR Arg/Pro vs. Arg/Arg = 1.10, 95 % CI = 1.00-1.22, P OR = 0.048). Arginine 169-172 tumor protein p53 Homo sapiens 54-57 23715779-10 2013 Additionally, subgroup analysis by the smoking status demonstrated that the p53 codon 72 variant seemed to play a protective role in lung carcinogenesis among the non-smokers but not the smokers in the contrast model of Arg/Pro vs. Arg/Arg (OR Arg/Pro vs. Arg/Arg = 0.71, 95 % CI = 0.50-1.00, P OR = 0.049). Arginine 232-235 tumor protein p53 Homo sapiens 76-79 23715779-10 2013 Additionally, subgroup analysis by the smoking status demonstrated that the p53 codon 72 variant seemed to play a protective role in lung carcinogenesis among the non-smokers but not the smokers in the contrast model of Arg/Pro vs. Arg/Arg (OR Arg/Pro vs. Arg/Arg = 0.71, 95 % CI = 0.50-1.00, P OR = 0.049). Arginine 232-235 tumor protein p53 Homo sapiens 76-79 23715779-10 2013 Additionally, subgroup analysis by the smoking status demonstrated that the p53 codon 72 variant seemed to play a protective role in lung carcinogenesis among the non-smokers but not the smokers in the contrast model of Arg/Pro vs. Arg/Arg (OR Arg/Pro vs. Arg/Arg = 0.71, 95 % CI = 0.50-1.00, P OR = 0.049). Arginine 232-235 tumor protein p53 Homo sapiens 76-79 23715779-10 2013 Additionally, subgroup analysis by the smoking status demonstrated that the p53 codon 72 variant seemed to play a protective role in lung carcinogenesis among the non-smokers but not the smokers in the contrast model of Arg/Pro vs. Arg/Arg (OR Arg/Pro vs. Arg/Arg = 0.71, 95 % CI = 0.50-1.00, P OR = 0.049). Arginine 232-235 tumor protein p53 Homo sapiens 76-79 23715779-10 2013 Additionally, subgroup analysis by the smoking status demonstrated that the p53 codon 72 variant seemed to play a protective role in lung carcinogenesis among the non-smokers but not the smokers in the contrast model of Arg/Pro vs. Arg/Arg (OR Arg/Pro vs. Arg/Arg = 0.71, 95 % CI = 0.50-1.00, P OR = 0.049). Arginine 232-235 tumor protein p53 Homo sapiens 76-79 23812725-3 2013 Thus, we performed a meta-analysis by pooling all currently available case-control studies to estimate the effect of p53 codon 72 Arg/Pro polymorphism on the development of lung cancer. Arginine 130-133 tumor protein p53 Homo sapiens 117-120 23812725-6 2013 The overall OR for the dominant genetic model indicated that the p53 codon 72 Arg/Pro variant was positively correlated with lung cancer risk (ORArg/Pro + Pro/Pro vs. Arg/Arg = 1.14, 95 %CI 1.07-1.23, P OR < 0.001). Arginine 78-81 tumor protein p53 Homo sapiens 65-68 23812725-6 2013 The overall OR for the dominant genetic model indicated that the p53 codon 72 Arg/Pro variant was positively correlated with lung cancer risk (ORArg/Pro + Pro/Pro vs. Arg/Arg = 1.14, 95 %CI 1.07-1.23, P OR < 0.001). Arginine 145-148 tumor protein p53 Homo sapiens 65-68 23812725-6 2013 The overall OR for the dominant genetic model indicated that the p53 codon 72 Arg/Pro variant was positively correlated with lung cancer risk (ORArg/Pro + Pro/Pro vs. Arg/Arg = 1.14, 95 %CI 1.07-1.23, P OR < 0.001). Arginine 145-148 tumor protein p53 Homo sapiens 65-68 23812725-10 2013 The updated meta-analysis suggests that the p53 codon 72 Arg/Pro polymorphism is a risk factor for lung cancer in the Asian population. Arginine 57-60 tumor protein p53 Homo sapiens 44-47 23860773-1 2013 P53 codon 72 Arg/Pro is a C/G variation upstream of the p53 gene on human chromosome 17p13. Arginine 13-16 tumor protein p53 Homo sapiens 0-3 23860773-1 2013 P53 codon 72 Arg/Pro is a C/G variation upstream of the p53 gene on human chromosome 17p13. Arginine 13-16 tumor protein p53 Homo sapiens 56-59 23860773-2 2013 Many case-control studies have investigated the association between p53 codon 72 Arg/Pro polymorphism and glioma risk but provided inconsistent findings. Arginine 81-84 tumor protein p53 Homo sapiens 68-71 23860773-5 2013 The pooled odds ratio (OR) with 95 % confidence interval (95 % CI) was calculated to estimate the effect of p53 codon 72 Arg/Pro variant on the development of glioma. Arginine 121-124 tumor protein p53 Homo sapiens 108-111 23860773-9 2013 Our study suggests that the polymorphism of p53 codon 72 Arg/Pro may play a protective role in the development of glioblastoma. Arginine 57-60 tumor protein p53 Homo sapiens 44-47 23860773-10 2013 The relationship of p53 codon 72 Arg/Pro polymorphism with the susceptibility to glioma needs further estimation by more individual studies with high quality across ethnicities. Arginine 33-36 tumor protein p53 Homo sapiens 20-23 23483183-1 2013 PURPOSE: It was shown that individuals homozygous for the Arg-encoding allele of codon 72 TP53 gene may have an increased risk to human papillomavirus (HPV)-related cervical carcinomas. Arginine 58-61 tumor protein p53 Homo sapiens 90-94 24019961-2 2013 We previously reported that the proline 72 polymorphic variant of p53 (P72) demonstrates increased ability to transactivate a subset of genes, relative to arginine 72 (R72); one of these genes is macrophage colony stimulating factor (CSF1). Arginine 155-163 tumor protein p53 Homo sapiens 66-69 23483183-9 2013 RESULTS: The distribution of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of codon 72 of TP53 gene was: 63.3, 34.7, and 2.0 % in the cervical carcinomas and 58.1, 33.8, and 8.1 % in the control group. Arginine 29-32 tumor protein p53 Homo sapiens 84-88 23483183-9 2013 RESULTS: The distribution of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of codon 72 of TP53 gene was: 63.3, 34.7, and 2.0 % in the cervical carcinomas and 58.1, 33.8, and 8.1 % in the control group. Arginine 33-36 tumor protein p53 Homo sapiens 84-88 23483183-9 2013 RESULTS: The distribution of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of codon 72 of TP53 gene was: 63.3, 34.7, and 2.0 % in the cervical carcinomas and 58.1, 33.8, and 8.1 % in the control group. Arginine 33-36 tumor protein p53 Homo sapiens 84-88 23483183-11 2013 CONCLUSIONS: The results indicate that carriers of Arg allele of codon 72 TP53 gene have an increased risk for development of cervical carcinoma in Serbian women. Arginine 51-54 tumor protein p53 Homo sapiens 74-78 23683469-5 2013 The p53 gene contains a single nucleotide polymorphism at codon 72 of exon 4 which encodes either proline (Pro) or arginine (Arg). Arginine 115-123 tumor protein p53 Homo sapiens 4-7 23649769-1 2013 The close relationship between aflatoxins and 249ser TP53 gene mutation (AGG to AGT, Arg to Ser) in hepatocellular carcinoma (HCC) makes this mutation an indirect indicator of dietary contamination with this toxin. Arginine 85-88 tumor protein p53 Homo sapiens 53-57 23683469-5 2013 The p53 gene contains a single nucleotide polymorphism at codon 72 of exon 4 which encodes either proline (Pro) or arginine (Arg). Arginine 125-128 tumor protein p53 Homo sapiens 4-7 23632240-6 2013 The miR-34b/c CC-TP53 Arg/Arg combination significantly increased the risk of HCC (AOR: 13.644; 95% CI: 1.451-128.301). Arginine 22-25 tumor protein p53 Homo sapiens 17-21 23632240-6 2013 The miR-34b/c CC-TP53 Arg/Arg combination significantly increased the risk of HCC (AOR: 13.644; 95% CI: 1.451-128.301). Arginine 26-29 tumor protein p53 Homo sapiens 17-21 23632240-8 2013 CONCLUSIONS: Our findings suggest that loss of the T allele in miR-34b/c T>C, and the miR-34b/c CC-TP53 Arg/Arg combination increases the risk of HCC in the Korean population. Arginine 107-110 tumor protein p53 Homo sapiens 102-106 23632240-8 2013 CONCLUSIONS: Our findings suggest that loss of the T allele in miR-34b/c T>C, and the miR-34b/c CC-TP53 Arg/Arg combination increases the risk of HCC in the Korean population. Arginine 111-114 tumor protein p53 Homo sapiens 102-106 23793604-7 2013 The P53 Arg/Pro genotype or Pro/Pro genotype was significantly associated with an increased risk of developing breast cancer, compared to the P53 Arg/Arg genotype in both the case-control sets (all P < 0.05). Arginine 8-11 tumor protein p53 Homo sapiens 4-7 23564481-0 2013 Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Arginine 37-40 tumor protein p53 Homo sapiens 24-27 23624782-9 2013 The combination of SNP309 GG + TG and TP53 codon 72 Arg/Arg significantly increased endometrial cancer risk. Arginine 52-55 tumor protein p53 Homo sapiens 38-42 23624782-9 2013 The combination of SNP309 GG + TG and TP53 codon 72 Arg/Arg significantly increased endometrial cancer risk. Arginine 56-59 tumor protein p53 Homo sapiens 38-42 23624782-12 2013 The presence of the SNP309 G allele and TP53 codon 72 Arg/Arg genotype is associated with an increased risk of endometrial cancer in Japanese women. Arginine 54-57 tumor protein p53 Homo sapiens 40-44 23624782-12 2013 The presence of the SNP309 G allele and TP53 codon 72 Arg/Arg genotype is associated with an increased risk of endometrial cancer in Japanese women. Arginine 58-61 tumor protein p53 Homo sapiens 40-44 23564481-1 2013 Previous studies regarding the association of p53 codon 72 Arg/Pro polymorphism with hepatocellular carcinoma (HCC) risk have provided conflicting and inconclusive findings. Arginine 59-62 tumor protein p53 Homo sapiens 46-49 23564481-4 2013 The strength of the association of p53 codon 72 Arg/Pro polymorphism with HCC risk was estimated by the pooled odds ratio (OR) with its corresponding 95 % confidence interval (95 % CI). Arginine 48-51 tumor protein p53 Homo sapiens 35-38 23564481-9 2013 This meta-analysis suggests that the p53 codon 72 Arg/Pro polymorphism may play a critical role in the development of HCC, and gender and family history of HCC may not modulate the effect of p53 codon 72 Arg/Pro in HCC risk. Arginine 50-53 tumor protein p53 Homo sapiens 37-40 23522190-5 2013 The frequency of p53 protein degradation was also much higher in HPV 16/18 E6-positive/Arg/Arg lung tumors than in the other 3 groups. Arginine 87-90 tumor protein p53 Homo sapiens 17-20 23663243-1 2013 BACKGROUND: Codon 72 (Arg/Pro), the most frequently studied single nucleotide polymorphism (SNP) of p53 to date, is associated with the ability of the gene to induce cell apoptosis. Arginine 22-25 tumor protein p53 Homo sapiens 100-103 23639512-3 2013 The wild-type p53 codon has two common polymorphic variants from a single-base-pair substitution at codon 72, where either C-C-C encodes proline (p53-p72) or C-G-C encodes arginine (p53-R72). Arginine 172-180 tumor protein p53 Homo sapiens 14-17 23423487-5 2013 However, the TP53 codon 72 polymorphism had a prominent correlation with clinical outcome of patients receiving 5-fluorouracil (5-Fu)-based postoperative chemotherapy [Arg/Arg + Arg/Pro vs. Pro/Pro, adjusted hazard ratio (HR) = 1.63, 95 % confidence interval (CI) = 1.08-2.44]. Arginine 172-175 tumor protein p53 Homo sapiens 13-17 23423487-5 2013 However, the TP53 codon 72 polymorphism had a prominent correlation with clinical outcome of patients receiving 5-fluorouracil (5-Fu)-based postoperative chemotherapy [Arg/Arg + Arg/Pro vs. Pro/Pro, adjusted hazard ratio (HR) = 1.63, 95 % confidence interval (CI) = 1.08-2.44]. Arginine 172-175 tumor protein p53 Homo sapiens 13-17 23423487-5 2013 However, the TP53 codon 72 polymorphism had a prominent correlation with clinical outcome of patients receiving 5-fluorouracil (5-Fu)-based postoperative chemotherapy [Arg/Arg + Arg/Pro vs. Pro/Pro, adjusted hazard ratio (HR) = 1.63, 95 % confidence interval (CI) = 1.08-2.44]. Arginine 168-171 tumor protein p53 Homo sapiens 13-17 23184052-7 2013 Subgroup analyses by ethnicity showed that TP53 Arg72Pro polymorphism contributed to bladder cancer risk in East Asians in three genetic models (For Pro vs. Arg, Fixed-effects OR 1.18, 95 % CI 1.05-1.32; For ProPro vs. ArgArg, Fixed-effects OR 1.40, 95 % CI 1.11-1.77; For ProPro vs. ArgPro/ArgArg, Fixed-effects OR 1.32, 95 % CI 1.07-1.62). Arginine 48-51 tumor protein p53 Homo sapiens 43-47 23557559-14 2013 No p53 gene mutation was detected on the exon 4 - 9, and Pro/Arg SNPs on p53 codon 72 were detected in the cutaneous NK/T-cell lymphoma. Arginine 61-64 tumor protein p53 Homo sapiens 73-76 23433851-0 2013 Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia. Arginine 0-8 tumor protein p53 Homo sapiens 37-40 23192612-1 2013 Among many alterations within the TP53 gene the rs1042522 (C72G, p.Pro72Arg) has been associated with numerous cancers , however the results differ between populations for opposite Pro or Arg alleles. Arginine 72-75 tumor protein p53 Homo sapiens 34-38 23092908-7 2013 RESULTS: The distribution of Arg/Arg, Arg/Pro and Pro/Pro genotypes of codon 72 of the TP53 gene was: 46.8%, 46.8% and 6.4%, respectively in the ovarian carcinomas and 64.3%, 31.4% and 4.3%, respectively in the control group. Arginine 29-32 tumor protein p53 Homo sapiens 87-91 23192640-1 2013 The genetic polymorphism of p53 codon 72 Arg/Pro has been implicated in oral cancer risk, but the results of previous studies remain controversial and ambiguous. Arginine 41-44 tumor protein p53 Homo sapiens 28-31 23192640-2 2013 To estimate the effect of the p53 codon 72 Arg/Pro polymorphism on the risk of oral cancer, a meta-analysis was performed. Arginine 43-46 tumor protein p53 Homo sapiens 30-33 23192640-3 2013 Based on a comprehensive search in PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) databases, we identified all available publications assessing the association between p53 codon 72 Arg/Pro polymorphism and oral cancer risk. Arginine 217-220 tumor protein p53 Homo sapiens 204-207 23210739-3 2013 The frequencies of GG genotype at 309 position in the second promoter (P2) of MDM2 and Arginine in codon72 of p53 were found to be 3.5 (odds ratio [OR]=3.51; 95% confidence interval [CI]=1.93-6.4; p<0.0001) and 5 (OR=4.978; 95% CI=2.7-9.2; p<0.0001) fold higher, respectively, in cases than in the control. Arginine 87-95 tumor protein p53 Homo sapiens 110-113 23210739-4 2013 On gene-gene interactions between MDM2 and p53 polymorphisms, the frequency of MDM2 G/G and p53 Arg/Arg together was found to be 6.5-fold higher in cervical cancer patients compared with healthy controls (OR=6.497; 95% CI=2.987-14.13; p<0.0001). Arginine 96-99 tumor protein p53 Homo sapiens 43-46 23210739-4 2013 On gene-gene interactions between MDM2 and p53 polymorphisms, the frequency of MDM2 G/G and p53 Arg/Arg together was found to be 6.5-fold higher in cervical cancer patients compared with healthy controls (OR=6.497; 95% CI=2.987-14.13; p<0.0001). Arginine 96-99 tumor protein p53 Homo sapiens 92-95 23210739-4 2013 On gene-gene interactions between MDM2 and p53 polymorphisms, the frequency of MDM2 G/G and p53 Arg/Arg together was found to be 6.5-fold higher in cervical cancer patients compared with healthy controls (OR=6.497; 95% CI=2.987-14.13; p<0.0001). Arginine 100-103 tumor protein p53 Homo sapiens 43-46 23210739-4 2013 On gene-gene interactions between MDM2 and p53 polymorphisms, the frequency of MDM2 G/G and p53 Arg/Arg together was found to be 6.5-fold higher in cervical cancer patients compared with healthy controls (OR=6.497; 95% CI=2.987-14.13; p<0.0001). Arginine 100-103 tumor protein p53 Homo sapiens 92-95 23210739-5 2013 We found an association of p53 codon72 arginine and MDM2 SNP309 GG genotype with different clinical and histological grades, human papillomavirus (HPV) infection, and age at the time of diagnosis of cervical cancer. Arginine 39-47 tumor protein p53 Homo sapiens 27-30 23210739-6 2013 In conclusion, Arginine at codon72 of p53 and GG genotype at 309 in P2 of MDM2 together reveal a direct proportionality with the tumor grade of cervical cancer along with HPV infection in postmenopausal women. Arginine 15-23 tumor protein p53 Homo sapiens 38-41 23092908-7 2013 RESULTS: The distribution of Arg/Arg, Arg/Pro and Pro/Pro genotypes of codon 72 of the TP53 gene was: 46.8%, 46.8% and 6.4%, respectively in the ovarian carcinomas and 64.3%, 31.4% and 4.3%, respectively in the control group. Arginine 33-36 tumor protein p53 Homo sapiens 87-91 23092908-7 2013 RESULTS: The distribution of Arg/Arg, Arg/Pro and Pro/Pro genotypes of codon 72 of the TP53 gene was: 46.8%, 46.8% and 6.4%, respectively in the ovarian carcinomas and 64.3%, 31.4% and 4.3%, respectively in the control group. Arginine 33-36 tumor protein p53 Homo sapiens 87-91 23053979-0 2012 p53 Codon 72 arginine/proline polymorphism and cancer in Sudan. Arginine 13-21 tumor protein p53 Homo sapiens 0-3 23124863-1 2013 The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene in association with human papillomavirus (HPV) 16 E6 variants has been implicated as a risk marker in cervical neoplasia. Arginine 4-7 tumor protein p53 Homo sapiens 66-69 23124863-1 2013 The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene in association with human papillomavirus (HPV) 16 E6 variants has been implicated as a risk marker in cervical neoplasia. Arginine 8-11 tumor protein p53 Homo sapiens 66-69 23124863-1 2013 The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene in association with human papillomavirus (HPV) 16 E6 variants has been implicated as a risk marker in cervical neoplasia. Arginine 8-11 tumor protein p53 Homo sapiens 66-69 23124863-4 2013 The data obtained showed statistically significant different distribution of p53 genotypes between healthy controls and precursor lesions, with the p53 arginine homozygous increased in high-grade squamous intraepithelial lesions. Arginine 152-160 tumor protein p53 Homo sapiens 77-80 23124863-4 2013 The data obtained showed statistically significant different distribution of p53 genotypes between healthy controls and precursor lesions, with the p53 arginine homozygous increased in high-grade squamous intraepithelial lesions. Arginine 152-160 tumor protein p53 Homo sapiens 148-151 23124863-7 2013 In conclusion, p53 arginine homozygous was found to be increased in high-grade lesions, supporting the results of previous investigations indicating that HPV-positive patients with p53 Arg/Arg have an increased risk of developing pre-cancerous lesions. Arginine 19-27 tumor protein p53 Homo sapiens 15-18 23124863-7 2013 In conclusion, p53 arginine homozygous was found to be increased in high-grade lesions, supporting the results of previous investigations indicating that HPV-positive patients with p53 Arg/Arg have an increased risk of developing pre-cancerous lesions. Arginine 19-27 tumor protein p53 Homo sapiens 181-184 23124863-7 2013 In conclusion, p53 arginine homozygous was found to be increased in high-grade lesions, supporting the results of previous investigations indicating that HPV-positive patients with p53 Arg/Arg have an increased risk of developing pre-cancerous lesions. Arginine 185-188 tumor protein p53 Homo sapiens 15-18 23124863-7 2013 In conclusion, p53 arginine homozygous was found to be increased in high-grade lesions, supporting the results of previous investigations indicating that HPV-positive patients with p53 Arg/Arg have an increased risk of developing pre-cancerous lesions. Arginine 185-188 tumor protein p53 Homo sapiens 181-184 23124863-7 2013 In conclusion, p53 arginine homozygous was found to be increased in high-grade lesions, supporting the results of previous investigations indicating that HPV-positive patients with p53 Arg/Arg have an increased risk of developing pre-cancerous lesions. Arginine 189-192 tumor protein p53 Homo sapiens 15-18 23124863-7 2013 In conclusion, p53 arginine homozygous was found to be increased in high-grade lesions, supporting the results of previous investigations indicating that HPV-positive patients with p53 Arg/Arg have an increased risk of developing pre-cancerous lesions. Arginine 189-192 tumor protein p53 Homo sapiens 181-184 23124863-8 2013 In addition, T350G HPV 16 variant was over-represented in p53 Arg homozygous women with cervical lesions. Arginine 62-65 tumor protein p53 Homo sapiens 58-61 23469172-8 2013 Testing our method on models for the arginine catabolism and the negative feedback loop of the p53 signalling pathway, we found that it estimated the parameters with high accuracy and within a reasonable computation time compared to well-known approaches, including Particle Swarm Optimization, Nelder-Mead, and Firefly Algorithm. Arginine 37-45 tumor protein p53 Homo sapiens 95-98 23991369-2 2013 In human populations, the p53 gene contains a common single nucleotide polymorphism (SNP) affecting codon 72 that determines whether a proline (P72) or an arginine (R72) is present at this amino acid position of the polypeptide. Arginine 155-163 tumor protein p53 Homo sapiens 26-29 23053979-1 2012 The aim of this report is to determine frequencies and associations of p53 codon 72 arg/pro polymorphism with different types of cancer in Sudan. Arginine 84-87 tumor protein p53 Homo sapiens 71-74 23053979-2 2012 p53 codon72 arg/pro polymorphism distribution and allele frequencies in 264 samples of different types of cancers were investigated using PCR. Arginine 12-15 tumor protein p53 Homo sapiens 0-3 23053979-8 2012 We concluded that p53 arg/pro polymorphism has different pattern of frequency in different types of cancer among Sudanese patients, indicating perhaps different etiology and biology of these tumours. Arginine 22-25 tumor protein p53 Homo sapiens 18-21 22892830-1 2012 The Arg and Pro variants in p53 codon 72 were shown to have different regulation properties of p53-dependent DNA repair target genes that can affect various levels of cytogenetic aberrations in chronic hepatitis B patients. Arginine 4-7 tumor protein p53 Homo sapiens 28-31 22892830-1 2012 The Arg and Pro variants in p53 codon 72 were shown to have different regulation properties of p53-dependent DNA repair target genes that can affect various levels of cytogenetic aberrations in chronic hepatitis B patients. Arginine 4-7 tumor protein p53 Homo sapiens 95-98 22356895-9 2012 In contrast, the predictive utility of the 72 Arg/Pro SNP in p53 requires mutational analysis of p53, limiting its routine clinical use. Arginine 46-49 tumor protein p53 Homo sapiens 97-100 22692183-7 2012 p53 allele frequency for Arg/Arg was 43.6% (34/78), for Arg/Pro 37.2% (29/78) and for Pro/Pro 19.2% (15/78). Arginine 37-40 tumor protein p53 Homo sapiens 0-3 22692183-7 2012 p53 allele frequency for Arg/Arg was 43.6% (34/78), for Arg/Pro 37.2% (29/78) and for Pro/Pro 19.2% (15/78). Arginine 41-44 tumor protein p53 Homo sapiens 0-3 22692183-7 2012 p53 allele frequency for Arg/Arg was 43.6% (34/78), for Arg/Pro 37.2% (29/78) and for Pro/Pro 19.2% (15/78). Arginine 41-44 tumor protein p53 Homo sapiens 0-3 22692183-10 2012 Although the p53 arginine allele is itself an important risk factor for cervical cancer, the combined risk with LOH of Rb, which appears to be greater, might indicate a possible epistatic effect of the two genes/polymorphisms. Arginine 17-25 tumor protein p53 Homo sapiens 13-16 22707142-7 2012 Our study suggests that, among Asians, the p53 codon 72 Arg/Arg genotype is associated with a modestly decreased risk of gastric cancer, and that this difference in genotype distribution may be associated with cancer stage, location, differentiation and metastasis. Arginine 56-59 tumor protein p53 Homo sapiens 43-46 22707142-7 2012 Our study suggests that, among Asians, the p53 codon 72 Arg/Arg genotype is associated with a modestly decreased risk of gastric cancer, and that this difference in genotype distribution may be associated with cancer stage, location, differentiation and metastasis. Arginine 60-63 tumor protein p53 Homo sapiens 43-46 22052810-2 2012 A single nucleotide polymorphism of TP53 encoding either arginine or proline at codon 72 is suggested to alter in vitro p53 behavior. Arginine 57-65 tumor protein p53 Homo sapiens 36-40 22052810-2 2012 A single nucleotide polymorphism of TP53 encoding either arginine or proline at codon 72 is suggested to alter in vitro p53 behavior. Arginine 57-65 tumor protein p53 Homo sapiens 120-123 22249977-0 2012 Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Arginine 19-22 tumor protein p53 Homo sapiens 66-70 22356895-9 2012 In contrast, the predictive utility of the 72 Arg/Pro SNP in p53 requires mutational analysis of p53, limiting its routine clinical use. Arginine 46-49 tumor protein p53 Homo sapiens 61-64 22357201-2 2012 Among TP53 gene polymorphisms, the most studied is the G to C transversion in exon 4 at codon 72, which results in three distinct genotypes, Arg/Arg, Pro/Pro and Arg/Pro, each one encoding different p53 isoforms. Arginine 141-144 tumor protein p53 Homo sapiens 6-10 22258307-11 2012 CONCLUSION: This meta-analysis suggests that p53 codon 72 Pro/Pro + Arg/Pro genotypes are associated with increased risk of endometriosis in Asian. Arginine 68-71 tumor protein p53 Homo sapiens 45-48 21477265-9 2012 An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.19, 95% CI = 1.54-3.06) compared with the Arg/Arg genotype. Arginine 119-122 tumor protein p53 Homo sapiens 47-51 21477265-9 2012 An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.19, 95% CI = 1.54-3.06) compared with the Arg/Arg genotype. Arginine 123-126 tumor protein p53 Homo sapiens 47-51 22551548-6 2012 RESULTS: The analysis revealed a germline nonsense mutation in exon 8 at codon 306 of the codified region of the TP53 gene, causing a change of CGA to TGA (Arg Stop) in the proband, her mother, her cousin and her maternal uncle. Arginine 156-159 tumor protein p53 Homo sapiens 113-117 22357201-2 2012 Among TP53 gene polymorphisms, the most studied is the G to C transversion in exon 4 at codon 72, which results in three distinct genotypes, Arg/Arg, Pro/Pro and Arg/Pro, each one encoding different p53 isoforms. Arginine 145-148 tumor protein p53 Homo sapiens 6-10 22357201-2 2012 Among TP53 gene polymorphisms, the most studied is the G to C transversion in exon 4 at codon 72, which results in three distinct genotypes, Arg/Arg, Pro/Pro and Arg/Pro, each one encoding different p53 isoforms. Arginine 145-148 tumor protein p53 Homo sapiens 6-10 22357201-7 2012 In our population, p53 genotypes were in Hardy-Weinberg (HW) equilibrium (X2 HM less than 3.84), showing a predominance of arginine allele (total Arg allele frequency of 68%). Arginine 123-131 tumor protein p53 Homo sapiens 19-22 22357201-7 2012 In our population, p53 genotypes were in Hardy-Weinberg (HW) equilibrium (X2 HM less than 3.84), showing a predominance of arginine allele (total Arg allele frequency of 68%). Arginine 146-149 tumor protein p53 Homo sapiens 19-22 22210716-9 2012 Our study indicated that a high prevalence of the genotype Arg/Pro at the p53 codon 72 may contribute to susceptibility to OSCC, especially in combination with the use of carcinogenic tobacco-specific nitrosamine (TSNA)-rich toombak. Arginine 59-62 tumor protein p53 Homo sapiens 74-77 21607615-2 2012 A guanine (G)/cytosine (C) common single nucleotide polymorphism (SNP) at second position of codon 72 in exon 4 of p53 gene determines a arginine (Arg) to proline (Pro) (Arg72Pro) aminoacidic substitution within the proline-rich domain of p53 protein. Arginine 137-145 tumor protein p53 Homo sapiens 115-118 21607615-2 2012 A guanine (G)/cytosine (C) common single nucleotide polymorphism (SNP) at second position of codon 72 in exon 4 of p53 gene determines a arginine (Arg) to proline (Pro) (Arg72Pro) aminoacidic substitution within the proline-rich domain of p53 protein. Arginine 137-145 tumor protein p53 Homo sapiens 239-242 21607615-2 2012 A guanine (G)/cytosine (C) common single nucleotide polymorphism (SNP) at second position of codon 72 in exon 4 of p53 gene determines a arginine (Arg) to proline (Pro) (Arg72Pro) aminoacidic substitution within the proline-rich domain of p53 protein. Arginine 147-150 tumor protein p53 Homo sapiens 115-118 21607615-2 2012 A guanine (G)/cytosine (C) common single nucleotide polymorphism (SNP) at second position of codon 72 in exon 4 of p53 gene determines a arginine (Arg) to proline (Pro) (Arg72Pro) aminoacidic substitution within the proline-rich domain of p53 protein. Arginine 147-150 tumor protein p53 Homo sapiens 239-242 22289634-1 2012 Human TP53 gene is characterised by a polymorphism at codon 72 leading to an Arginine-to-Proline (R/P) substitution. Arginine 77-85 tumor protein p53 Homo sapiens 6-10 22901123-7 2012 RESULTS: Overall, a significant association was detected between the p53 Arg72Pro polymorphism and GC risk (Pro-allele vs. Arg-allele: OR=1.05, 95%CI=1.01-1.08; Pro/Pro vs. Arg/Arg: OR=1.13, 95%CI=1.04-1.22). Arginine 73-76 tumor protein p53 Homo sapiens 69-72 22901123-7 2012 RESULTS: Overall, a significant association was detected between the p53 Arg72Pro polymorphism and GC risk (Pro-allele vs. Arg-allele: OR=1.05, 95%CI=1.01-1.08; Pro/Pro vs. Arg/Arg: OR=1.13, 95%CI=1.04-1.22). Arginine 123-126 tumor protein p53 Homo sapiens 69-72 22901123-7 2012 RESULTS: Overall, a significant association was detected between the p53 Arg72Pro polymorphism and GC risk (Pro-allele vs. Arg-allele: OR=1.05, 95%CI=1.01-1.08; Pro/Pro vs. Arg/Arg: OR=1.13, 95%CI=1.04-1.22). Arginine 123-126 tumor protein p53 Homo sapiens 69-72 22901126-2 2012 Ser/Cys polymorphism in hOGG1 and Arg/Pro polymorphism in p53 among 124 patients with lung cancer and 128 normal people were detected using PCR-RFLP. Arginine 34-37 tumor protein p53 Homo sapiens 58-61 22103682-7 2012 We further demonstrate that the C-terminal glycine-arginine rich domain of nucleolin serves as the predominant binding domain for direct interaction with p53. Arginine 51-59 tumor protein p53 Homo sapiens 154-157 22103682-9 2012 Conversely, the adjacent glycine-arginine rich domain of nucleolin interacted with p53 causing a modest stimulatory effect on p53 ubiquitination. Arginine 33-41 tumor protein p53 Homo sapiens 83-86 22103682-9 2012 Conversely, the adjacent glycine-arginine rich domain of nucleolin interacted with p53 causing a modest stimulatory effect on p53 ubiquitination. Arginine 33-41 tumor protein p53 Homo sapiens 126-129 22502699-2 2012 A common single nucleotide polymorphism located within the proline rich region of TP53 gene at codon 72 in exon 4 encodes either proline or arginine. Arginine 140-148 tumor protein p53 Homo sapiens 82-86 22502699-3 2012 TP53 Arg 72 is more active than TP53 Pro 72 in inducing apoptosis. Arginine 5-8 tumor protein p53 Homo sapiens 0-4 22613405-1 2012 OBJECTIVE: The association between codon 72 polymorphism of the tumour protein p53 (TP53) gene - which results in a missense mutation of arginine (R) to proline (P) - and susceptibility to hepatocellular carcinoma (HCC) is controversial. Arginine 137-145 tumor protein p53 Homo sapiens 79-82 22613405-1 2012 OBJECTIVE: The association between codon 72 polymorphism of the tumour protein p53 (TP53) gene - which results in a missense mutation of arginine (R) to proline (P) - and susceptibility to hepatocellular carcinoma (HCC) is controversial. Arginine 137-145 tumor protein p53 Homo sapiens 84-88 23049825-3 2012 In this study we evaluate the association between a p53 variant functionally known to influence apoptosis (codon 72 Pro/Arg) and the subset of primary open angle glaucoma (POAG) patients with early loss of central visual field. Arginine 120-123 tumor protein p53 Homo sapiens 52-55 23071787-6 2012 The frequency of somatic TP53 inactivation was 25.4% in Arg/Arg, 20.9% in Arg/Pro, and 16.7% in Pro/Pro patients, which may reflect a higher selective pressure to mutate the Arg-allele. Arginine 56-59 tumor protein p53 Homo sapiens 25-29 23071787-6 2012 The frequency of somatic TP53 inactivation was 25.4% in Arg/Arg, 20.9% in Arg/Pro, and 16.7% in Pro/Pro patients, which may reflect a higher selective pressure to mutate the Arg-allele. Arginine 60-63 tumor protein p53 Homo sapiens 25-29 23071787-6 2012 The frequency of somatic TP53 inactivation was 25.4% in Arg/Arg, 20.9% in Arg/Pro, and 16.7% in Pro/Pro patients, which may reflect a higher selective pressure to mutate the Arg-allele. Arginine 60-63 tumor protein p53 Homo sapiens 25-29 23071787-6 2012 The frequency of somatic TP53 inactivation was 25.4% in Arg/Arg, 20.9% in Arg/Pro, and 16.7% in Pro/Pro patients, which may reflect a higher selective pressure to mutate the Arg-allele. Arginine 60-63 tumor protein p53 Homo sapiens 25-29 23049825-4 2012 METHODS: Genotypes for the p53 codon 72 polymorphism (Pro/Arg) were obtained for 264 POAG patients and 400 controls from the U.S. and in replication studies for 308 POAG patients and 178 controls from Australia (GIST). Arginine 58-61 tumor protein p53 Homo sapiens 27-30 22041521-9 2011 A functionally relevant p53 missense mutation in codon 273 of exon 8 [CGT (Arg) -> CAT (His)] was confirmed by direct sequencing. Arginine 75-78 tumor protein p53 Homo sapiens 24-27 21982800-6 2011 Subjects with the p53 Arg/Pro + Pro/Pro genotype or MDM2 SNP309 TG+GG genotype, in conjunction with high urinary total arsenic (>=14.02mug/L), had a signicantly higher RCC risk than those with the p53 Arg/Arg or MDM2 SNP309 TT genotypes and low urinary total arsenic. Arginine 22-25 tumor protein p53 Homo sapiens 18-21 21595775-4 2011 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in EC were 39.4%, 45.6%, and 15.0%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively. Arginine 47-50 tumor protein p53 Homo sapiens 19-22 21595775-4 2011 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in EC were 39.4%, 45.6%, and 15.0%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively. Arginine 51-54 tumor protein p53 Homo sapiens 19-22 21595775-4 2011 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in EC were 39.4%, 45.6%, and 15.0%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively. Arginine 51-54 tumor protein p53 Homo sapiens 19-22 22395499-10 2012 Frequency of Arg/Arg genotype of p53 gene was higher among cases (43%) compared with controls (33.3%), but the difference was not statistically significant (p=0.75). Arginine 13-16 tumor protein p53 Homo sapiens 33-36 22395499-10 2012 Frequency of Arg/Arg genotype of p53 gene was higher among cases (43%) compared with controls (33.3%), but the difference was not statistically significant (p=0.75). Arginine 17-20 tumor protein p53 Homo sapiens 33-36 22057999-9 2011 Meta-analysis results showed that the Pro allele and Pro carrier (Arg/Pro + Pro/Pro) of p53 codon 72 polymorphism were significantly related with endometrial cancer risk (OR = 1.25, 95%CI = 1.10-1.41, P = 0.0005; OR = 1.34, 95%CI = 1.12-1.59, P = 0.001, respectively). Arginine 67-70 tumor protein p53 Homo sapiens 89-92 22057999-11 2011 We concluded that the Pro allele (Arg/Pro + Pro/Pro) of p53 codon 72 polymorphism is a potential risk factor for endometrial cancer. Arginine 35-38 tumor protein p53 Homo sapiens 57-60 21626334-6 2011 This mutation causes a nonsense mutation (Arg-to-Stop codon) that has been shown to attenuate p53 function. Arginine 42-45 tumor protein p53 Homo sapiens 94-97 22331725-11 2011 The distribution of codon 72 TP53 genotypes was: Arg/Arg 38.5%, Arg/Pro 50.0%, Pro/Pro 11.5%. Arginine 49-52 tumor protein p53 Homo sapiens 29-33 21316118-4 2011 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in LC were 37.0%, 46.2%, and 16.7%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively (p<0.01). Arginine 47-50 tumor protein p53 Homo sapiens 19-22 21316118-4 2011 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in LC were 37.0%, 46.2%, and 16.7%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively (p<0.01). Arginine 51-54 tumor protein p53 Homo sapiens 19-22 21316118-4 2011 The frequencies of p53 codon 72 polymorphisms (Arg/Arg, Arg/Pro, and Pro/Pro) in LC were 37.0%, 46.2%, and 16.7%, respectively; frequencies in the controls were 43.2%, 45.6%, and 11.2%, respectively (p<0.01). Arginine 51-54 tumor protein p53 Homo sapiens 19-22 21461655-5 2011 RESULTS: The frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of the p53 codon 72 polymorphism were 43.3, 42.0, and 13.0% in the gastric cancer patients; 40.5, 45.0, and 14.0% in the colorectal cancer patients; and 43.2, 45.6, and 11.2% in the controls, respectively. Arginine 28-31 tumor protein p53 Homo sapiens 75-78 21461655-5 2011 RESULTS: The frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of the p53 codon 72 polymorphism were 43.3, 42.0, and 13.0% in the gastric cancer patients; 40.5, 45.0, and 14.0% in the colorectal cancer patients; and 43.2, 45.6, and 11.2% in the controls, respectively. Arginine 32-35 tumor protein p53 Homo sapiens 75-78 21461655-5 2011 RESULTS: The frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes of the p53 codon 72 polymorphism were 43.3, 42.0, and 13.0% in the gastric cancer patients; 40.5, 45.0, and 14.0% in the colorectal cancer patients; and 43.2, 45.6, and 11.2% in the controls, respectively. Arginine 32-35 tumor protein p53 Homo sapiens 75-78 21892948-10 2011 The mutation results in substitution of arginine for the highly conserved glycine at residue 199 located at the p53 dimer-dimer interface. Arginine 40-48 tumor protein p53 Homo sapiens 112-115 21843334-1 2011 BACKGROUND: Single-nucleotide polymorphisms within TP53 gene (codon 72 exon 4, rs1042522, encoding either arginine or proline) and MDM2 promoter (SNP309; rs2279744), have been independently associated with increased risk of several cancer types. Arginine 106-114 tumor protein p53 Homo sapiens 51-55 21402718-3 2011 By using human p53 knockin (Hupki) mice carrying a single nucleotide polymorphism (SNP) at codon 72 (arginine/proline), the arginine allele was demonstrated to produce higher uterine LIF levels during implantation than the proline allele. Arginine 124-132 tumor protein p53 Homo sapiens 15-18 21402718-4 2011 In humans, the diversity of haplotypes of the p53 gene has decreased during evolution, because the arginine allele, existing in only a subset of haplotypes, is under positive selection. Arginine 99-107 tumor protein p53 Homo sapiens 46-49 21454683-1 2011 The common polymorphism of p53 at codon 72, either encoding proline or arginine, has drawn attention as a genetic factor associated with clinical outcome or cancer risk for the last 2 decades. Arginine 71-79 tumor protein p53 Homo sapiens 27-30 21454683-3 2011 The arginine form (p53-72R) shows significantly enhanced phosphorylation at Ser-6 and Ser-20 compared with the proline form (p53-72P). Arginine 4-12 tumor protein p53 Homo sapiens 19-22 21454683-3 2011 The arginine form (p53-72R) shows significantly enhanced phosphorylation at Ser-6 and Ser-20 compared with the proline form (p53-72P). Arginine 4-12 tumor protein p53 Homo sapiens 125-128 21146884-4 2011 The association between BMI and diabetes depends on p53 polymorphism: Odds Ratio shows a high significant association between BMI and diabetes in *Arg/*Arg subjects (p=0.00001). Arginine 147-150 tumor protein p53 Homo sapiens 52-55 20729006-5 2011 RESULTS: We found that the P53 72Arg/Arg genotype was associated with increased RP risk compared with the 72Pro/Pro genotype. Arginine 33-36 tumor protein p53 Homo sapiens 27-30 21448430-5 2011 Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Arginine 72-75 tumor protein p53 Homo sapiens 53-57 21448430-5 2011 Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Arginine 76-79 tumor protein p53 Homo sapiens 53-57 21448430-5 2011 Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Arginine 76-79 tumor protein p53 Homo sapiens 53-57 21043833-10 2011 Interactions of betel quid with p53 genotypes in lung cancer showed significant increase for all the three genotypes, indicating a major role of betel quid (OR=5.90, CI=1.67-20.81, p=0.006; OR=5.44, CI=1.67-17.75, p=0.005; and OR=5.84, CI=1.70-19.97, p=0.005 for Arg/Arg, Arg/Pro, and Pro/Pro, respectively). Arginine 263-266 tumor protein p53 Homo sapiens 32-35 21043833-10 2011 Interactions of betel quid with p53 genotypes in lung cancer showed significant increase for all the three genotypes, indicating a major role of betel quid (OR=5.90, CI=1.67-20.81, p=0.006; OR=5.44, CI=1.67-17.75, p=0.005; and OR=5.84, CI=1.70-19.97, p=0.005 for Arg/Arg, Arg/Pro, and Pro/Pro, respectively). Arginine 267-270 tumor protein p53 Homo sapiens 32-35 21043833-10 2011 Interactions of betel quid with p53 genotypes in lung cancer showed significant increase for all the three genotypes, indicating a major role of betel quid (OR=5.90, CI=1.67-20.81, p=0.006; OR=5.44, CI=1.67-17.75, p=0.005; and OR=5.84, CI=1.70-19.97, p=0.005 for Arg/Arg, Arg/Pro, and Pro/Pro, respectively). Arginine 267-270 tumor protein p53 Homo sapiens 32-35 21454715-7 2011 A citrulline-mimicking Arg-NLS-Gln ING4 mutant, which has all Arg residues in the NLS mutated to Gln, loses its affinity for p53, can no longer promote p53 acetylation, and results in repression of downstream p21 expression. Arginine 23-26 tumor protein p53 Homo sapiens 125-128 21454715-7 2011 A citrulline-mimicking Arg-NLS-Gln ING4 mutant, which has all Arg residues in the NLS mutated to Gln, loses its affinity for p53, can no longer promote p53 acetylation, and results in repression of downstream p21 expression. Arginine 23-26 tumor protein p53 Homo sapiens 152-155 21291320-10 2011 CONCLUSIONS: These data suggest that the p53 codon 72 Arg/Arg genotype and Arg allele are associated with a lower risk of bladder cancer in Chinese population. Arginine 54-57 tumor protein p53 Homo sapiens 41-44 21291320-10 2011 CONCLUSIONS: These data suggest that the p53 codon 72 Arg/Arg genotype and Arg allele are associated with a lower risk of bladder cancer in Chinese population. Arginine 58-61 tumor protein p53 Homo sapiens 41-44 21291320-10 2011 CONCLUSIONS: These data suggest that the p53 codon 72 Arg/Arg genotype and Arg allele are associated with a lower risk of bladder cancer in Chinese population. Arginine 58-61 tumor protein p53 Homo sapiens 41-44 21357744-3 2011 The p53 tumor suppressor protein, an important transcriptional regulator of apoptosis, naturally occurs in humans in two variants with single nucleotide polymorphisms resulting in Arg or Pro at residue 72. Arginine 180-183 tumor protein p53 Homo sapiens 4-7 21357744-6 2011 In primary cultured neurons, Arg(72)-p53, but not Pro(72)-p53, interacted directly with mitochondrial Bcl-xL and activated the intrinsic apoptotic pathway, increasing vulnerability to ischemia-induced apoptotic cell death. Arginine 29-32 tumor protein p53 Homo sapiens 37-40 21357744-7 2011 These results suggest that the Tp53 Arg/Arg genotype governs neuronal vulnerability to apoptosis and can be considered as a genetic marker predicting poor functional outcome after stroke. Arginine 36-39 tumor protein p53 Homo sapiens 31-35 21357744-7 2011 These results suggest that the Tp53 Arg/Arg genotype governs neuronal vulnerability to apoptosis and can be considered as a genetic marker predicting poor functional outcome after stroke. Arginine 40-43 tumor protein p53 Homo sapiens 31-35 21123835-3 2011 Furthermore, prior research suggests that TP53 mutations preferentially occur on the arginine allele to selectively inactivate the p63 pathway. Arginine 85-93 tumor protein p53 Homo sapiens 42-46 21146884-4 2011 The association between BMI and diabetes depends on p53 polymorphism: Odds Ratio shows a high significant association between BMI and diabetes in *Arg/*Arg subjects (p=0.00001). Arginine 152-155 tumor protein p53 Homo sapiens 52-55 22393962-7 2011 CONCLUSIONS: Our results suggest that the codon 72 SNP which results in amino acid substitution of Arginine to Proline in cell cycle regulatory gene P53, is associated with sporadic CRC risk and carriers of Pro/Pro genotype and more than 50 years old may have high susceptibility. Arginine 99-107 tumor protein p53 Homo sapiens 149-152 22292621-2 2011 In exon 4 of the gene TP53, a codon 72 polymorphism causing an Arg/Pro substitution has been reported in breast and other cancers. Arginine 63-66 tumor protein p53 Homo sapiens 22-26 20419384-4 2011 PCR amplification for the analysis of p53 codon 72 arginine/proline alleles was carried out in a separate reaction. Arginine 51-59 tumor protein p53 Homo sapiens 38-41 21245169-8 2011 Recruitment of BRCA1 to the p53-binding region of the p21 promoter in response to DNA damage required methylation of Arg 754 of p300 by CARM1. Arginine 117-120 tumor protein p53 Homo sapiens 28-31 21598212-6 2011 PCR amplification of TP53 codon 72 polymorphism: TP53 codon 72 genotypes were detected by PCR using specific primer pairs for amplifying the proline or the arginine Alleles. Arginine 156-164 tumor protein p53 Homo sapiens 49-53 21598212-13 2011 In control samples, the genotype distribution for TP53 polymorphism showed 30.4%, 45.2% and 24.4% for the arginine/arginine, arginine/proline and proline/proline genotypes, respectively. Arginine 106-114 tumor protein p53 Homo sapiens 50-54 21598212-13 2011 In control samples, the genotype distribution for TP53 polymorphism showed 30.4%, 45.2% and 24.4% for the arginine/arginine, arginine/proline and proline/proline genotypes, respectively. Arginine 115-123 tumor protein p53 Homo sapiens 50-54 21598212-13 2011 In control samples, the genotype distribution for TP53 polymorphism showed 30.4%, 45.2% and 24.4% for the arginine/arginine, arginine/proline and proline/proline genotypes, respectively. Arginine 115-123 tumor protein p53 Homo sapiens 50-54 21598212-18 2011 Overexpression of p53 was observed in 50.8 percent of cancer specimens which most of them were arginine/arginine genotype (P<0.001). Arginine 95-103 tumor protein p53 Homo sapiens 18-21 21598212-18 2011 Overexpression of p53 was observed in 50.8 percent of cancer specimens which most of them were arginine/arginine genotype (P<0.001). Arginine 104-112 tumor protein p53 Homo sapiens 18-21 21672450-4 2011 However, only few reports have shown an association between the Arginine (R) variant at position 52 of p53 and increased susceptibility to HPV E6 mediated degradation and thus to increased cancer susceptibility. Arginine 64-72 tumor protein p53 Homo sapiens 103-106 21672450-7 2011 This variant seems to be differently segregated in different ethnic/geographical locations; therefore, there might be a possible role of this genetic variant associated with a certain genetic background, which can explain why some studies reveal increased risk of cervical cancer development associated with Arginine p53 variant. Arginine 308-316 tumor protein p53 Homo sapiens 317-320 21790217-3 2011 The ERE-linked p53 gene with the proline variant at codon 72 showed lower transfection rates than the gene without ERE or with the arginine variant at codon 72. Arginine 131-139 tumor protein p53 Homo sapiens 15-18 22212723-4 2011 RESULTS: In subjects with the *Arg/*Arg genotype of p53 codon 72, no association was observed between CAD and PTPN22. Arginine 31-34 tumor protein p53 Homo sapiens 52-55 22101376-8 2011 The individuals carrying the heterozygous genotype (Arg/Trp-Arg/Gln) in the p53 codon 248 polymorphism showed high BC risk (p < 0.001). Arginine 52-55 tumor protein p53 Homo sapiens 76-79 22101376-8 2011 The individuals carrying the heterozygous genotype (Arg/Trp-Arg/Gln) in the p53 codon 248 polymorphism showed high BC risk (p < 0.001). Arginine 60-63 tumor protein p53 Homo sapiens 76-79 22212723-4 2011 RESULTS: In subjects with the *Arg/*Arg genotype of p53 codon 72, no association was observed between CAD and PTPN22. Arginine 36-39 tumor protein p53 Homo sapiens 52-55 20935061-5 2010 Stratification analyses showed that a reduced risk associated with the -606CC genotype was more pronounced in subgroups of non-smokers, non-drinkers, younger subjects (defined as <=57 years), carriers of the TP53 Arg/Arg (rs1042522) genotype, patients with oropharyngeal cancer or late-stage SCCHN. Arginine 216-219 tumor protein p53 Homo sapiens 211-215 21932578-5 2011 A large increase of p53 *Arg/*Arg was observed in T1D patients with age at onset < 6 years. Arginine 25-28 tumor protein p53 Homo sapiens 20-23 21932578-5 2011 A large increase of p53 *Arg/*Arg was observed in T1D patients with age at onset < 6 years. Arginine 30-33 tumor protein p53 Homo sapiens 20-23 20935061-5 2010 Stratification analyses showed that a reduced risk associated with the -606CC genotype was more pronounced in subgroups of non-smokers, non-drinkers, younger subjects (defined as <=57 years), carriers of the TP53 Arg/Arg (rs1042522) genotype, patients with oropharyngeal cancer or late-stage SCCHN. Arginine 220-223 tumor protein p53 Homo sapiens 211-215 20309662-2 2010 The most commonly and extensively studied single nucleotide polymorphism (SNP) of p53 is Arg>Pro substitution on codon 72 (R72P). Arginine 89-92 tumor protein p53 Homo sapiens 82-85 20427142-1 2010 A common polymorphism at codon 72 of human TP53 gene determines a proline to arginine aminoacidic substitution within the proline-rich domain of p53 protein. Arginine 77-85 tumor protein p53 Homo sapiens 43-47 21384570-2 2010 The p53 gene is characterized by Arg/Pro polymorphism in codon 72 whose alleles exhibit differential functional activity. Arginine 33-36 tumor protein p53 Homo sapiens 4-7 21086258-6 2010 The genotype p53Arg Arg was associated with a low risk for thyroid cancer (OR = 0.15; P < 0.0001), indicating that the arginine allele in homozygosis could have a protective effect against carcinogenesis. Arginine 122-130 tumor protein p53 Homo sapiens 13-16 20427142-1 2010 A common polymorphism at codon 72 of human TP53 gene determines a proline to arginine aminoacidic substitution within the proline-rich domain of p53 protein. Arginine 77-85 tumor protein p53 Homo sapiens 145-148 20427142-9 2010 Because of the presence of arginine, a selective trypsin proteolytic cleavage at R(72), giving rise to two selective shorter peptides, occurred in p53R(72), but was missing in the case of p53P(72) trypsin digest, in which an uncleaved longer peptide was instead identified. Arginine 27-35 tumor protein p53 Homo sapiens 147-150 20538734-2 2010 Although its metabolites bind at several positions in TP53, a mutation at codon 249 (AGG to AGT, arginine to serine, p.R249S) accounts for 90% of TP53 mutations in AFB(1)-related HCC. Arginine 97-105 tumor protein p53 Homo sapiens 146-150 20577877-1 2010 The TP53 tumor suppressor gene contains a well-studied polymorphism that encodes either proline (P) or arginine (R) at codon 72, and over half of the world"s population is homozygous for R at this codon. Arginine 103-111 tumor protein p53 Homo sapiens 4-8 20532936-3 2010 Polymorphisms at codon 72 of p53 (arginine (Arg72) to proline transition) confers differences in mitochondrial translocation and apoptosis inducing capabilities of p53 in vitro. Arginine 34-42 tumor protein p53 Homo sapiens 29-32 20532936-3 2010 Polymorphisms at codon 72 of p53 (arginine (Arg72) to proline transition) confers differences in mitochondrial translocation and apoptosis inducing capabilities of p53 in vitro. Arginine 34-42 tumor protein p53 Homo sapiens 164-167 20732856-4 2010 We observed an increased risk of cervical cancer associated with the p53 Arg/Arg (OR, 2.25; 95% CI, 1.11-4.54) or p21 Ser/Ser (OR, 2.09; 95% CI, 1.04-4.19) genotype, compared with the p53 Pro/Pro or p21 Arg/Arg genotype, respectively. Arginine 73-76 tumor protein p53 Homo sapiens 69-72 20732856-4 2010 We observed an increased risk of cervical cancer associated with the p53 Arg/Arg (OR, 2.25; 95% CI, 1.11-4.54) or p21 Ser/Ser (OR, 2.09; 95% CI, 1.04-4.19) genotype, compared with the p53 Pro/Pro or p21 Arg/Arg genotype, respectively. Arginine 77-80 tumor protein p53 Homo sapiens 69-72 20703075-4 2010 We previously reported that the highly conserved p53 Arg(R)-174 is substituted by lysine (K) in Spalax, identical to a tumor-associated mutation. Arginine 53-56 tumor protein p53 Homo sapiens 49-52 19851859-12 2010 All the HPV-positive cases were homozygous for arginine at TP53 codon 72, a genotype associated with HPV-related cancer risk, and the tumors showed p16(INK4A) immunostaining, a marker of HPV-associated cancers. Arginine 47-55 tumor protein p53 Homo sapiens 59-63 20412452-4 2010 Therefore, P53 Arg is an ameloblastoma-susceptible allele [OR (95% CI) = 2.06 (1.28-3.31), P = 0.002]. Arginine 15-18 tumor protein p53 Homo sapiens 11-14 20412452-6 2010 Therefore, the increased risk associated with P53 Arg may not be influenced by either the sex of patients or clinical characteristics of the tumours. Arginine 50-53 tumor protein p53 Homo sapiens 46-49 20412452-7 2010 Moreover, when compared with homozygous P53 Pro, people who carried the Arg allele had a remarkably high risk of developing ameloblastoma [adjusted OR (95% CI) = 7.26 (2.34-23.41), P < 10(-3)]. Arginine 72-75 tumor protein p53 Homo sapiens 40-43 20412452-8 2010 CONCLUSION: The Arg allele of P53 gene codon 72 may increase susceptibility, and P53 may be important in the aetiology of ameloblastoma. Arginine 16-19 tumor protein p53 Homo sapiens 30-33 20732856-4 2010 We observed an increased risk of cervical cancer associated with the p53 Arg/Arg (OR, 2.25; 95% CI, 1.11-4.54) or p21 Ser/Ser (OR, 2.09; 95% CI, 1.04-4.19) genotype, compared with the p53 Pro/Pro or p21 Arg/Arg genotype, respectively. Arginine 77-80 tumor protein p53 Homo sapiens 69-72 20732856-4 2010 We observed an increased risk of cervical cancer associated with the p53 Arg/Arg (OR, 2.25; 95% CI, 1.11-4.54) or p21 Ser/Ser (OR, 2.09; 95% CI, 1.04-4.19) genotype, compared with the p53 Pro/Pro or p21 Arg/Arg genotype, respectively. Arginine 77-80 tumor protein p53 Homo sapiens 69-72 20732856-5 2010 In additional, interaction between these p53 and p21 polymorphisms increased the risk of cervical cancer in a multiplicative manner, with the OR being 3.96 (95% CI, 1.51-10.41) for subjects carrying both p53 Arg/Arg and p21 Ser/Ser genotypes. Arginine 208-211 tumor protein p53 Homo sapiens 41-44 20732856-5 2010 In additional, interaction between these p53 and p21 polymorphisms increased the risk of cervical cancer in a multiplicative manner, with the OR being 3.96 (95% CI, 1.51-10.41) for subjects carrying both p53 Arg/Arg and p21 Ser/Ser genotypes. Arginine 208-211 tumor protein p53 Homo sapiens 204-207 20732856-5 2010 In additional, interaction between these p53 and p21 polymorphisms increased the risk of cervical cancer in a multiplicative manner, with the OR being 3.96 (95% CI, 1.51-10.41) for subjects carrying both p53 Arg/Arg and p21 Ser/Ser genotypes. Arginine 212-215 tumor protein p53 Homo sapiens 41-44 20732856-5 2010 In additional, interaction between these p53 and p21 polymorphisms increased the risk of cervical cancer in a multiplicative manner, with the OR being 3.96 (95% CI, 1.51-10.41) for subjects carrying both p53 Arg/Arg and p21 Ser/Ser genotypes. Arginine 212-215 tumor protein p53 Homo sapiens 204-207 20827430-4 2010 However, we found that the p53 Arg72Pro was associated with an increased risk of esophageal cancer ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.20, 95%CI=1.06-1.36) without any between-study heterogeneity. Arginine 31-34 tumor protein p53 Homo sapiens 27-30 20827430-4 2010 However, we found that the p53 Arg72Pro was associated with an increased risk of esophageal cancer ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.20, 95%CI=1.06-1.36) without any between-study heterogeneity. Arginine 105-108 tumor protein p53 Homo sapiens 27-30 20827430-4 2010 However, we found that the p53 Arg72Pro was associated with an increased risk of esophageal cancer ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.20, 95%CI=1.06-1.36) without any between-study heterogeneity. Arginine 105-108 tumor protein p53 Homo sapiens 27-30 20827430-5 2010 In the stratified analysis by ethnicity, we found that the increased esophageal cancer risk associated with p53 Arg72Pro polymorphism was more evident in Asian group ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.35, 95%CI=1.14-1.60, P=0.09 for heterogeneity test), although we still failed to find any significant association between GSTP1 Ile105Val polymorphism and esophageal cancer risk in different ethnicity. Arginine 112-115 tumor protein p53 Homo sapiens 108-111 20827430-5 2010 In the stratified analysis by ethnicity, we found that the increased esophageal cancer risk associated with p53 Arg72Pro polymorphism was more evident in Asian group ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.35, 95%CI=1.14-1.60, P=0.09 for heterogeneity test), although we still failed to find any significant association between GSTP1 Ile105Val polymorphism and esophageal cancer risk in different ethnicity. Arginine 172-175 tumor protein p53 Homo sapiens 108-111 20827430-5 2010 In the stratified analysis by ethnicity, we found that the increased esophageal cancer risk associated with p53 Arg72Pro polymorphism was more evident in Asian group ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.35, 95%CI=1.14-1.60, P=0.09 for heterogeneity test), although we still failed to find any significant association between GSTP1 Ile105Val polymorphism and esophageal cancer risk in different ethnicity. Arginine 172-175 tumor protein p53 Homo sapiens 108-111 19771536-4 2010 The purpose of this study was to examine whether p53 Arg at the polymorphic position 72 could represents a risk factor for women with high-risk HPV-associated malignant cervical lesions. Arginine 53-56 tumor protein p53 Homo sapiens 49-52 20630574-8 2010 However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians. Arginine 97-100 tumor protein p53 Homo sapiens 78-82 20630574-8 2010 However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians. Arginine 101-104 tumor protein p53 Homo sapiens 78-82 20630574-8 2010 However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians. Arginine 101-104 tumor protein p53 Homo sapiens 78-82 20630574-8 2010 However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians. Arginine 101-104 tumor protein p53 Homo sapiens 78-82 20630574-8 2010 However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians. Arginine 101-104 tumor protein p53 Homo sapiens 78-82 20512840-3 2010 Actually, polymorphic variants Arg and Pro were found to have different properties of regulation of TP53-dependent DNA repair target genes, that can effect various levels of chromosome aberrations in cancer patients with these genotypes. Arginine 31-34 tumor protein p53 Homo sapiens 100-104 20421238-6 2010 We identified a novel germ line variant of the 177 mutant (Pro to Arg; P177R) of p53 by genomic sequencing. Arginine 66-69 tumor protein p53 Homo sapiens 81-84 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 195-198 tumor protein p53 Homo sapiens 23-26 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 195-198 tumor protein p53 Homo sapiens 175-178 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 195-198 tumor protein p53 Homo sapiens 175-178 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 199-202 tumor protein p53 Homo sapiens 175-178 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 199-202 tumor protein p53 Homo sapiens 175-178 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 199-202 tumor protein p53 Homo sapiens 175-178 19948747-4 2010 Since mutations in the p53 gene are present in approximately 40% of all human lung cancers and are more common in smokers than in nonsmokers, we aimed to detect the status of p53 at codon 72 for Arg/Arg or Arg/Pro or Pro/Pro allele polymorphism and p53 codon 249 mutation in smokers and nonsmokers of South India. Arginine 199-202 tumor protein p53 Homo sapiens 175-178 20380571-4 2010 The frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes for P53 codon 72 were 51.7%, 41.4%, and 6.9% in patients and 42.6%, 47.3%, and 10.1% in controls, respectively. Arginine 19-22 tumor protein p53 Homo sapiens 63-66 20380571-4 2010 The frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes for P53 codon 72 were 51.7%, 41.4%, and 6.9% in patients and 42.6%, 47.3%, and 10.1% in controls, respectively. Arginine 23-26 tumor protein p53 Homo sapiens 63-66 20380571-4 2010 The frequencies of Arg/Arg, Arg/Pro, and Pro/Pro genotypes for P53 codon 72 were 51.7%, 41.4%, and 6.9% in patients and 42.6%, 47.3%, and 10.1% in controls, respectively. Arginine 23-26 tumor protein p53 Homo sapiens 63-66 20512840-5 2010 It was shown that the Arg variant of TP53 gene is associated with high frequency of AC and chromatid breaks. Arginine 22-25 tumor protein p53 Homo sapiens 37-41 20398418-6 2010 An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. Arginine 117-120 tumor protein p53 Homo sapiens 47-51 20658010-1 2010 UNLABELLED: p53 tumoral suppressor gene harbors a functional polymorphism which codes either arginine (Arg) or proline (Pro) in the protein p53 of codon 72. Arginine 93-101 tumor protein p53 Homo sapiens 12-15 20658010-1 2010 UNLABELLED: p53 tumoral suppressor gene harbors a functional polymorphism which codes either arginine (Arg) or proline (Pro) in the protein p53 of codon 72. Arginine 93-101 tumor protein p53 Homo sapiens 140-143 20658010-1 2010 UNLABELLED: p53 tumoral suppressor gene harbors a functional polymorphism which codes either arginine (Arg) or proline (Pro) in the protein p53 of codon 72. Arginine 103-106 tumor protein p53 Homo sapiens 12-15 20658010-1 2010 UNLABELLED: p53 tumoral suppressor gene harbors a functional polymorphism which codes either arginine (Arg) or proline (Pro) in the protein p53 of codon 72. Arginine 103-106 tumor protein p53 Homo sapiens 140-143 20019240-0 2010 Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. Arginine 67-75 tumor protein p53 Homo sapiens 40-43 20019240-0 2010 Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. Arginine 67-75 tumor protein p53 Homo sapiens 98-101 20019240-0 2010 Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. Arginine 107-115 tumor protein p53 Homo sapiens 40-43 20019240-0 2010 Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. Arginine 107-115 tumor protein p53 Homo sapiens 98-101 20019240-4 2010 The largest difference between p53-arginine and p53-proline was found with the PERP gene involved in cell-cell adhesion and apoptosis. Arginine 35-43 tumor protein p53 Homo sapiens 31-34 20225330-8 2010 Furthermore, stratification analyses showed that the risk of SPM associated with p53 variant genotypes (Arg/Pro + Pro/Pro) was more pronounced in several subgroups. Arginine 104-107 tumor protein p53 Homo sapiens 81-84 20398418-6 2010 An increased risk was also associated with the TP53 Pro/Pro genotype (OR = 2.22, 95% CI = 1.58-3.10) compared to the Arg/Arg genotype. Arginine 121-124 tumor protein p53 Homo sapiens 47-51 19810096-5 2010 In the Arg/Arg variant, apoptotic cells induced by 5-FU treatment in patients without inactive p53 mutation were more markedly increased than those in patients with inactive p53 mutation (p = 0.037). Arginine 7-10 tumor protein p53 Homo sapiens 95-98 19810096-5 2010 In the Arg/Arg variant, apoptotic cells induced by 5-FU treatment in patients without inactive p53 mutation were more markedly increased than those in patients with inactive p53 mutation (p = 0.037). Arginine 7-10 tumor protein p53 Homo sapiens 174-177 19810096-4 2010 5-FU sensitivity of tumor cells without inactive p53 mutation in the arginine/arginine (Arg/Arg) variant was significantly higher than that of tumor cells with or without inactive p53 mutation in other variants (p = 0.022), whereas the 5-FU sensitivity of tumor cells with inactive p53 mutation in the Arg/Arg variant was significantly lower than that of tumor cells with or without inactive p53 mutation in other variants (p = 0.002). Arginine 69-77 tumor protein p53 Homo sapiens 49-52 19810096-5 2010 In the Arg/Arg variant, apoptotic cells induced by 5-FU treatment in patients without inactive p53 mutation were more markedly increased than those in patients with inactive p53 mutation (p = 0.037). Arginine 11-14 tumor protein p53 Homo sapiens 95-98 19810096-5 2010 In the Arg/Arg variant, apoptotic cells induced by 5-FU treatment in patients without inactive p53 mutation were more markedly increased than those in patients with inactive p53 mutation (p = 0.037). Arginine 11-14 tumor protein p53 Homo sapiens 174-177 20082853-2 2010 To investigate the frequency of proline and arginine alleles of TP53 codon 72, the present study analyzed the DNA from blood samples of 30 Iranian women with endometrial cancer, in comparison with 32 healthy women. Arginine 44-52 tumor protein p53 Homo sapiens 64-68 20022955-4 2010 In a promoter-specific context, inhibition of H3R17 methylation represses expression of p21, a p53-responsive gene, thus implicating a possible role for H3 Arg-17 methylation in tumor suppressor function. Arginine 156-159 tumor protein p53 Homo sapiens 95-98 20193843-9 2010 Moreover, we identified mutation of TP53 gene in codon 273; triplet CGT coding Arg was changed to CAG coding His. Arginine 79-82 tumor protein p53 Homo sapiens 36-40 20193851-1 2010 Polymorphism at codon 72 of TP53, resulting in either the arginine (Arg) or proline (Pro) form of p53 (R72P), has been associated with the susceptibility to different cancers. Arginine 58-66 tumor protein p53 Homo sapiens 28-32 20193851-1 2010 Polymorphism at codon 72 of TP53, resulting in either the arginine (Arg) or proline (Pro) form of p53 (R72P), has been associated with the susceptibility to different cancers. Arginine 58-66 tumor protein p53 Homo sapiens 98-101 20193851-1 2010 Polymorphism at codon 72 of TP53, resulting in either the arginine (Arg) or proline (Pro) form of p53 (R72P), has been associated with the susceptibility to different cancers. Arginine 68-71 tumor protein p53 Homo sapiens 28-32 20193851-1 2010 Polymorphism at codon 72 of TP53, resulting in either the arginine (Arg) or proline (Pro) form of p53 (R72P), has been associated with the susceptibility to different cancers. Arginine 68-71 tumor protein p53 Homo sapiens 98-101 20130515-5 2010 RESULTS: Women homozygous for the p53 codon 72 Arg genotype were at a 5.6-fold higher risk for developing cervical intraepithelial neoplasia (CIN) 2 or 3 compared with those showing homozygosity for the Pro genotype or heterozygosity for the Pro/Arg genotype. Arginine 47-50 tumor protein p53 Homo sapiens 34-37 21338227-2 2010 In the tumour suppressor Trp53 gene, a codon 72 polymorphism is frequent in the form of a single nucleotide polymorphism that leads to substitution of an arginine for a proline. Arginine 154-162 tumor protein p53 Homo sapiens 25-30 21133638-5 2010 OBJECTIVE: The purpose of this study was to investigate the p53 polymorphism at codon 72 which results in encoding of either proline or arginine. Arginine 136-144 tumor protein p53 Homo sapiens 60-63 20130515-5 2010 RESULTS: Women homozygous for the p53 codon 72 Arg genotype were at a 5.6-fold higher risk for developing cervical intraepithelial neoplasia (CIN) 2 or 3 compared with those showing homozygosity for the Pro genotype or heterozygosity for the Pro/Arg genotype. Arginine 246-249 tumor protein p53 Homo sapiens 34-37 20117988-10 2010 In cells treated with a low concentration of L-Arg, the expressions of VEGF and COX-2 were increased as compared with those in the control cells; higher concentrations of L-Arg obviously decreased the expressions of p53 and bcl-2 and increased the expression of bax. Arginine 45-50 tumor protein p53 Homo sapiens 216-219 20505276-7 2010 Furthermore, polymerase chain reaction-single-strand conformation polymorphism and following nucleotide sequencing showed that the p53 gene was mutated at codon 215, leading to an amino acid substitution from Ser to Arg. Arginine 216-219 tumor protein p53 Homo sapiens 131-134 20563922-6 2010 The TP53 polymorphism distribution in this population was 64 (21.1%) Arg/Arg, 55 (18.1%) Pro/Pro, and 185 (60.9%) Arg/Pro. Arginine 69-72 tumor protein p53 Homo sapiens 4-8 20563922-6 2010 The TP53 polymorphism distribution in this population was 64 (21.1%) Arg/Arg, 55 (18.1%) Pro/Pro, and 185 (60.9%) Arg/Pro. Arginine 73-76 tumor protein p53 Homo sapiens 4-8 20563922-6 2010 The TP53 polymorphism distribution in this population was 64 (21.1%) Arg/Arg, 55 (18.1%) Pro/Pro, and 185 (60.9%) Arg/Pro. Arginine 73-76 tumor protein p53 Homo sapiens 4-8 20117988-10 2010 In cells treated with a low concentration of L-Arg, the expressions of VEGF and COX-2 were increased as compared with those in the control cells; higher concentrations of L-Arg obviously decreased the expressions of p53 and bcl-2 and increased the expression of bax. Arginine 171-176 tumor protein p53 Homo sapiens 216-219 20117988-13 2010 The mechanism of L-Arg- induced cell apoptosis may be related to the up-regulation of bax protein and the down-regulation of p53 and bcl-2 proteins. Arginine 17-22 tumor protein p53 Homo sapiens 125-128 19764997-6 2009 Single nucleotide polymorphisms (SNPs) in TP53 (codon 72, arginine > proline) and MDM2 (SNP309, T > G) were genotyped using PCR-RFLP, and nuclear expression levels of p53 were examined using immunohistochemistry. Arginine 58-66 tumor protein p53 Homo sapiens 42-46 19843866-5 2009 The PADI4 gene encodes an enzyme catalyzing the citrullination of arginine residues in proteins, and ectopic expression of p53 or PADI4 induced protein citrullination. Arginine 66-74 tumor protein p53 Homo sapiens 123-126 18853251-1 2009 The p53 tumor suppressor gene has a central role in the defense against cancer, including breast cancer, and contains a polymorphic variant (Arg/Pro) at codon 72 that has been shown to have different biological properties regarding apoptosis and cell cycle arrest. Arginine 141-144 tumor protein p53 Homo sapiens 4-7 18930193-1 2009 OBJECTIVE: To determine whether the p53 codon 72 single nucleotide polymorphism, a change of the amino acid arginine (Arg) to proline (Pro) resulting from a single nucleotide mutation of guanine (G) to cytosine (C), has a clinically significant effect on implantation rate in fresh IVF cycles. Arginine 118-121 tumor protein p53 Homo sapiens 36-39 19874399-6 2009 Interestingly, the combination of the homozygous Arg/Arg genotype of p53 codon 72 and homozygous GG genotype of MDM2 SNP309 polymorphisms was significantly associated with the risk of endometrial cancer (odds ratio = 3.28, 95% confidence interval = 1.13 to 9.53, P= 0.0212). Arginine 49-52 tumor protein p53 Homo sapiens 69-72 19874399-6 2009 Interestingly, the combination of the homozygous Arg/Arg genotype of p53 codon 72 and homozygous GG genotype of MDM2 SNP309 polymorphisms was significantly associated with the risk of endometrial cancer (odds ratio = 3.28, 95% confidence interval = 1.13 to 9.53, P= 0.0212). Arginine 53-56 tumor protein p53 Homo sapiens 69-72 19423162-2 2009 A G-C exchange at p53 codon 72 polymorphism results in a substitution of proline (Pro) for arginine (Arg) in the transactivation domain, which was shown to alter the primary structure of the p53 protein. Arginine 91-99 tumor protein p53 Homo sapiens 18-21 19423162-2 2009 A G-C exchange at p53 codon 72 polymorphism results in a substitution of proline (Pro) for arginine (Arg) in the transactivation domain, which was shown to alter the primary structure of the p53 protein. Arginine 91-99 tumor protein p53 Homo sapiens 191-194 19423162-2 2009 A G-C exchange at p53 codon 72 polymorphism results in a substitution of proline (Pro) for arginine (Arg) in the transactivation domain, which was shown to alter the primary structure of the p53 protein. Arginine 101-104 tumor protein p53 Homo sapiens 18-21 19423162-2 2009 A G-C exchange at p53 codon 72 polymorphism results in a substitution of proline (Pro) for arginine (Arg) in the transactivation domain, which was shown to alter the primary structure of the p53 protein. Arginine 101-104 tumor protein p53 Homo sapiens 191-194 19657586-4 2009 We observed that carrying the Pro/Pro genotype of P53 Arg72Pro was a risk factor with respect to the Pro/Arg + Arg/Arg genotypes [Odds Ratio (OR) = 2.02; 95% Confidence Interval (CI) 1.02-4.00; p = 0.047]. Arginine 54-57 tumor protein p53 Homo sapiens 50-53 19465072-4 2009 Effectiveness of the Pas segment in the intracellular delivery of bioactive peptides using arginine-rich CPPs was exemplified through the enhanced growth inhibition activity of the malignant glioma cells by a retro-inverso peptide derived from the p53 C-terminal 22-amino-acid segment (positions 361-382). Arginine 91-99 tumor protein p53 Homo sapiens 248-251 19521721-5 2009 Similarly, the alleles of rs1042522 in TP53 that encode arginine (G-allele) or proline (C-allele) at codon 72, which cause increased pro-apoptotic (G-allele) or cell-cycle arrest activities (C-allele), respectively, may moderate p53"s ability to prevent DNA damage. Arginine 56-64 tumor protein p53 Homo sapiens 39-43 19521721-5 2009 Similarly, the alleles of rs1042522 in TP53 that encode arginine (G-allele) or proline (C-allele) at codon 72, which cause increased pro-apoptotic (G-allele) or cell-cycle arrest activities (C-allele), respectively, may moderate p53"s ability to prevent DNA damage. Arginine 56-64 tumor protein p53 Homo sapiens 229-232 19784392-8 2009 CONCLUSIONS: Our preliminary results indicate that the arginine variant of rs1042522 within p53 is associated with increased risk of POAG. Arginine 55-63 tumor protein p53 Homo sapiens 92-95 19657586-4 2009 We observed that carrying the Pro/Pro genotype of P53 Arg72Pro was a risk factor with respect to the Pro/Arg + Arg/Arg genotypes [Odds Ratio (OR) = 2.02; 95% Confidence Interval (CI) 1.02-4.00; p = 0.047]. Arginine 105-108 tumor protein p53 Homo sapiens 50-53 19657586-4 2009 We observed that carrying the Pro/Pro genotype of P53 Arg72Pro was a risk factor with respect to the Pro/Arg + Arg/Arg genotypes [Odds Ratio (OR) = 2.02; 95% Confidence Interval (CI) 1.02-4.00; p = 0.047]. Arginine 105-108 tumor protein p53 Homo sapiens 50-53 19434453-8 2009 Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. Arginine 203-206 tumor protein p53 Homo sapiens 31-34 19625214-11 2009 Null results were noted in studies with sound epidemiological design and conduct (1.06 [0.87-1.29] for arginine homozygotes compared with heterozygotes), and studies in which TP53 genotype was determined from white blood cells (1.06 [0.87-1.29] for arginine homozygotes compared with heterozygotes). Arginine 103-111 tumor protein p53 Homo sapiens 175-179 21475903-4 2009 Polymorphisms of TP53 include codon 72 containing either arginine (CGC) or proline (CCC). Arginine 57-65 tumor protein p53 Homo sapiens 17-21 19434453-8 2009 Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. Arginine 203-206 tumor protein p53 Homo sapiens 48-51 19434453-8 2009 Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. Arginine 203-206 tumor protein p53 Homo sapiens 48-51 19434453-8 2009 Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. Arginine 207-210 tumor protein p53 Homo sapiens 31-34 19434453-8 2009 Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. Arginine 207-210 tumor protein p53 Homo sapiens 48-51 19434453-8 2009 Notably, stage I patients with p53 mutation and p53 codon 72 Pro/Pro genotype experienced a 2.66-fold hazard ratio (95% CI 1.21-5.85) for overall survival when compared with those with p53 wild-type and Arg/Arg genotype. Arginine 207-210 tumor protein p53 Homo sapiens 48-51 19052714-4 2009 RESULTS: The Arg/Pro and Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to the combination chemotherapy when compared to the Arg/Arg genotype (35.7 vs. 66.7%, P-value 0.019) in a logistic regression analysis. Arginine 13-16 tumor protein p53 Homo sapiens 46-50 19052714-4 2009 RESULTS: The Arg/Pro and Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to the combination chemotherapy when compared to the Arg/Arg genotype (35.7 vs. 66.7%, P-value 0.019) in a logistic regression analysis. Arginine 170-173 tumor protein p53 Homo sapiens 46-50 19052714-4 2009 RESULTS: The Arg/Pro and Pro/Pro genotypes of TP53 codon 72 were significantly correlated with a lower response rate to the combination chemotherapy when compared to the Arg/Arg genotype (35.7 vs. 66.7%, P-value 0.019) in a logistic regression analysis. Arginine 170-173 tumor protein p53 Homo sapiens 46-50 19052714-5 2009 A multivariate survival analysis also showed that the time to progression for the patients with the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 was worse than for the patients with the Arg/Arg genotype (Hazard ratio = 3.056, P-value = 0.047), whereas the overall survival was not significantly different. Arginine 100-103 tumor protein p53 Homo sapiens 133-137 19052714-5 2009 A multivariate survival analysis also showed that the time to progression for the patients with the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 was worse than for the patients with the Arg/Arg genotype (Hazard ratio = 3.056, P-value = 0.047), whereas the overall survival was not significantly different. Arginine 188-191 tumor protein p53 Homo sapiens 133-137 19052714-5 2009 A multivariate survival analysis also showed that the time to progression for the patients with the Arg/Pro and Pro/Pro genotypes of TP53 codon 72 was worse than for the patients with the Arg/Arg genotype (Hazard ratio = 3.056, P-value = 0.047), whereas the overall survival was not significantly different. Arginine 188-191 tumor protein p53 Homo sapiens 133-137 19470478-3 2009 The p53 allele encoding proline at codon 72 (P72) was found to be significantly enriched over the allele encoding arginine (R72) among in vitro fertilization (IVF) patients. Arginine 114-122 tumor protein p53 Homo sapiens 4-7 19217391-6 2009 Additionally, they suggest that the increased affinity of Taz2 for p53(1-39) phosphorylated at Thr(18) is due in part to electrostatic interactions of the phosphate with neighboring arginine residues in Taz2. Arginine 182-190 tumor protein p53 Homo sapiens 67-70 19451596-7 2009 Subjects carrying the TP53 Arg72Pro polymorphism were found to have a significantly increased death risk (Pro/Pro versus Arg/Arg; hazard ratio, 2.90; 95% CI, 1.28-6.66). Arginine 27-30 tumor protein p53 Homo sapiens 22-26 19451596-7 2009 Subjects carrying the TP53 Arg72Pro polymorphism were found to have a significantly increased death risk (Pro/Pro versus Arg/Arg; hazard ratio, 2.90; 95% CI, 1.28-6.66). Arginine 121-124 tumor protein p53 Homo sapiens 22-26 19451596-8 2009 In the subgroup of 130 high-grade osteosarcomas, the TP53 Arg72Pro was an independent marker of EFS (Pro/Pro versus Arg/Arg; hazard ratio, 2.67; 95% CI, 1.17-6.11). Arginine 58-61 tumor protein p53 Homo sapiens 53-57 19451596-8 2009 In the subgroup of 130 high-grade osteosarcomas, the TP53 Arg72Pro was an independent marker of EFS (Pro/Pro versus Arg/Arg; hazard ratio, 2.67; 95% CI, 1.17-6.11). Arginine 116-119 tumor protein p53 Homo sapiens 53-57 18462472-8 2009 Multivariate analysis showed that those with TP53 codon 72 Arg/Pro allele had significantly shorter survival than those with Arg/Arg allele (hazard ratio 1.35; 95% CI = 1.07-1.71). Arginine 59-62 tumor protein p53 Homo sapiens 45-49 19212643-1 2009 The impact of a polymorphism of the wild-type human tumour suppressor gene p53(wt) on carcinogenesis is subject of controversy ever since a higher susceptibility of p53 to HPV-E6 mediated degradation when encoding for Arginine at codon 72 (p53Arg) was first reported. Arginine 218-226 tumor protein p53 Homo sapiens 75-78 19212643-1 2009 The impact of a polymorphism of the wild-type human tumour suppressor gene p53(wt) on carcinogenesis is subject of controversy ever since a higher susceptibility of p53 to HPV-E6 mediated degradation when encoding for Arginine at codon 72 (p53Arg) was first reported. Arginine 218-226 tumor protein p53 Homo sapiens 165-168 19383811-7 2009 p53 Pro/Pro was strongly associated with shorter survival in the entire cohort (MS of 11.8 versus 29.1 months, P < 0.0001; adjusted hazard ratio for death, 2.05; 95% confidence interval, 1.30-3.24; P = 0.002 for Pro/Pro versus Arg/Arg). Arginine 230-233 tumor protein p53 Homo sapiens 0-3 19383811-7 2009 p53 Pro/Pro was strongly associated with shorter survival in the entire cohort (MS of 11.8 versus 29.1 months, P < 0.0001; adjusted hazard ratio for death, 2.05; 95% confidence interval, 1.30-3.24; P = 0.002 for Pro/Pro versus Arg/Arg). Arginine 234-237 tumor protein p53 Homo sapiens 0-3 19046801-12 2009 Mutations of p53 determined in NHL cases (30%) were of Arg-176 (1/20: 5%), Phe-238 (1/20: 5%), Ser-249 (2/20; 10%), Lys-249 (1/20: 5%) and Phe-250 (1/20: 5%). Arginine 55-58 tumor protein p53 Homo sapiens 13-16 19221494-0 2009 p53 methylation--the Arg-ument is clear. Arginine 21-24 tumor protein p53 Homo sapiens 0-3 19221494-5 2009 Most recently, arginine methylation mediated by PRMT5, has been identified as an additional and important p53 modification. Arginine 15-23 tumor protein p53 Homo sapiens 106-109 19221494-6 2009 DNA damage induced p53 arginine methylation impacts on the biochemical properties and functional outcome of the p53 response. Arginine 23-31 tumor protein p53 Homo sapiens 19-22 19221494-6 2009 DNA damage induced p53 arginine methylation impacts on the biochemical properties and functional outcome of the p53 response. Arginine 23-31 tumor protein p53 Homo sapiens 112-115 19212663-3 2009 For p53 genotype analysis, breast cancer patients presented a significant (p<0.05) over-representation of p53 Arg homozygosity (55.5%) compared with the healthy control group (33.3%). Arginine 113-116 tumor protein p53 Homo sapiens 109-112 19212663-6 2009 It is possible that p53 Arg homozygosity is associated with breast cancer and may represent a potential risk factor for breast tumorigenesis. Arginine 24-27 tumor protein p53 Homo sapiens 20-23 19414966-6 2009 Presence of homozygous arginine at codon 72 renders p53 about seven times more susceptible to E6-mediated proteolytic degradation. Arginine 23-31 tumor protein p53 Homo sapiens 52-55 19291875-2 2009 The p53 codon 72 Arg-Pro (CGC to CCC) polymorphism of exon 4 affects various biological properties; recently, it was reported that this polymorphism affects the ability to induce apoptosis in vitro. Arginine 17-20 tumor protein p53 Homo sapiens 4-7 19291875-10 2009 We concluded that the p53 codon 72 Arg/Pro polymorphism is not associated with glaucoma in Brazilian patients. Arginine 35-38 tumor protein p53 Homo sapiens 22-25 23675098-3 2008 The TP53 codon 72 polymorphism is a single-nucleotide polymorphism (SNP) in exon 4, resulting in the expression of either arginine (CGC) or proline (CCC) residues. Arginine 122-130 tumor protein p53 Homo sapiens 4-8 19940524-1 2009 OBJECTIVES: Several studies have examined the association of codon 72 polymorphism of the TP53 gene, encoding either arginine or proline, in several tumor types but none have investigated its role in Kaposi"s sarcoma (KS) development. Arginine 117-125 tumor protein p53 Homo sapiens 90-94 19263877-4 2009 STUDY DESIGN: In a genetic association study, PD1.5 (7785) C/T, CTLA-4 +49 A/G, and p53 codon 72 Arg/Pro SNPs were genotyped in case-control groups with patient/control ratios of 92:295, 83:84 and 85:150, respectively. Arginine 97-100 tumor protein p53 Homo sapiens 84-87 19137883-9 2008 RESULTS: The genetic genotype of p53 gene codon 72 in keloids included Arg/Arg in 7 cases, Pro/Arg in 21 cases, Pro/ Pro in 7 cases. Arginine 71-74 tumor protein p53 Homo sapiens 33-36 19011621-0 2008 Arginine methylation regulates the p53 response. Arginine 0-8 tumor protein p53 Homo sapiens 35-38 19011621-5 2008 Arginine methylation is regulated during the p53 response and affects the target gene specificity of p53. Arginine 0-8 tumor protein p53 Homo sapiens 45-48 19011621-5 2008 Arginine methylation is regulated during the p53 response and affects the target gene specificity of p53. Arginine 0-8 tumor protein p53 Homo sapiens 101-104 19011621-7 2008 Thus, methylation on arginine residues is an underlying mechanism of control during the p53 response. Arginine 21-29 tumor protein p53 Homo sapiens 88-91 19127115-7 2008 Direct sequencing of TP53 gene exons 5, 6, 8, 9, and 11 revealed a ermline missense mutation, resulting in an amino acid change from an arginine to a histidine (g.13203G>A, p.R175H). Arginine 136-144 tumor protein p53 Homo sapiens 21-25 19043433-2 2008 Now, arginine methylation joins a panoply of other post-translational modifications that regulate p53. Arginine 5-13 tumor protein p53 Homo sapiens 98-101 19137883-9 2008 RESULTS: The genetic genotype of p53 gene codon 72 in keloids included Arg/Arg in 7 cases, Pro/Arg in 21 cases, Pro/ Pro in 7 cases. Arginine 75-78 tumor protein p53 Homo sapiens 33-36 19137883-9 2008 RESULTS: The genetic genotype of p53 gene codon 72 in keloids included Arg/Arg in 7 cases, Pro/Arg in 21 cases, Pro/ Pro in 7 cases. Arginine 75-78 tumor protein p53 Homo sapiens 33-36 17931634-9 2008 An interaction between p53 and PTPN22 was observed: a protective action by the Arg/Arg genotype against endometriosis seems to be present only in carriers of the ( *)T allele of PTPN22. Arginine 79-82 tumor protein p53 Homo sapiens 23-26 18692035-4 2008 RESULTS: The -765GC+CC genotypes of COX2 and Pro/Pro+Pro/Arg genotypes of p53 were prevalent in patients with significant odds ratio, 2.05 and 2.30, respectively (p=0.001; p=0.009, respectively), as a consequence, the -765C and 72Pro alleles were prevalent (p<or=0.001). Arginine 57-60 tumor protein p53 Homo sapiens 74-77 19145674-17 2008 CONCLUSION: Our results showed low incidence of p53 mutations and prevalence of Arg/Arg genotype polymorphic variant of codon 72 of p53 gene in early stages of cervical carcinoma. Arginine 80-83 tumor protein p53 Homo sapiens 132-135 19145674-17 2008 CONCLUSION: Our results showed low incidence of p53 mutations and prevalence of Arg/Arg genotype polymorphic variant of codon 72 of p53 gene in early stages of cervical carcinoma. Arginine 84-87 tumor protein p53 Homo sapiens 132-135 18058229-6 2008 However, combined analysis of the SNP"s showed that p53 (Arg/Arg and Arg/Pro) with TGFbeta1 (Pro/Pro and Leu/Pro) were associated with greater than 2 fold increased risk for breast cancer in Univariate (P=0.01) and Multivariate (P=0.003) analysis. Arginine 57-60 tumor protein p53 Homo sapiens 52-55 18058229-6 2008 However, combined analysis of the SNP"s showed that p53 (Arg/Arg and Arg/Pro) with TGFbeta1 (Pro/Pro and Leu/Pro) were associated with greater than 2 fold increased risk for breast cancer in Univariate (P=0.01) and Multivariate (P=0.003) analysis. Arginine 61-64 tumor protein p53 Homo sapiens 52-55 18058229-6 2008 However, combined analysis of the SNP"s showed that p53 (Arg/Arg and Arg/Pro) with TGFbeta1 (Pro/Pro and Leu/Pro) were associated with greater than 2 fold increased risk for breast cancer in Univariate (P=0.01) and Multivariate (P=0.003) analysis. Arginine 61-64 tumor protein p53 Homo sapiens 52-55 18758421-2 2008 A common polymorphism at codon 72 of exon 4 of the p53 gene encoding either an arginine or proline has been shown to confer susceptibility to the development of different human malignancies. Arginine 79-87 tumor protein p53 Homo sapiens 51-54 17931634-9 2008 An interaction between p53 and PTPN22 was observed: a protective action by the Arg/Arg genotype against endometriosis seems to be present only in carriers of the ( *)T allele of PTPN22. Arginine 83-86 tumor protein p53 Homo sapiens 23-26 17931634-10 2008 CONCLUSION(S): The negative association between the Arg/Arg genotype of p53 codon 72 found in Chinese people has not been observed in Japanese and Italian populations. Arginine 52-55 tumor protein p53 Homo sapiens 72-75 17931634-10 2008 CONCLUSION(S): The negative association between the Arg/Arg genotype of p53 codon 72 found in Chinese people has not been observed in Japanese and Italian populations. Arginine 56-59 tumor protein p53 Homo sapiens 72-75 18954551-5 2008 Only three from the eight TP53 polymorphisms described in the analyzed region were polymorphic within our samples: the 11827 base from intron 2, the 16bp duplication in the intron3 and the codon 72 (Arg>Pro) from exon 4. Arginine 199-202 tumor protein p53 Homo sapiens 26-30 18505818-1 2008 Histone Arg methylation has been correlated with transcriptional activation of p53 target genes. Arginine 8-11 tumor protein p53 Homo sapiens 79-82 18249029-0 2008 Arsenic-induced health effects and genetic damage in keratotic individuals: involvement of p53 arginine variant and chromosomal aberrations in arsenic susceptibility. Arginine 95-103 tumor protein p53 Homo sapiens 91-94 18249029-6 2008 Previously we have reported that the p53 codon 72 arginine (Arg) homozygous genotype is associated with the development of arsenic-induced keratosis. Arginine 50-58 tumor protein p53 Homo sapiens 37-40 18249029-6 2008 Previously we have reported that the p53 codon 72 arginine (Arg) homozygous genotype is associated with the development of arsenic-induced keratosis. Arginine 60-63 tumor protein p53 Homo sapiens 37-40 18249029-13 2008 This study suggests that individuals with keratosis are more susceptible to arsenic-induced health effects and genetic damage and that the arginine variant of p53 can further influence the repair capacity of arsenic-exposed individuals, leading to increased accumulation of chromosomal aberrations. Arginine 139-147 tumor protein p53 Homo sapiens 159-162 18472002-0 2008 Arginine methylation of hnRNP K enhances p53 transcriptional activity. Arginine 0-8 tumor protein p53 Homo sapiens 41-44 18472002-1 2008 Previous studies have illustrated that hnRNP K, which could be methylated at arginine residues, plays a key role in coordinating transcriptional responses to DNA damage as a cofactor for p53. Arginine 77-85 tumor protein p53 Homo sapiens 187-190 18472002-3 2008 Furthermore, arginine methylation of hnRNP K enhanced its affinity with p53. Arginine 13-21 tumor protein p53 Homo sapiens 72-75 18472002-5 2008 These data suggested that arginine methylation of hnRNP K is a key element for p53 transcriptional activity. Arginine 26-34 tumor protein p53 Homo sapiens 79-82 18630481-8 2008 In patients with GSTM1 null genotype and p53 Arg/Pro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1+ and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Arginine 45-48 tumor protein p53 Homo sapiens 41-44 18630481-8 2008 In patients with GSTM1 null genotype and p53 Arg/Pro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1+ and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Arginine 171-174 tumor protein p53 Homo sapiens 167-170 18630481-8 2008 In patients with GSTM1 null genotype and p53 Arg/Pro heterozygotes or Pro/Pro homozygotes the chance of survival is significantly lower than in the case of GSTM1+ and p53 Arg/Arg variants (p=0.009 and p=0.008, respectively). Arginine 171-174 tumor protein p53 Homo sapiens 167-170 18355840-9 2008 In p53 codon72 Arg/Pro + Pro/Pro carriers the frequency of the AG + GG genotype of MSH3 exon23 was significantly increased in patients compared to controls (OR 2.1, 95% CI 1.05-4.34). Arginine 15-18 tumor protein p53 Homo sapiens 3-6 18423915-4 2008 A G-to-C SNP at p53 codon 72 results in an Arg/Pro polymorphism, which is associated with apoptosis induction potential and p53 mutation status. Arginine 43-46 tumor protein p53 Homo sapiens 16-19 18423915-4 2008 A G-to-C SNP at p53 codon 72 results in an Arg/Pro polymorphism, which is associated with apoptosis induction potential and p53 mutation status. Arginine 43-46 tumor protein p53 Homo sapiens 124-127 18423915-7 2008 p53 codon 72 SNP Arg/Arg polymorphism was associated with the progression of OSCC, and the overall (OS) and disease-free survival (DFS) of irradiated patients. Arginine 17-20 tumor protein p53 Homo sapiens 0-3 18423915-7 2008 p53 codon 72 SNP Arg/Arg polymorphism was associated with the progression of OSCC, and the overall (OS) and disease-free survival (DFS) of irradiated patients. Arginine 21-24 tumor protein p53 Homo sapiens 0-3 18423915-9 2008 The combination of MDM2 SNP309 G/G and p53 codon 72 Arg/Arg polymorphism is associated with the worst OS and DFS. Arginine 52-55 tumor protein p53 Homo sapiens 39-42 18423915-9 2008 The combination of MDM2 SNP309 G/G and p53 codon 72 Arg/Arg polymorphism is associated with the worst OS and DFS. Arginine 56-59 tumor protein p53 Homo sapiens 39-42 18414047-8 2008 An association has been reported between women carrying the p53 codon 72 polymorphism (a proline to arginine change) with recurrent implantation failure, suggesting a similar function for p53 in humans. Arginine 100-108 tumor protein p53 Homo sapiens 60-63 17998932-1 2008 Codon 72 of human p53 gene is polymorphic, encoding arginine or proline. Arginine 52-60 tumor protein p53 Homo sapiens 18-21 18414047-8 2008 An association has been reported between women carrying the p53 codon 72 polymorphism (a proline to arginine change) with recurrent implantation failure, suggesting a similar function for p53 in humans. Arginine 100-108 tumor protein p53 Homo sapiens 188-191 18189286-6 2008 The p53 residues that are mainly involved in binding to Tat(47-57) are E343 and E349, which bind to the positively charged arginine-rich motif of Tat by a partly electrostatic mechanism. Arginine 123-131 tumor protein p53 Homo sapiens 4-7 18288414-2 2008 Several reports have focused on p53 polymorphisms as risk factors in lung cancer, in particular at codon 72 of exon 4, encoding either an arginine (Arg72R) or a proline (Pro72P) amino acid. Arginine 138-146 tumor protein p53 Homo sapiens 32-35 18250140-4 2008 Odds ratio (OR) for patients with SLE and p53 Arg/Arg genotype was 1.875 [95% CI = 1.180-2.979], P = 0.0075 and OR of the Arg/Arg and Arg/Pro genotypes was 1.549 [95% CI = 0.752-3.195], P = 0.2328. Arginine 46-49 tumor protein p53 Homo sapiens 42-45 18250140-4 2008 Odds ratio (OR) for patients with SLE and p53 Arg/Arg genotype was 1.875 [95% CI = 1.180-2.979], P = 0.0075 and OR of the Arg/Arg and Arg/Pro genotypes was 1.549 [95% CI = 0.752-3.195], P = 0.2328. Arginine 50-53 tumor protein p53 Homo sapiens 42-45 18250140-4 2008 Odds ratio (OR) for patients with SLE and p53 Arg/Arg genotype was 1.875 [95% CI = 1.180-2.979], P = 0.0075 and OR of the Arg/Arg and Arg/Pro genotypes was 1.549 [95% CI = 0.752-3.195], P = 0.2328. Arginine 50-53 tumor protein p53 Homo sapiens 42-45 18250140-4 2008 Odds ratio (OR) for patients with SLE and p53 Arg/Arg genotype was 1.875 [95% CI = 1.180-2.979], P = 0.0075 and OR of the Arg/Arg and Arg/Pro genotypes was 1.549 [95% CI = 0.752-3.195], P = 0.2328. Arginine 50-53 tumor protein p53 Homo sapiens 42-45 18250140-4 2008 Odds ratio (OR) for patients with SLE and p53 Arg/Arg genotype was 1.875 [95% CI = 1.180-2.979], P = 0.0075 and OR of the Arg/Arg and Arg/Pro genotypes was 1.549 [95% CI = 0.752-3.195], P = 0.2328. Arginine 50-53 tumor protein p53 Homo sapiens 42-45 18272203-2 2008 In humans, we recently found that a TP53 codon 72 Arginine (Arg) to Proline (Pro) polymorphism affected both cancer incidence and longevity as well. Arginine 50-58 tumor protein p53 Homo sapiens 36-40 18272203-2 2008 In humans, we recently found that a TP53 codon 72 Arginine (Arg) to Proline (Pro) polymorphism affected both cancer incidence and longevity as well. Arginine 50-53 tumor protein p53 Homo sapiens 36-40 18205229-2 2008 The presence of Arg/Arg genotype at codon 72 of TP53 gene was characterized as a risk factor in development of cervical cancer. Arginine 16-19 tumor protein p53 Homo sapiens 48-52 18205229-2 2008 The presence of Arg/Arg genotype at codon 72 of TP53 gene was characterized as a risk factor in development of cervical cancer. Arginine 20-23 tumor protein p53 Homo sapiens 48-52 17918207-4 2008 p53 Arg/Arg genotype was significantly increased in ESCC cases compared with control subjects (85.7 vs. 49.6%, P < 0.001), resulting in an elevated ESCC risk (OR = 6.48, 95% CI = 4.65-9.03). Arginine 4-7 tumor protein p53 Homo sapiens 0-3 17918207-4 2008 p53 Arg/Arg genotype was significantly increased in ESCC cases compared with control subjects (85.7 vs. 49.6%, P < 0.001), resulting in an elevated ESCC risk (OR = 6.48, 95% CI = 4.65-9.03). Arginine 8-11 tumor protein p53 Homo sapiens 0-3 17918207-5 2008 In addition, among p53 Arg/Arg carriers, HPV infection, smoking, and drinking might further increase the risk of ESCC development. Arginine 23-26 tumor protein p53 Homo sapiens 19-22 17918207-5 2008 In addition, among p53 Arg/Arg carriers, HPV infection, smoking, and drinking might further increase the risk of ESCC development. Arginine 27-30 tumor protein p53 Homo sapiens 19-22 18803266-0 2008 p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases. Arginine 21-29 tumor protein p53 Homo sapiens 0-3 19065769-3 2008 TP53 codon 72 polymorphism results in either the arginine or proline form of the p53 protein; several studies have investigated whether codon 72 polymorphisms are risk and prognostic factors for cancer. Arginine 49-57 tumor protein p53 Homo sapiens 0-4 18714570-11 2008 The frequency of p53 Arg/Arg was 57% and of the heterozygous allele Arg/Pro it was 39%. Arginine 21-24 tumor protein p53 Homo sapiens 17-20 18714570-11 2008 The frequency of p53 Arg/Arg was 57% and of the heterozygous allele Arg/Pro it was 39%. Arginine 25-28 tumor protein p53 Homo sapiens 17-20 18714570-11 2008 The frequency of p53 Arg/Arg was 57% and of the heterozygous allele Arg/Pro it was 39%. Arginine 25-28 tumor protein p53 Homo sapiens 17-20 18803266-7 2008 In conclusion, HT patients feature a greater ratio of arginine homozygosity at p53 codon 72 than in the case for normal subjects. Arginine 54-62 tumor protein p53 Homo sapiens 79-82 18803266-8 2008 The p53 codon 72 proline/arginine polymorphism may be a genetic marker to predict the increased susceptibility of development of HT. Arginine 25-33 tumor protein p53 Homo sapiens 4-7 18006764-6 2007 RESULTS: The p53 codon 72 Arg/Arg genotype was associated with increased PSA recurrence risk compared with the Arg/Pro and Pro/Pro genotypes, although the difference did not reach significance (30.3% versus 20.4%, P = 0.247). Arginine 26-29 tumor protein p53 Homo sapiens 13-16 18612219-0 2008 Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Arginine 21-29 tumor protein p53 Homo sapiens 8-11 18612219-1 2008 BACKGROUND: The p53 codon 72 polymorphism, which results in either an arginine or proline residue, plays a different role in vitro and in vivo in cell survival and drug resistance. Arginine 70-78 tumor protein p53 Homo sapiens 16-19 18006764-6 2007 RESULTS: The p53 codon 72 Arg/Arg genotype was associated with increased PSA recurrence risk compared with the Arg/Pro and Pro/Pro genotypes, although the difference did not reach significance (30.3% versus 20.4%, P = 0.247). Arginine 30-33 tumor protein p53 Homo sapiens 13-16 18006764-6 2007 RESULTS: The p53 codon 72 Arg/Arg genotype was associated with increased PSA recurrence risk compared with the Arg/Pro and Pro/Pro genotypes, although the difference did not reach significance (30.3% versus 20.4%, P = 0.247). Arginine 30-33 tumor protein p53 Homo sapiens 13-16 17912468-3 2007 In vitro studies have suggested that HPV-E6 interacts more efficiently with the arginine (Arg) p53 variant at position 72 as it appears to be more susceptible to degradation through the ubiquitin proteasome pathway. Arginine 80-88 tumor protein p53 Homo sapiens 95-98 17653713-3 2007 On the other hand, a common polymorphism of the tumour suppressor P53 gene results in either arginine (A) or proline (P) at amino-acid position 72. Arginine 93-101 tumor protein p53 Homo sapiens 66-69 17912468-3 2007 In vitro studies have suggested that HPV-E6 interacts more efficiently with the arginine (Arg) p53 variant at position 72 as it appears to be more susceptible to degradation through the ubiquitin proteasome pathway. Arginine 90-93 tumor protein p53 Homo sapiens 95-98 17400331-9 2007 RFLP analysis of p53 codon 72 revealed 32 homozygotes for arg/arg allele (50.8%), 26 heterozygotes for arg/pro allele (41.3%), and 5 homozygotes for pro/pro allele (7.9%). Arginine 58-61 tumor protein p53 Homo sapiens 17-20 17954263-1 2007 A common polymorphism at codon 72 of TP53, the gene encoding the tumor suppressor protein p53, encodes either arginine or proline. Arginine 110-118 tumor protein p53 Homo sapiens 37-41 17954263-1 2007 A common polymorphism at codon 72 of TP53, the gene encoding the tumor suppressor protein p53, encodes either arginine or proline. Arginine 110-118 tumor protein p53 Homo sapiens 90-93 17079356-6 2007 Among the germline p53 codon 72 heterozygotes, the Pro allele was preferentially lost (p = 0.02) while the Arg allele was mutated in the majority of cases. Arginine 107-110 tumor protein p53 Homo sapiens 19-22 17400331-9 2007 RFLP analysis of p53 codon 72 revealed 32 homozygotes for arg/arg allele (50.8%), 26 heterozygotes for arg/pro allele (41.3%), and 5 homozygotes for pro/pro allele (7.9%). Arginine 62-65 tumor protein p53 Homo sapiens 17-20 17400331-9 2007 RFLP analysis of p53 codon 72 revealed 32 homozygotes for arg/arg allele (50.8%), 26 heterozygotes for arg/pro allele (41.3%), and 5 homozygotes for pro/pro allele (7.9%). Arginine 62-65 tumor protein p53 Homo sapiens 17-20 17531965-3 2007 RESULTS: The age-adjusted odds ratios (ORs) for the Ile/Val genotype of CYP1A1 Ile462Val polymorphism in women and the Arg/Pro genotype of TP53 Arg72Pro polymorphism in men were observed to be 2.70 (95% CI: 1.14-6.40) and 4.32 (95% CI: 1.08-17.2), respectively. Arginine 119-122 tumor protein p53 Homo sapiens 139-143 17914225-4 2007 By computing the free energies of wild-type and mutant p53c binding to DNA and decomposing them into contributions from individual residues, the DNA-binding loss upon charge/noncharge -conserving mutation of Arg 273 was attributed not only to the loss of DNA phosphate contacts, but also to longer-range structural changes caused by the loss of the Asp 281 salt-bridge. Arginine 208-211 tumor protein p53 Homo sapiens 55-58 17914225-5 2007 The results herein and in previous works suggest that Asp 281 plays a critical role in the sequence-specific DNA-binding function of p53c by (i)orienting Arg 273 and Arg 280 in an optimal position to interact with the phosphate and base groups of the consensus DNA, respectively, and (ii) helping to maintain the proper DNA-binding protein conformation. Arginine 154-157 tumor protein p53 Homo sapiens 133-136 17914225-5 2007 The results herein and in previous works suggest that Asp 281 plays a critical role in the sequence-specific DNA-binding function of p53c by (i)orienting Arg 273 and Arg 280 in an optimal position to interact with the phosphate and base groups of the consensus DNA, respectively, and (ii) helping to maintain the proper DNA-binding protein conformation. Arginine 166-169 tumor protein p53 Homo sapiens 133-136 17535973-5 2007 The overall 12-yr survival was increased in p53 Arg/Pro heterozygotes with 3% (P = 0.003) and in Pro/Pro homozygotes with 6% (P = 0.002) versus Arg/Arg homozygotes, corresponding to an increase in median survival of 3 yr for Pro/Pro versus Arg/Arg homozygotes. Arginine 48-51 tumor protein p53 Homo sapiens 44-47 17980096-10 2007 p53 Arg/Arg genotype may be a genetically susceptible factor to HPV-associated cervical carcinoma in Uigur. Arginine 4-7 tumor protein p53 Homo sapiens 0-3 17980096-10 2007 p53 Arg/Arg genotype may be a genetically susceptible factor to HPV-associated cervical carcinoma in Uigur. Arginine 8-11 tumor protein p53 Homo sapiens 0-3 17492690-2 2007 The TP53 polymorphism, in which an arginine (R) is changed to proline (P) at codon 72, is functionally significant and could therefore be a predisposing genetic defect. Arginine 35-43 tumor protein p53 Homo sapiens 4-8 17371868-6 2007 Interestingly, Lys to Arg mutations that inhibited ubiquitination restored nuclear localization to mutant p53 but had no apparent effect on p53 conformation. Arginine 22-25 tumor protein p53 Homo sapiens 106-109 16973168-4 2007 The high-arsenic exposure group with GSTP1 variant genotypes of Ile/Val and Val/Val, and with the p53 variant genotypes of Arg/Pro and Pro/Pro had 6.0- and 3.1-fold higher risks of carotid atherosclerosis, respectively. Arginine 123-126 tumor protein p53 Homo sapiens 98-101 17403527-1 2007 A very common polymorphism of p53, that of codon 72, codes either for a proline (P72) or an arginine (R72). Arginine 92-100 tumor protein p53 Homo sapiens 30-33 17208332-1 2007 The TP53 gene has a polymorphism in exon 4 at codon 72 that presents the arginine or proline genotype. Arginine 73-81 tumor protein p53 Homo sapiens 4-8 17595776-6 2007 Those who had Arg/Arg at p53 codon 72 showed a 2.68-fold (95% confidence interval = 1.19-6.01) increased risk of oral cancer compared to those with Pro/Pro. Arginine 14-17 tumor protein p53 Homo sapiens 25-28 17595776-6 2007 Those who had Arg/Arg at p53 codon 72 showed a 2.68-fold (95% confidence interval = 1.19-6.01) increased risk of oral cancer compared to those with Pro/Pro. Arginine 18-21 tumor protein p53 Homo sapiens 25-28 17595776-9 2007 CONCLUSION: Our findings suggest that the homozygous Arg allele of the p53 codon 72 may be associated with the development of oral cancer and be a useful marker for primary prevention and anticancer intervention. Arginine 53-56 tumor protein p53 Homo sapiens 71-74 17331670-7 2007 The p53 72 Arg allele showed a borderline association (p = 0.07). Arginine 11-14 tumor protein p53 Homo sapiens 4-7 17599946-1 2007 A TP53 gene polymorphism, resulting in an arginine (R) to proline (P) at codon 72 (TP53 R72P), has been associated with the susceptibility to various cancers. Arginine 42-50 tumor protein p53 Homo sapiens 2-6 17599946-1 2007 A TP53 gene polymorphism, resulting in an arginine (R) to proline (P) at codon 72 (TP53 R72P), has been associated with the susceptibility to various cancers. Arginine 42-50 tumor protein p53 Homo sapiens 83-87 17631738-2 2007 The wild type p53 protein presents a common polymorphism at position 72 resulting in either a proline or an arginine residue at this position, leading to differences between the two variants in the induction of apoptosis. Arginine 108-116 tumor protein p53 Homo sapiens 14-17 17631738-7 2007 All of the RA patients and controls were genotyped by the polymerase chain reaction and allele-specific oligonucleotide techniques for p53 gene polymorphism Arg/Pro at codon 72. Arginine 157-160 tumor protein p53 Homo sapiens 135-138 17474797-3 2007 The two non-synonymous single-nucleotide polymorphisms (SNPs) TP53 codon 72 Arg/Pro G>C and CDKN1A codon 31 Ser/Arg C>A were genotyped in 92 normal fibroblast cell strains of different radiosensitivity. Arginine 76-79 tumor protein p53 Homo sapiens 62-66 17406354-1 2007 The preferential retention of the arginine allele at the p53 codon 72 locus is commonly observed in tumours from arginine/proline heterozygotes. Arginine 34-42 tumor protein p53 Homo sapiens 57-60 17406354-1 2007 The preferential retention of the arginine allele at the p53 codon 72 locus is commonly observed in tumours from arginine/proline heterozygotes. Arginine 113-121 tumor protein p53 Homo sapiens 57-60 17406354-3 2007 Here, we show that the transient transfection of the proline allele in p53 null cancer cells exposed to low oxygen tension or to the hypoxia-mimetic drug Desferoxamine induces a higher amount of cell death than the arginine allele. Arginine 215-223 tumor protein p53 Homo sapiens 71-74 17406354-6 2007 These data indicate that the p53 codon 72 proline allele is less permissive for the growth of cancer cells in a hypoxic environment, and suggest that the preferential retention of the arginine allele in the tumour tissues of arginine/proline heterozygous patients may depend upon its lowered capacity to induce cell death in a hypoxic tumour environment. Arginine 184-192 tumor protein p53 Homo sapiens 29-32 17406354-6 2007 These data indicate that the p53 codon 72 proline allele is less permissive for the growth of cancer cells in a hypoxic environment, and suggest that the preferential retention of the arginine allele in the tumour tissues of arginine/proline heterozygous patients may depend upon its lowered capacity to induce cell death in a hypoxic tumour environment. Arginine 225-233 tumor protein p53 Homo sapiens 29-32 17297916-9 2007 We, therefore, generated an artificial p53, containing arginine residues N-terminal to the phospho-acceptor site, creating a better DAPK-1 peptide consensus and demonstrated that the Km for p531-66[ET-->RR] and ATP is elevated. Arginine 55-63 tumor protein p53 Homo sapiens 39-42 17223878-1 2007 BACKGROUND: p53 has a common polymorphism at amino acid 72, encoding either arginine or proline. Arginine 76-84 tumor protein p53 Homo sapiens 12-15 17319790-11 2007 In the younger women group, the p53 BstUI polymorphism genotype frequencies were 6.2% for BstUIPro/Pro, 31.0% for BstUIArg/Pro and 62.8% for BstUIArg/Arg in controls and 11.11 %, 40.74% and 48.15% in cases respectively. Arginine 119-122 tumor protein p53 Homo sapiens 32-35 17945002-0 2007 Implication of BRCA2 -26G>A 5" untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Arginine 146-149 tumor protein p53 Homo sapiens 133-136 17945002-9 2007 The p53 codon 72 Arg homozygous genotype was found to be over-represented in patients (P = 0.0005, OR = 2.3, 95% CI = 1.4 to 3.6). Arginine 17-20 tumor protein p53 Homo sapiens 4-7 17189187-4 2006 Mutation of K120 to arginine, as occurs in human cancer, debilitates K120 acetylation and diminishes p53-mediated apoptosis without affecting cell-cycle arrest. Arginine 20-28 tumor protein p53 Homo sapiens 101-104 17123452-6 2006 When evaluated by several pathway and biological process analysis programs, these proteins are demonstrated to be involved with a high degree of confidence (p values < 2.0 E-05) in glycolysis, propanoate metabolism, pyruvate metabolism, urea cycle and arginine/proline metabolism, as well as in the non-metabolic p53 and FAS pathways. Arginine 255-263 tumor protein p53 Homo sapiens 316-319 17177838-8 2006 In conclusion, based on the findings of this study, it is suggested that p53 Arg homozygosity could act as a potential risk factor for the tumorigenesis of the cervix. Arginine 77-80 tumor protein p53 Homo sapiens 73-76 17177838-10 2006 p53 Arg homozygosity and HR-HPV E6 positive simultaneously can predict the fate of cervical lesions. Arginine 4-7 tumor protein p53 Homo sapiens 0-3 17062352-2 2006 It was found that the p53 gene condon 282 mutation (Arg/Leu) may destabilize the H2 helix and DNA binding in the major groove by compromising the contacts of p53 protein with the beta-hairpin of DNA binding surface. Arginine 52-55 tumor protein p53 Homo sapiens 22-25 16721787-3 2006 Among 856 colorectal adenoma cases and 1,184 controls, we observed a modest association with p53 Arg72Pro genotype (multivariate odds ratio (OR) = 1.25, 95% confidence interval (CI) = 1.04-1.50 for Arg/Pro and Pro/Pro vs. Arg/Arg). Arginine 97-100 tumor protein p53 Homo sapiens 93-96 16721787-3 2006 Among 856 colorectal adenoma cases and 1,184 controls, we observed a modest association with p53 Arg72Pro genotype (multivariate odds ratio (OR) = 1.25, 95% confidence interval (CI) = 1.04-1.50 for Arg/Pro and Pro/Pro vs. Arg/Arg). Arginine 198-201 tumor protein p53 Homo sapiens 93-96 16721787-3 2006 Among 856 colorectal adenoma cases and 1,184 controls, we observed a modest association with p53 Arg72Pro genotype (multivariate odds ratio (OR) = 1.25, 95% confidence interval (CI) = 1.04-1.50 for Arg/Pro and Pro/Pro vs. Arg/Arg). Arginine 198-201 tumor protein p53 Homo sapiens 93-96 17062352-2 2006 It was found that the p53 gene condon 282 mutation (Arg/Leu) may destabilize the H2 helix and DNA binding in the major groove by compromising the contacts of p53 protein with the beta-hairpin of DNA binding surface. Arginine 52-55 tumor protein p53 Homo sapiens 158-161 16790523-4 2006 The integrin receptor is near the Arg-Gly-Asp (RGD) recognition site on the integrin; an integrin-binding RGD peptide inhibits induction by resveratrol of ERK1/2- and p53-dependent apoptosis. Arginine 34-37 tumor protein p53 Homo sapiens 167-170 17007666-5 2006 DNA was extracted from the buccal swabs obtained from 70 women experiencing implantation failure and polymerase chain reaction amplification of p53 arginine (Arg) 72 and proline (Pro) 72 variants were performed. Arginine 148-156 tumor protein p53 Homo sapiens 144-147 17094395-0 2006 The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections. Arginine 17-20 tumor protein p53 Homo sapiens 4-7 17094395-0 2006 The p53 codon 72 arg/arg homozygous women in central Italy are at increased risk for HPV infections. Arginine 21-24 tumor protein p53 Homo sapiens 4-7 17094395-1 2006 BACKGROUND: The oncoprotein E6 binds to and degrades the p53 tumor suppressor protein, with different efficacy depending on the p53 codon 72 (arg/pro) polymorphism. Arginine 142-145 tumor protein p53 Homo sapiens 57-60 16835507-3 2006 We evaluated the linkage of the polymorphic variants (Arg/Pro) on TP53 codon 72 with nasopharyngeal cancer development in a case-control study with 392 individuals from a northern Portuguese population, including 107 patients with nasopharyngeal carcinoma and 285 healthy controls. Arginine 54-57 tumor protein p53 Homo sapiens 66-70 16788846-6 2006 CONCLUSIONS: We were unable to demonstrate any association between the GST genotypes studied and the risk of ovarian cancer but the inheritance of a heterozygous Arg/Pro genotype of p53 increased the risk of ovarian cancer more than 2.5 times (OR = 2.571; 95% CI = 1.453-4.550). Arginine 162-165 tumor protein p53 Homo sapiens 182-185 16579792-6 2006 The p53(F270A:6KR) chimaeric mutant (where 6KR refers to the simultaneous mutation of lysine residues at positions 370, 372, 373, 381, 382 and 386 to arginine) maintains the high-molecular-mass covalent adducts and is modified in an MDM2-dependent manner. Arginine 150-158 tumor protein p53 Homo sapiens 4-7 16786124-1 2006 The TP53 polymorphism occurs at codon 72 of exon 4 with two alleles encoding either arginine or proline. Arginine 84-92 tumor protein p53 Homo sapiens 4-8 16499995-11 2006 Somatic TP53 mutations were found in 62 out of 240 NSCLC patients (26%), more frequently in Pro carriers (31%) than in Arg homozygotes (20%, p = 0.06). Arginine 119-122 tumor protein p53 Homo sapiens 8-12 16761419-9 2006 The frequency of p53 Arg homozygosity in HRHPV E6-positive cervical squamous cancers (64.06%) was greater than in HRHPV E6-negative cervical squamous cancers (35.29%) and in HRHPV E6-positive normal samples (33.33%). Arginine 21-24 tumor protein p53 Homo sapiens 17-20 16697770-9 2006 Higher ORs for COPD were seen for persons with p53 Pro/Pro or Pro/Arg genotypes against Arg/Arg genotype [OR = 2.35, 95% CI 1.27-4.39, P = 0.008], or p21 Arg/Arg and Arg/Ser genotypes against Ser/Ser genotype [OR = 2.07, 95% CI 1.06-4.05, P = 0.033]. Arginine 66-69 tumor protein p53 Homo sapiens 47-50 16697770-9 2006 Higher ORs for COPD were seen for persons with p53 Pro/Pro or Pro/Arg genotypes against Arg/Arg genotype [OR = 2.35, 95% CI 1.27-4.39, P = 0.008], or p21 Arg/Arg and Arg/Ser genotypes against Ser/Ser genotype [OR = 2.07, 95% CI 1.06-4.05, P = 0.033]. Arginine 88-91 tumor protein p53 Homo sapiens 47-50 16697770-9 2006 Higher ORs for COPD were seen for persons with p53 Pro/Pro or Pro/Arg genotypes against Arg/Arg genotype [OR = 2.35, 95% CI 1.27-4.39, P = 0.008], or p21 Arg/Arg and Arg/Ser genotypes against Ser/Ser genotype [OR = 2.07, 95% CI 1.06-4.05, P = 0.033]. Arginine 88-91 tumor protein p53 Homo sapiens 47-50 16697770-9 2006 Higher ORs for COPD were seen for persons with p53 Pro/Pro or Pro/Arg genotypes against Arg/Arg genotype [OR = 2.35, 95% CI 1.27-4.39, P = 0.008], or p21 Arg/Arg and Arg/Ser genotypes against Ser/Ser genotype [OR = 2.07, 95% CI 1.06-4.05, P = 0.033]. Arginine 88-91 tumor protein p53 Homo sapiens 47-50 16697770-9 2006 Higher ORs for COPD were seen for persons with p53 Pro/Pro or Pro/Arg genotypes against Arg/Arg genotype [OR = 2.35, 95% CI 1.27-4.39, P = 0.008], or p21 Arg/Arg and Arg/Ser genotypes against Ser/Ser genotype [OR = 2.07, 95% CI 1.06-4.05, P = 0.033]. Arginine 88-91 tumor protein p53 Homo sapiens 47-50 16697770-9 2006 Higher ORs for COPD were seen for persons with p53 Pro/Pro or Pro/Arg genotypes against Arg/Arg genotype [OR = 2.35, 95% CI 1.27-4.39, P = 0.008], or p21 Arg/Arg and Arg/Ser genotypes against Ser/Ser genotype [OR = 2.07, 95% CI 1.06-4.05, P = 0.033]. Arginine 88-91 tumor protein p53 Homo sapiens 47-50 16761419-4 2006 RESULTS: The frequencies of p53 Arg homozygosity in cervical squamous cancer, cervical adenocarcinoma and CIN (II - III) were 58.020%, 55.55% and 59.09% respectively, greater than those of p53 Arg/Pro heterozygosity (30.86%, 27.78%, 21.59%) and those of p53 Pro homozygosity (11.12%, 16.67%, 19.32%). Arginine 32-35 tumor protein p53 Homo sapiens 28-31 16761419-4 2006 RESULTS: The frequencies of p53 Arg homozygosity in cervical squamous cancer, cervical adenocarcinoma and CIN (II - III) were 58.020%, 55.55% and 59.09% respectively, greater than those of p53 Arg/Pro heterozygosity (30.86%, 27.78%, 21.59%) and those of p53 Pro homozygosity (11.12%, 16.67%, 19.32%). Arginine 193-196 tumor protein p53 Homo sapiens 28-31 16761419-5 2006 The normal cervical samples also showed less frequency of p53 Arg homozygosity (23.33%) than cervical squamous cancer. Arginine 62-65 tumor protein p53 Homo sapiens 58-61 16605112-3 2006 AAG to AGT transversion at codon 249 of the P53 gene arg-ser (249ser) has been identified as a hotspot, reflecting DNA damage caused by aflatoxin B1 metabolites in HCC. Arginine 53-56 tumor protein p53 Homo sapiens 44-47 17113725-1 2006 BACKGROUND: A common Arg/Pro polymorphism at codon 72 of the TP53 gene has been investigated as a risk factor for cancer in different populations. Arginine 21-24 tumor protein p53 Homo sapiens 61-65 16646561-2 2006 The codon 72 polymorphism on exon 4 in the p53 gene produces variant proteins with either arginine (Arg) or proline (Pro), and is associated with an increased susceptibility of cancers of the lung, esophagus, breast, cervix and nasopharynx on a genetic basis. Arginine 90-98 tumor protein p53 Homo sapiens 43-46 16646561-2 2006 The codon 72 polymorphism on exon 4 in the p53 gene produces variant proteins with either arginine (Arg) or proline (Pro), and is associated with an increased susceptibility of cancers of the lung, esophagus, breast, cervix and nasopharynx on a genetic basis. Arginine 100-103 tumor protein p53 Homo sapiens 43-46 16646561-8 2006 As the frequency of p53 Arg allele increased, the cancer was of a more poorly differentiated type. Arginine 24-27 tumor protein p53 Homo sapiens 20-23 16646561-10 2006 Increased frequency of p53 Arg allele is associated with more poorly differentiated cancers. Arginine 27-30 tumor protein p53 Homo sapiens 23-26 16569330-6 2006 DNA was extracted from the buccal swabs and PCR amplification of p53 arginine(Arg)72 and proline(Pro)72 variants was performed. Arginine 69-77 tumor protein p53 Homo sapiens 65-68 16552814-8 2006 CONCLUSION: The findings of the present study indicate that p53 codon 72 arginine homozygous genotype may represent a genetic predisposing factor for colon cancer development. Arginine 73-81 tumor protein p53 Homo sapiens 60-63 16318864-6 2006 After adjustment for other possible confounders, the incidence of p53 overexpression was significantly decreased in patients with Pro/Pro genotype with an odds ratio (OR) of 0.21 (95% CI: 0.067-0.64) (p = 0.0065) compared with incidence in patients with Arg/Arg genotype. Arginine 254-257 tumor protein p53 Homo sapiens 66-69 16318864-6 2006 After adjustment for other possible confounders, the incidence of p53 overexpression was significantly decreased in patients with Pro/Pro genotype with an odds ratio (OR) of 0.21 (95% CI: 0.067-0.64) (p = 0.0065) compared with incidence in patients with Arg/Arg genotype. Arginine 258-261 tumor protein p53 Homo sapiens 66-69 16318864-11 2006 There was also a higher incidence of, but without reaching a statistical significance, p53 mutation in patients with p53 overexpression (OR[95% CI]: 2.18 [0.52-9.6]) and codon 72 Arg/Arg genotype (OR [95% CI] of 0.8 [0.13-4.2], comparing genotypes of Pro/Pro and Arg/Pro with Arg/Arg). Arginine 179-182 tumor protein p53 Homo sapiens 87-90 16318864-11 2006 There was also a higher incidence of, but without reaching a statistical significance, p53 mutation in patients with p53 overexpression (OR[95% CI]: 2.18 [0.52-9.6]) and codon 72 Arg/Arg genotype (OR [95% CI] of 0.8 [0.13-4.2], comparing genotypes of Pro/Pro and Arg/Pro with Arg/Arg). Arginine 183-186 tumor protein p53 Homo sapiens 87-90 16318864-11 2006 There was also a higher incidence of, but without reaching a statistical significance, p53 mutation in patients with p53 overexpression (OR[95% CI]: 2.18 [0.52-9.6]) and codon 72 Arg/Arg genotype (OR [95% CI] of 0.8 [0.13-4.2], comparing genotypes of Pro/Pro and Arg/Pro with Arg/Arg). Arginine 183-186 tumor protein p53 Homo sapiens 87-90 16318864-11 2006 There was also a higher incidence of, but without reaching a statistical significance, p53 mutation in patients with p53 overexpression (OR[95% CI]: 2.18 [0.52-9.6]) and codon 72 Arg/Arg genotype (OR [95% CI] of 0.8 [0.13-4.2], comparing genotypes of Pro/Pro and Arg/Pro with Arg/Arg). Arginine 183-186 tumor protein p53 Homo sapiens 87-90 16318864-11 2006 There was also a higher incidence of, but without reaching a statistical significance, p53 mutation in patients with p53 overexpression (OR[95% CI]: 2.18 [0.52-9.6]) and codon 72 Arg/Arg genotype (OR [95% CI] of 0.8 [0.13-4.2], comparing genotypes of Pro/Pro and Arg/Pro with Arg/Arg). Arginine 183-186 tumor protein p53 Homo sapiens 87-90 16699611-4 2006 AIM: To investigate the possible association between p53 arginine/72 proline polymorphism and susceptibility to colorectal cancer. Arginine 57-65 tumor protein p53 Homo sapiens 53-56 16354872-7 2005 CONCLUSIONS: HPV detected in a small proportion of lung cancer patients in India demonstrated an exclusive prevalence of HPV type 18, and there was a significantly higher frequency of p53 Arg/Arg genotype when compared to that of control subjects. Arginine 188-191 tumor protein p53 Homo sapiens 184-187 16168468-3 2006 RESULTS: When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). Arginine 73-76 tumor protein p53 Homo sapiens 14-17 16168468-3 2006 RESULTS: When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). Arginine 77-80 tumor protein p53 Homo sapiens 14-17 16168468-3 2006 RESULTS: When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). Arginine 77-80 tumor protein p53 Homo sapiens 14-17 16168468-3 2006 RESULTS: When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). Arginine 77-80 tumor protein p53 Homo sapiens 14-17 16168468-3 2006 RESULTS: When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). Arginine 77-80 tumor protein p53 Homo sapiens 14-17 16168468-3 2006 RESULTS: When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). Arginine 77-80 tumor protein p53 Homo sapiens 14-17 16168468-6 2006 CONCLUSION: Homozygous Arg at codon 72 of the p53 gene may be a risk factor for developing endometrial cancer in a Japanese population. Arginine 23-26 tumor protein p53 Homo sapiens 46-49 16896365-4 2006 P53 gene polymorphisms include codon11 Glu/Gln or Lys (GAG->CAG or AAG), codon 72 Arg/Pro (CGC->CCC), and codon 248 Arg/Thr (CGG->TCG). Arginine 85-88 tumor protein p53 Homo sapiens 0-3 16554913-9 2006 Our results suggest that Arg allele at codon 72 of p53 gene might affect the risk of ultraviolet-induced basal cell carcinoma. Arginine 25-28 tumor protein p53 Homo sapiens 51-54 16362795-2 2005 TP53 codon 72, which produces variant proteins with an arginine (Arg) or proline (Pro), has been reported to be associated with cancers of the lung, oesophagus, stomach and cervix. Arginine 55-63 tumor protein p53 Homo sapiens 0-4 16362795-2 2005 TP53 codon 72, which produces variant proteins with an arginine (Arg) or proline (Pro), has been reported to be associated with cancers of the lung, oesophagus, stomach and cervix. Arginine 65-68 tumor protein p53 Homo sapiens 0-4 16362795-9 2005 The allele frequencies of the TP53 polymorphism were: Arg=0.74 and Pro=0.26. Arginine 54-57 tumor protein p53 Homo sapiens 30-34 16354872-7 2005 CONCLUSIONS: HPV detected in a small proportion of lung cancer patients in India demonstrated an exclusive prevalence of HPV type 18, and there was a significantly higher frequency of p53 Arg/Arg genotype when compared to that of control subjects. Arginine 192-195 tumor protein p53 Homo sapiens 184-187 16354872-8 2005 Observation of a shorter duration of symptoms (< or = 4 months) in as many as 78% (seven of nine stage IV patients) with Arg/Pro genotype may be an indication that lung cancer patients with the heterozygous p53 genotype are more susceptible to early progression. Arginine 124-127 tumor protein p53 Homo sapiens 210-213 16307686-2 2005 Furthermore, the polymorphism at codon 72 (encoding either arginine or proline) of the p53 tumor-suppressor gene is discussed as a possible determinant for cancer risk. Arginine 59-67 tumor protein p53 Homo sapiens 87-90 15905205-2 2005 The codon 72 polymorphism has been proposed to alter the phenotype of TP53 mutations, and TP53 mutations have been reported to occur preferentially on the arginine allele. Arginine 155-163 tumor protein p53 Homo sapiens 90-94 16230424-5 2005 We observed an increased risk of ESCC associated with the P53 Pro/Pro (OR, 1.83; 95% CI, 1.43-2.35; P < 0.001) or MDM2 GG (OR, 1.49; 95% CI, 1.16-1.91; P = 0.002) genotype, compared with the P53 Arg/Arg or MDM2 TT genotype, respectively. Arginine 198-201 tumor protein p53 Homo sapiens 58-61 16230424-5 2005 We observed an increased risk of ESCC associated with the P53 Pro/Pro (OR, 1.83; 95% CI, 1.43-2.35; P < 0.001) or MDM2 GG (OR, 1.49; 95% CI, 1.16-1.91; P = 0.002) genotype, compared with the P53 Arg/Arg or MDM2 TT genotype, respectively. Arginine 202-205 tumor protein p53 Homo sapiens 58-61 16054204-8 2005 The p21 arginine allele was significantly associated with CaCx in the p53 proline non-homozygous group of subjects (OR(age-adjusted) = 2.68; 95% CI: 1.21-5.91; P = 0.01), and specifically in the p53 heterozygous group (OR(age-adjusted) = 2.91; 95% CI = 1.12-7.56; P = 0.03). Arginine 8-16 tumor protein p53 Homo sapiens 70-73 16203772-1 2005 PURPOSE: The Arg/Pro polymorphism in codon 72 of p53 was recently associated with age of onset of colorectal cancer in Lynch syndrome. Arginine 13-16 tumor protein p53 Homo sapiens 49-52 16054204-8 2005 The p21 arginine allele was significantly associated with CaCx in the p53 proline non-homozygous group of subjects (OR(age-adjusted) = 2.68; 95% CI: 1.21-5.91; P = 0.01), and specifically in the p53 heterozygous group (OR(age-adjusted) = 2.91; 95% CI = 1.12-7.56; P = 0.03). Arginine 8-16 tumor protein p53 Homo sapiens 195-198 16172238-1 2005 Polymorphism at codon 72 of p53 results in either the arginine or proline form of p53, whose functional significance in carcinogenesis is controversial. Arginine 54-62 tumor protein p53 Homo sapiens 28-31 16199549-1 2005 The polymorphic variants at codon 72 of the p53 gene were shown to be functionally distinct in vitro, whereby the arginine (arg) variant induces apoptosis more efficiently than the proline (pro) variant. Arginine 114-122 tumor protein p53 Homo sapiens 44-47 16199549-1 2005 The polymorphic variants at codon 72 of the p53 gene were shown to be functionally distinct in vitro, whereby the arginine (arg) variant induces apoptosis more efficiently than the proline (pro) variant. Arginine 114-117 tumor protein p53 Homo sapiens 44-47 16082224-1 2005 A common polymorphism at codon 72 in p53 gene leads to an arginine to proline aminoacidic substitution which affects in an age-dependent manner the susceptibility of cells to undergo apoptosis after oxidative stress. Arginine 58-66 tumor protein p53 Homo sapiens 37-40 16172238-2 2005 We have investigated if the expression of these p53 polymorphs is selectively regulated, using mRNA from peripheral blood of healthy Asian (Chinese) and the Caucasian (Polish) arginine/proline (arg/pro) heterozygote subjects. Arginine 176-184 tumor protein p53 Homo sapiens 48-51 16172238-2 2005 We have investigated if the expression of these p53 polymorphs is selectively regulated, using mRNA from peripheral blood of healthy Asian (Chinese) and the Caucasian (Polish) arginine/proline (arg/pro) heterozygote subjects. Arginine 176-179 tumor protein p53 Homo sapiens 48-51 16172238-6 2005 Together, the data suggest that the expression of the different p53 polymorphs is selectively regulated in different ethnic populations, and that the arg allele is activated during cancer development in Asians. Arginine 150-153 tumor protein p53 Homo sapiens 64-67 16007417-11 2005 CONCLUSION: The Arg/Arg genotype of the Arg72Pro polymorphism in p53 is associated with increased likelihood of a bad outcome at discharge from the SICU. Arginine 16-19 tumor protein p53 Homo sapiens 65-68 16007417-11 2005 CONCLUSION: The Arg/Arg genotype of the Arg72Pro polymorphism in p53 is associated with increased likelihood of a bad outcome at discharge from the SICU. Arginine 20-23 tumor protein p53 Homo sapiens 65-68 16109171-1 2005 BACKGROUND: A common sequence polymorphism at codon 72 of the p53 gene encoding either arginine or proline was recently shown to be functionally relevant for apoptosis induction in vitro. Arginine 87-95 tumor protein p53 Homo sapiens 62-65 16140998-8 2005 CONCLUSIONS: The p53 codon 72 Arg/Pro polymorphism is not associated with age of onset or severity of glaucoma. Arginine 30-33 tumor protein p53 Homo sapiens 17-20 16009172-6 2005 MAIN OUTCOME MEASURE(S): Genotyping was performed by polymerase chain reaction-based amplification of the Arg and Pro variants at codon 72 of the p53 gene and by restriction fragment length polymorphism analysis of the G/G and G/A alleles in exon 4 of the ANGPT2 gene. Arginine 106-109 tumor protein p53 Homo sapiens 146-149 16048565-1 2005 BACKGROUND AND AIMS: A specific mutation at codon 249 of the p53 tumor suppressor gene (guanine to thymine; arginine to serine [249(serine)p53]) is present in the cell-free plasma of 30-47% of patients with hepatocellular carcinoma (HCC) in regions with uniformly high levels of dietary exposure to the fungal toxin, aflatoxin B(1). Arginine 108-116 tumor protein p53 Homo sapiens 61-64 16048565-1 2005 BACKGROUND AND AIMS: A specific mutation at codon 249 of the p53 tumor suppressor gene (guanine to thymine; arginine to serine [249(serine)p53]) is present in the cell-free plasma of 30-47% of patients with hepatocellular carcinoma (HCC) in regions with uniformly high levels of dietary exposure to the fungal toxin, aflatoxin B(1). Arginine 108-116 tumor protein p53 Homo sapiens 139-142 15899386-2 2005 TP53 has two common polymorphic forms encoding either proline or arginine, at position 72, and the presence of homozygous arginine has been reported as a risk factor for cervical cancer in many populations. Arginine 65-73 tumor protein p53 Homo sapiens 0-4 15899386-2 2005 TP53 has two common polymorphic forms encoding either proline or arginine, at position 72, and the presence of homozygous arginine has been reported as a risk factor for cervical cancer in many populations. Arginine 122-130 tumor protein p53 Homo sapiens 0-4 15942101-4 2005 Direct sequencing revealed that they all had missense mutation in codon 175 (G to A) of arginine switched to histidine, suggesting a germline mutation of TP53. Arginine 88-96 tumor protein p53 Homo sapiens 154-158 16158823-10 2005 We found overexpression of the p53 protein in lymphoid cells and a point missense mutation in codon 280 at exon 8 that changed AGA (Arg) to AGT (Ser). Arginine 132-135 tumor protein p53 Homo sapiens 31-34 15966238-0 2005 Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Arginine 0-8 tumor protein p53 Homo sapiens 36-39 15814626-2 2005 An Arg/Pro polymorphism at codon 72 of the p53 gene alters the ability of the p53 protein to induce apoptosis, influences the behavior of mutant p53, decreases DNA repair capacity, and may be linked with an increased risk of lung cancer. Arginine 3-6 tumor protein p53 Homo sapiens 43-46 15814626-2 2005 An Arg/Pro polymorphism at codon 72 of the p53 gene alters the ability of the p53 protein to induce apoptosis, influences the behavior of mutant p53, decreases DNA repair capacity, and may be linked with an increased risk of lung cancer. Arginine 3-6 tumor protein p53 Homo sapiens 78-81 15814626-2 2005 An Arg/Pro polymorphism at codon 72 of the p53 gene alters the ability of the p53 protein to induce apoptosis, influences the behavior of mutant p53, decreases DNA repair capacity, and may be linked with an increased risk of lung cancer. Arginine 3-6 tumor protein p53 Homo sapiens 78-81 15814626-7 2005 p53 mutations were significantly (P = 0.01) associated with the number of codon 72 Pro alleles: Pro/Pro homozygotes, 17 of 26 (65%); Arg/Pro heterozygotes, 45 of 79 (57%); and Arg/Arg homozygotes, 31 of 77 (40%). Arginine 133-136 tumor protein p53 Homo sapiens 0-3 15814626-7 2005 p53 mutations were significantly (P = 0.01) associated with the number of codon 72 Pro alleles: Pro/Pro homozygotes, 17 of 26 (65%); Arg/Pro heterozygotes, 45 of 79 (57%); and Arg/Arg homozygotes, 31 of 77 (40%). Arginine 176-179 tumor protein p53 Homo sapiens 0-3 15814626-7 2005 p53 mutations were significantly (P = 0.01) associated with the number of codon 72 Pro alleles: Pro/Pro homozygotes, 17 of 26 (65%); Arg/Pro heterozygotes, 45 of 79 (57%); and Arg/Arg homozygotes, 31 of 77 (40%). Arginine 176-179 tumor protein p53 Homo sapiens 0-3 15608028-6 2005 METHODS: Genotyping was performed by PCR-based amplification of the p53 Arg and Pro variants at codon 72 in 175 cases of IRM and 143 controls. Arginine 72-75 tumor protein p53 Homo sapiens 68-71 15583690-7 2005 Thus, the present study revealed that (a) the Arg allele is associated with p53 mutations, (b) the Pro allele is preferentially lost in OSCCs associated with cigarette smoking and AQ chewing, while the frequency of Arg allele loss is increased with alcohol drinking, and (c) haploinsufficiency of p53 is in itself likely to contribute to tumour progression in Taiwanese OSCCs. Arginine 46-49 tumor protein p53 Homo sapiens 76-79 15756275-6 2005 We conclude that arginine homozygosity at codon 72 of the p53 gene is associated with a significant increased breast cancer risk in Jewish high-risk population. Arginine 17-25 tumor protein p53 Homo sapiens 58-61 15583690-7 2005 Thus, the present study revealed that (a) the Arg allele is associated with p53 mutations, (b) the Pro allele is preferentially lost in OSCCs associated with cigarette smoking and AQ chewing, while the frequency of Arg allele loss is increased with alcohol drinking, and (c) haploinsufficiency of p53 is in itself likely to contribute to tumour progression in Taiwanese OSCCs. Arginine 215-218 tumor protein p53 Homo sapiens 297-300 16122882-1 2005 BACKGROUND: The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated in increasing susceptibility of the cervix to human papillomavirus (HPV) infection and thus altering cancer risk. Arginine 16-19 tumor protein p53 Homo sapiens 78-81 15732191-9 2005 Replacement of arginine (Arg) by proline (Pro) at position 72 of human p53 decreases its apoptotic potential [Dumont et al., 2003. Arginine 15-23 tumor protein p53 Homo sapiens 71-74 15732191-9 2005 Replacement of arginine (Arg) by proline (Pro) at position 72 of human p53 decreases its apoptotic potential [Dumont et al., 2003. Arginine 25-28 tumor protein p53 Homo sapiens 71-74 15732191-14 2005 Using a formal meta-analysis of the published literature we show that carriers of the TP53 codon 72 Pro/Pro genotype have an increased cancer risk compared to Arg/Arg carriers (p<0.05). Arginine 159-162 tumor protein p53 Homo sapiens 86-90 15732191-14 2005 Using a formal meta-analysis of the published literature we show that carriers of the TP53 codon 72 Pro/Pro genotype have an increased cancer risk compared to Arg/Arg carriers (p<0.05). Arginine 163-166 tumor protein p53 Homo sapiens 86-90 16289503-5 2005 The TP53 Arg/Arg codon 72 genotype was detected in 21.9% of ICSCC and in 18.2% of CIN3 but only in 6% of CIN1-2 and in 5.2% of controls (P<0.05). Arginine 9-12 tumor protein p53 Homo sapiens 4-8 16289503-5 2005 The TP53 Arg/Arg codon 72 genotype was detected in 21.9% of ICSCC and in 18.2% of CIN3 but only in 6% of CIN1-2 and in 5.2% of controls (P<0.05). Arginine 13-16 tumor protein p53 Homo sapiens 4-8 16289503-8 2005 We conclude that TP53 Arg/Arg codon 72 genotype is a relevant risk factor for invasive squamous cell carcinoma of the conjunctiva and for CIN3 in the Ugandan population. Arginine 22-25 tumor protein p53 Homo sapiens 17-21 16289503-8 2005 We conclude that TP53 Arg/Arg codon 72 genotype is a relevant risk factor for invasive squamous cell carcinoma of the conjunctiva and for CIN3 in the Ugandan population. Arginine 26-29 tumor protein p53 Homo sapiens 17-21 16122882-1 2005 BACKGROUND: The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated in increasing susceptibility of the cervix to human papillomavirus (HPV) infection and thus altering cancer risk. Arginine 20-23 tumor protein p53 Homo sapiens 78-81 16122882-1 2005 BACKGROUND: The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated in increasing susceptibility of the cervix to human papillomavirus (HPV) infection and thus altering cancer risk. Arginine 20-23 tumor protein p53 Homo sapiens 78-81 15623478-1 2005 BACKGROUND: The predictive value of codon 72 arginine homozygosity at the p53 gene for human papilloma virus associated cervical cancer risk remains inconclusive. Arginine 45-53 tumor protein p53 Homo sapiens 74-77 15623478-7 2005 The p53 codon 72 arginine homozygous genotype was significantly over represented in patients compared with controls. Arginine 17-25 tumor protein p53 Homo sapiens 4-7 15623478-10 2005 CONCLUSION: p53 codon 72 arginine homozygotes appear to be at greater risk of developing squamous cell carcinoma of the uterine cervix. Arginine 25-33 tumor protein p53 Homo sapiens 12-15 15183530-1 2004 A common germline polymorphism of p53 gene produces an Arginine to Proline change at aminoacid position 72. Arginine 55-63 tumor protein p53 Homo sapiens 34-37 15365822-2 2004 A recent report suggests that a polymorphism of the p53 tumor suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in the malignant transformation of colorectal adenoma to cancer. Arginine 140-148 tumor protein p53 Homo sapiens 52-55 15365822-2 2004 A recent report suggests that a polymorphism of the p53 tumor suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in the malignant transformation of colorectal adenoma to cancer. Arginine 140-148 tumor protein p53 Homo sapiens 179-182 15548361-1 2004 According to recent reports, some cancer types exhibit nonrandom allele loss at codon 72 in exon 4 of the p53 gene [coding for proline (72Pro) or arginine (72Arg)]. Arginine 146-154 tumor protein p53 Homo sapiens 106-109 15554555-8 2004 Our results suggest that homozygous arginine at codon 72 of p53 may represent a risk factor for developing ovarian malignancies and may affect the differentiation of endometrial cancer. Arginine 36-44 tumor protein p53 Homo sapiens 60-63 16302680-7 2005 In conclusion, our finding suggests the functional p53 codon 72 polymorphism may be associated with SLE susceptibility, suggesting individuals who carry the Pro allele may have a higher risk to SLE susceptibility than those with the Arg allele. Arginine 233-236 tumor protein p53 Homo sapiens 51-54 15844595-1 2005 OBJECTIVE: To investigate the codon-72 polymorphism of the tumor suppressor gene p53, codon-72 encodes arginine (Arg) or proline (Pro) for a genetic predisposition,to keloid or hypertrophic scar. Arginine 103-111 tumor protein p53 Homo sapiens 81-84 15844595-1 2005 OBJECTIVE: To investigate the codon-72 polymorphism of the tumor suppressor gene p53, codon-72 encodes arginine (Arg) or proline (Pro) for a genetic predisposition,to keloid or hypertrophic scar. Arginine 113-116 tumor protein p53 Homo sapiens 81-84 15547693-8 2004 DNA sequencing in FaDu cells showed a G/T point mutation at codon 248 in exon 7 of p53 gene, resulting in an arginine-to-leucine substitution. Arginine 109-117 tumor protein p53 Homo sapiens 83-86 15364927-2 2004 Here we show that via its acidic domain, Daxx binds to the COOH-terminal domain of p53, whose positive charges are critical for this interaction, as Lys to Arg mutations preserved, but Lys to Ala or Ser to Glu mutations abolished Daxx-p53 interaction. Arginine 156-159 tumor protein p53 Homo sapiens 83-86 15364927-2 2004 Here we show that via its acidic domain, Daxx binds to the COOH-terminal domain of p53, whose positive charges are critical for this interaction, as Lys to Arg mutations preserved, but Lys to Ala or Ser to Glu mutations abolished Daxx-p53 interaction. Arginine 156-159 tumor protein p53 Homo sapiens 235-238 15533911-1 2004 A polymorphism at codon 72 of the human tumor suppressor p53 determines translation into either arginine or proline. Arginine 96-104 tumor protein p53 Homo sapiens 57-60 15131588-1 2004 A common arginine to proline polymorphism is harboured at codon 72 of the human p53 gene. Arginine 9-17 tumor protein p53 Homo sapiens 80-83 15302922-6 2004 Multiple p53 sequence alignments with 41 additional species confirmed that Arg-174 is highly conserved. Arginine 75-78 tumor protein p53 Homo sapiens 9-12 15302922-10 2004 A DNA-free p53 structure model predicts that Arg-174 is important for dimerization, whereas Spalax Lys-174 prevents such interactions. Arginine 45-48 tumor protein p53 Homo sapiens 11-14 15183535-12 2004 The higher frequency of p53 somatic mutation in p5372Arg/Arg homozygotes than p5372Pro/Pro homozygotes is consistent with the thesis that the function of p5372Pro/Pro is impaired so that a further alteration of p53 gene is less required in p5372Pro/Pro homozygotes than p5372Arg/Arg homozygotes. Arginine 53-56 tumor protein p53 Homo sapiens 24-27 15183535-12 2004 The higher frequency of p53 somatic mutation in p5372Arg/Arg homozygotes than p5372Pro/Pro homozygotes is consistent with the thesis that the function of p5372Pro/Pro is impaired so that a further alteration of p53 gene is less required in p5372Pro/Pro homozygotes than p5372Arg/Arg homozygotes. Arginine 53-56 tumor protein p53 Homo sapiens 48-51 15183535-12 2004 The higher frequency of p53 somatic mutation in p5372Arg/Arg homozygotes than p5372Pro/Pro homozygotes is consistent with the thesis that the function of p5372Pro/Pro is impaired so that a further alteration of p53 gene is less required in p5372Pro/Pro homozygotes than p5372Arg/Arg homozygotes. Arginine 57-60 tumor protein p53 Homo sapiens 24-27 15183535-12 2004 The higher frequency of p53 somatic mutation in p5372Arg/Arg homozygotes than p5372Pro/Pro homozygotes is consistent with the thesis that the function of p5372Pro/Pro is impaired so that a further alteration of p53 gene is less required in p5372Pro/Pro homozygotes than p5372Arg/Arg homozygotes. Arginine 57-60 tumor protein p53 Homo sapiens 48-51 15257943-1 2004 A single nucleotide polymorphism at TP53 codon 72 means that two alleles exist: A1 (proline residue, Pro72) and A2 (arginine residue, Arg72). Arginine 116-124 tumor protein p53 Homo sapiens 36-40 15145278-1 2004 OBJECTIVES: Although some studies have reported that the arginine isoform on codon 72 of p53 increases the susceptibility to invasive cervical cancer, such data remain controversial. Arginine 57-65 tumor protein p53 Homo sapiens 89-92 15230885-0 2004 Association of p53 arginine polymorphism with skin cancer. Arginine 19-27 tumor protein p53 Homo sapiens 15-18 15230885-1 2004 BACKGROUND: The presence of arginine at codon 72 in p53 protein is proposed to be a genetic risk factor in human papillomavirus (HPV)-related carcinogenesis. Arginine 28-36 tumor protein p53 Homo sapiens 52-55 15230885-4 2004 RESULTS: All EV patients with the malignant form of EV were homozygous for arginine (Arg/Arg) at codon 72 of the p53 gene, in contrast to none with the benign form (P < 0.0001). Arginine 75-83 tumor protein p53 Homo sapiens 113-116 15230885-4 2004 RESULTS: All EV patients with the malignant form of EV were homozygous for arginine (Arg/Arg) at codon 72 of the p53 gene, in contrast to none with the benign form (P < 0.0001). Arginine 85-88 tumor protein p53 Homo sapiens 113-116 15230885-4 2004 RESULTS: All EV patients with the malignant form of EV were homozygous for arginine (Arg/Arg) at codon 72 of the p53 gene, in contrast to none with the benign form (P < 0.0001). Arginine 89-92 tumor protein p53 Homo sapiens 113-116 15230885-5 2004 CONCLUSIONS: p53 arginine polymorphism is likely to be associated with the development of skin malignancies in EV patients from Brazil. Arginine 17-25 tumor protein p53 Homo sapiens 13-16 15095302-2 2004 A selective mutation in TP53 (AGG-->AGT at codon 249, Arg-->Ser) has been identified as a hotspot in HCCs from such areas, reflecting DNA damage caused by aflatoxin metabolites. Arginine 57-60 tumor protein p53 Homo sapiens 24-28 15242600-5 2004 The alpha helix in loop L3 of Cep-1 orients the side chains of two conserved arginines toward DNA; in human p53, both arginines are mutation hotspots, but only one contacts DNA. Arginine 118-127 tumor protein p53 Homo sapiens 108-111 15140517-1 2004 OBJECTIVE: To test the hypothesis that p53 homozygous Arg/Arg genotype at codon 72 is a significant risk factor for the development of HPV induced cervical cancer. Arginine 54-57 tumor protein p53 Homo sapiens 39-42 15140517-1 2004 OBJECTIVE: To test the hypothesis that p53 homozygous Arg/Arg genotype at codon 72 is a significant risk factor for the development of HPV induced cervical cancer. Arginine 58-61 tumor protein p53 Homo sapiens 39-42 15105048-3 2004 The p53 gene displays a common genetic Arg/Pro polymorphism at codon 72 with functional significance, that has been investigated as risk factor in several cancer models. Arginine 39-42 tumor protein p53 Homo sapiens 4-7 15216398-9 2004 The frequency of pro/pro, pro/arg, and arg/arg in p53 codon 72 in cases was 15% (15/99), 58% (57/99), and 27% (27/99) and in controls was 17% (34/193), 48% (92/193), and 35% (67/193), respectively, which was not significantly different. Arginine 30-33 tumor protein p53 Homo sapiens 50-53 15099969-2 2004 In this regard, genetic polymorphism at codon 72 (CCC/proline to CGC/arginine [Pro(72)Arg]) of the p53 gene is one of the most frequently studied subjects. Arginine 69-77 tumor protein p53 Homo sapiens 99-102 15099969-3 2004 An association between endometrial cancer and the polymorphism at codon 31 (AGC/serine to AGA/arginine [Ser(31)Arg]) of the p21 gene, which is known to be a downstream mediator of p53, has also been reported. Arginine 94-102 tumor protein p53 Homo sapiens 180-183 15216398-9 2004 The frequency of pro/pro, pro/arg, and arg/arg in p53 codon 72 in cases was 15% (15/99), 58% (57/99), and 27% (27/99) and in controls was 17% (34/193), 48% (92/193), and 35% (67/193), respectively, which was not significantly different. Arginine 39-42 tumor protein p53 Homo sapiens 50-53 15216398-9 2004 The frequency of pro/pro, pro/arg, and arg/arg in p53 codon 72 in cases was 15% (15/99), 58% (57/99), and 27% (27/99) and in controls was 17% (34/193), 48% (92/193), and 35% (67/193), respectively, which was not significantly different. Arginine 39-42 tumor protein p53 Homo sapiens 50-53 15077186-1 2004 A single-nucleotide polymorphism (SNP) in exon 4 results in expression of either arginine (72R) or proline (72P) at codon 72 of p53. Arginine 81-89 tumor protein p53 Homo sapiens 128-131 15844633-1 2004 The arginine variant of the p53 codon 72 polymorphism as well as anogenital and epidermodysplasia verruciformis (EV) types of human papilloma virus (HPV) are suggested to confer increased risk for developing cutaneous squamous cell carcinoma (SCC). Arginine 4-12 tumor protein p53 Homo sapiens 28-31 15041222-4 2004 The TP53 gene has a single polymorphism at codon 72 of exon 4 that encodes either arginine (Arg) or proline (Pro). Arginine 82-90 tumor protein p53 Homo sapiens 4-8 15041222-4 2004 The TP53 gene has a single polymorphism at codon 72 of exon 4 that encodes either arginine (Arg) or proline (Pro). Arginine 92-95 tumor protein p53 Homo sapiens 4-8 15069555-2 2004 The p53 codon 72 Arg right curved arrow Pro polymorphism has been suggested to be associated with risk for different kind of cancers, but the data on gastric cancer (GC) is very limited. Arginine 17-20 tumor protein p53 Homo sapiens 4-7 15069555-5 2004 The frequency of the p53 Arg allele was 57.4% in the cases and 54.9% in the controls, and the genotype frequencies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 29.6%, 55.6%, and 14.8%, respectively, in the cases, and 29.6%, 50.5%, and 19.9%, respectively, in the controls (p=0.207). Arginine 25-28 tumor protein p53 Homo sapiens 21-24 15069555-5 2004 The frequency of the p53 Arg allele was 57.4% in the cases and 54.9% in the controls, and the genotype frequencies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 29.6%, 55.6%, and 14.8%, respectively, in the cases, and 29.6%, 50.5%, and 19.9%, respectively, in the controls (p=0.207). Arginine 122-125 tumor protein p53 Homo sapiens 118-121 15069555-5 2004 The frequency of the p53 Arg allele was 57.4% in the cases and 54.9% in the controls, and the genotype frequencies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 29.6%, 55.6%, and 14.8%, respectively, in the cases, and 29.6%, 50.5%, and 19.9%, respectively, in the controls (p=0.207). Arginine 122-125 tumor protein p53 Homo sapiens 118-121 15069555-5 2004 The frequency of the p53 Arg allele was 57.4% in the cases and 54.9% in the controls, and the genotype frequencies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 29.6%, 55.6%, and 14.8%, respectively, in the cases, and 29.6%, 50.5%, and 19.9%, respectively, in the controls (p=0.207). Arginine 122-125 tumor protein p53 Homo sapiens 118-121 15039212-0 2004 Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Arginine 17-25 tumor protein p53 Homo sapiens 52-55 15039212-9 2004 p53 mutations were detected in 29.6% of SCCHN and preferentially occurred at the arginine allele (P = 0.01). Arginine 81-89 tumor protein p53 Homo sapiens 0-3 14634213-7 2003 Further mutational analysis showed that arginines at positions 175 and 248 were essential for dicoumarol-induced p53 degradation. Arginine 40-49 tumor protein p53 Homo sapiens 113-116 14744727-1 2004 The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated as a risk marker in cervical neoplasia. Arginine 4-7 tumor protein p53 Homo sapiens 66-69 14744727-1 2004 The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated as a risk marker in cervical neoplasia. Arginine 8-11 tumor protein p53 Homo sapiens 66-69 14744727-1 2004 The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated as a risk marker in cervical neoplasia. Arginine 8-11 tumor protein p53 Homo sapiens 66-69 14764039-6 2004 The women who had p53 (Arg/Arg), IRF-1 (T/T), and <6 years of education showed a 14.7-fold increased risk of cervix cancer compared to the women who had p53 ( approximately Pro), IRF-1 ( approximately C), and >15 years of education. Arginine 23-26 tumor protein p53 Homo sapiens 18-21 14764039-6 2004 The women who had p53 (Arg/Arg), IRF-1 (T/T), and <6 years of education showed a 14.7-fold increased risk of cervix cancer compared to the women who had p53 ( approximately Pro), IRF-1 ( approximately C), and >15 years of education. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 14764039-7 2004 The women who had p53 (Arg/Arg), p21 (Ser/Ser), and >3 children showed a 6.4-fold increased risk of cervix cancer compared to the women who had p53 ( approximately Pro), p21 ( approximately Arg), and no children. Arginine 23-26 tumor protein p53 Homo sapiens 18-21 14764039-7 2004 The women who had p53 (Arg/Arg), p21 (Ser/Ser), and >3 children showed a 6.4-fold increased risk of cervix cancer compared to the women who had p53 ( approximately Pro), p21 ( approximately Arg), and no children. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 14764039-7 2004 The women who had p53 (Arg/Arg), p21 (Ser/Ser), and >3 children showed a 6.4-fold increased risk of cervix cancer compared to the women who had p53 ( approximately Pro), p21 ( approximately Arg), and no children. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 14764039-8 2004 The women who had p53 (Arg/Arg), IRF-1 (T/T), and first sexual intercourse before 22 years old showed a 5.5-fold increased risk of cervix cancer compared to the women who had p53 ( approximately Pro), IRF-1 ( approximately C), and first sexual intercourse after 26 years old. Arginine 23-26 tumor protein p53 Homo sapiens 18-21 15263792-7 2004 The proline form of p53 gene codon 72 was significantly higher than the arginine form, with an odds ratio of 2.606 (95% CI = 1.052-6.455). Arginine 72-80 tumor protein p53 Homo sapiens 20-23 15263792-11 2004 The proline form of p53 gene codon 72 might be a more significant risk factor for the development of metastasis than the arginine form. Arginine 121-129 tumor protein p53 Homo sapiens 20-23 14734460-8 2004 TP53 codon 72 Arg/Pro or Pro/Pro variants were associated with negative axillary lymph node status (OR, 0.7; 95% confidence interval, 0.49-0.94). Arginine 14-17 tumor protein p53 Homo sapiens 0-4 14734461-5 2004 However, the age-related increase in the percentage of codon 72 arginine p53 was not correlated to the prognosis for gastric cancer patients. Arginine 64-72 tumor protein p53 Homo sapiens 73-76 14734461-8 2004 CONCLUSIONS: These findings indicate that codon 72 arginine p53 may not be associated with a prolonged survival in patients with advanced gastric adenocarcinoma, but further study is needed to assess whether this polymorphism is associated with a late onset or slow progress of early gastric adenocarcinoma. Arginine 51-59 tumor protein p53 Homo sapiens 60-63 15651660-2 2004 The functional oligonucleotide polymorphism of the p53 gene causes the substitution of arginine (Arg) for praline (Pro) in the codon 72. Arginine 87-95 tumor protein p53 Homo sapiens 51-54 15651660-2 2004 The functional oligonucleotide polymorphism of the p53 gene causes the substitution of arginine (Arg) for praline (Pro) in the codon 72. Arginine 97-100 tumor protein p53 Homo sapiens 51-54 12893432-2 2003 To address on the genetic risk factor for NPC, we investigated association between the p53 codon 72 polymorphism (Pro/Arg) and NPC susceptibility in the Thai. Arginine 118-121 tumor protein p53 Homo sapiens 87-90 14675203-0 2003 p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. Arginine 13-16 tumor protein p53 Homo sapiens 0-3 14675203-6 2003 The frequency of the p53 Arg allele was 78.2% in cases and 73.2% in controls (p=0.045), and the genotype frequencies of p53 Arg/Arg, Arg/Pro, and Pro/Pro were 62.6%, 31.1%, and 6.3%, respectively, in the cases, and 53.9%, 38.6%, and 7.5%, respectively, in the controls (p=0.096). Arginine 25-28 tumor protein p53 Homo sapiens 21-24 14675203-7 2003 Logistic regression analysis revealed that the p53 Arg/Arg genotype was associated with a significantly increased risk of melanoma (adjusted odds ratio (OR)=1.43; 95% confidence interval (CI)=1.02-2.02) compared with other genotypes, and this association was more evident in subgroups of older subjects (OR=2.32; 95% CI=1.39-388), and subjects with Fitzpatrick"s skin type III or IV (OR=1.69; 95% CI=1.11-2.59). Arginine 51-54 tumor protein p53 Homo sapiens 47-50 14675203-7 2003 Logistic regression analysis revealed that the p53 Arg/Arg genotype was associated with a significantly increased risk of melanoma (adjusted odds ratio (OR)=1.43; 95% confidence interval (CI)=1.02-2.02) compared with other genotypes, and this association was more evident in subgroups of older subjects (OR=2.32; 95% CI=1.39-388), and subjects with Fitzpatrick"s skin type III or IV (OR=1.69; 95% CI=1.11-2.59). Arginine 55-58 tumor protein p53 Homo sapiens 47-50 14675203-8 2003 In conclusion, this study found some evidence that in subjects over 50, p53 Arg/Arg genotype is associated with increased risk of CM as compared to genotypes Arg/Pro or Pro/Pro. Arginine 76-79 tumor protein p53 Homo sapiens 72-75 14675203-8 2003 In conclusion, this study found some evidence that in subjects over 50, p53 Arg/Arg genotype is associated with increased risk of CM as compared to genotypes Arg/Pro or Pro/Pro. Arginine 80-83 tumor protein p53 Homo sapiens 72-75 14675203-8 2003 In conclusion, this study found some evidence that in subjects over 50, p53 Arg/Arg genotype is associated with increased risk of CM as compared to genotypes Arg/Pro or Pro/Pro. Arginine 80-83 tumor protein p53 Homo sapiens 72-75 14577584-0 2003 Polymorphism of the p53 codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Arginine 33-36 tumor protein p53 Homo sapiens 20-23 14577584-3 2003 This degradation is controlled by a common polymorphism of the p53 gene encoding either a proline or an arginine at its codon 72 in exon 4. Arginine 104-112 tumor protein p53 Homo sapiens 63-66 14577584-4 2003 Recently, it has been demonstrated that the presence of homozygous arginine at codon 72 renders p53 about seven times more susceptible to E6-mediated proteolytic degradation as well as to cervical cancer than those with proline homozygotes or proline/arginine heterozygotes. Arginine 67-75 tumor protein p53 Homo sapiens 96-99 14577584-4 2003 Recently, it has been demonstrated that the presence of homozygous arginine at codon 72 renders p53 about seven times more susceptible to E6-mediated proteolytic degradation as well as to cervical cancer than those with proline homozygotes or proline/arginine heterozygotes. Arginine 251-259 tumor protein p53 Homo sapiens 96-99 14577584-12 2003 Thus the interaction between HPV oncoproteins and the p53 gene polymorphism specifically, homozygous arginine at codon 72 appears to play no role in the development of either cervical or oral cancer and also it can not serve as a biomarker for early identification of cervical, oral or breast cancer. Arginine 101-109 tumor protein p53 Homo sapiens 54-57 12919725-1 2003 The p53 gene has a polymorphism at codon 72 that presents the arginine or proline genotype, although this polymorphism has been associated with genetically determined susceptibility to lung cancers, the literature has not been consistent with this association. Arginine 62-70 tumor protein p53 Homo sapiens 4-7 15147044-12 2003 Combined study on the distribution of GSTM1, GSTT1 and p53 genotypes revealed that null GSTM1 genotype was associated with the Arg allele of p53 codon 72 in 58 lung carcinoma cells and null GSTT1 genotype was associated with the Pro/Pro homozygote in 104 tumor cell lines examined. Arginine 127-130 tumor protein p53 Homo sapiens 55-58 15147044-12 2003 Combined study on the distribution of GSTM1, GSTT1 and p53 genotypes revealed that null GSTM1 genotype was associated with the Arg allele of p53 codon 72 in 58 lung carcinoma cells and null GSTT1 genotype was associated with the Pro/Pro homozygote in 104 tumor cell lines examined. Arginine 127-130 tumor protein p53 Homo sapiens 141-144 14581358-0 2003 Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Arginine 30-38 tumor protein p53 Homo sapiens 17-20 14581358-0 2003 Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Arginine 117-125 tumor protein p53 Homo sapiens 17-20 14581358-5 2003 RESULTS: We found that the retention of the p53 codon 72 arginine allele in the tumor tissue of proline/arginine heterozygous breast cancer patients is associated with statistically significant reduced disease-free and overall survivals. Arginine 57-65 tumor protein p53 Homo sapiens 44-47 14581358-5 2003 RESULTS: We found that the retention of the p53 codon 72 arginine allele in the tumor tissue of proline/arginine heterozygous breast cancer patients is associated with statistically significant reduced disease-free and overall survivals. Arginine 104-112 tumor protein p53 Homo sapiens 44-47 14581358-6 2003 CONCLUSIONS: Our findings suggest that the genotyping for p53 codon 72 locus in both the tumor tissue and in the lymph node of breast cancer patients could contribute to identify a subset of arginine/proline heterozygous patients who have a reduced survival that is associated with the specific retention of the arginine allele in the tumor tissue. Arginine 191-199 tumor protein p53 Homo sapiens 58-61 14581358-6 2003 CONCLUSIONS: Our findings suggest that the genotyping for p53 codon 72 locus in both the tumor tissue and in the lymph node of breast cancer patients could contribute to identify a subset of arginine/proline heterozygous patients who have a reduced survival that is associated with the specific retention of the arginine allele in the tumor tissue. Arginine 312-320 tumor protein p53 Homo sapiens 58-61 12844488-8 2003 However, the p53 mutation frequency increased with the increased number of the combined genotypes among XPD 312WT (Asp/Asp), XPD 751VT (Lys/Gln or Gln/Gln) or XRCC1 399VT (Arg/Gln or Gln/Gln) (P = 0.01, trend test). Arginine 172-175 tumor protein p53 Homo sapiens 13-16 12824702-6 2003 When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53-1.88] and 2.80 (95% CI 1.04-7.53), respectively. Arginine 229-232 tumor protein p53 Homo sapiens 45-48 12818446-1 2003 OBJECTIVE: [corrected] An experimental study has indicated that individuals homozygous for the Arg-encoding allele of p53 gene may have an increased susceptibility to HPV-related cervical cancer but many epidemiological studies have failed to repeat this result. Arginine 95-98 tumor protein p53 Homo sapiens 118-121 12818446-3 2003 The aim of the present work was to investigate whether the p53 arginine allele confers a risk factor for cervical carcinogenesis. Arginine 63-71 tumor protein p53 Homo sapiens 59-62 12821336-1 2003 INTRODUCTION: We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. Arginine 61-64 tumor protein p53 Homo sapiens 84-87 12821336-1 2003 INTRODUCTION: We aimed to verify not only whether homozygous Arg at codon 72 of the p53 apoptotic domain is a possible risk factor for cervical human papillomavirus (HPV)-related cancer, but whether degraded p53 may have an effect on a G2 checkpoint of the cell cycle. Arginine 61-64 tumor protein p53 Homo sapiens 208-211 12824702-6 2003 When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53-1.88] and 2.80 (95% CI 1.04-7.53), respectively. Arginine 233-236 tumor protein p53 Homo sapiens 45-48 12824702-6 2003 When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53-1.88] and 2.80 (95% CI 1.04-7.53), respectively. Arginine 233-236 tumor protein p53 Homo sapiens 45-48 12648751-2 2003 We performed a case-control association study between sporadic AD and the common proline/arginine polymorphism at codon 72 in the pro-apoptotic gene p53, in 109 sporadic AD patients and in 111 controls. Arginine 89-97 tumor protein p53 Homo sapiens 149-152 12796380-0 2003 Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Arginine 36-44 tumor protein p53 Homo sapiens 45-48 12796380-6 2003 A significant stepwise increased frequency of codon 72 Arg p53 with age was observed in patients with gastric cancer, but not in noncancer patients (P = 0.01). Arginine 55-58 tumor protein p53 Homo sapiens 59-62 12796380-8 2003 After adjustment for age and gender, a logistic regression analysis suggested that the risk for a p53 Arg homozygous patient to develop cardia cancer is 3.1 95% confidence interval, 1.4-7.3) times greater than for p53 Pro homozygous and p53 Arg/Pro heterozygous patients. Arginine 102-105 tumor protein p53 Homo sapiens 98-101 12796380-8 2003 After adjustment for age and gender, a logistic regression analysis suggested that the risk for a p53 Arg homozygous patient to develop cardia cancer is 3.1 95% confidence interval, 1.4-7.3) times greater than for p53 Pro homozygous and p53 Arg/Pro heterozygous patients. Arginine 102-105 tumor protein p53 Homo sapiens 214-217 12796380-8 2003 After adjustment for age and gender, a logistic regression analysis suggested that the risk for a p53 Arg homozygous patient to develop cardia cancer is 3.1 95% confidence interval, 1.4-7.3) times greater than for p53 Pro homozygous and p53 Arg/Pro heterozygous patients. Arginine 102-105 tumor protein p53 Homo sapiens 214-217 12796380-8 2003 After adjustment for age and gender, a logistic regression analysis suggested that the risk for a p53 Arg homozygous patient to develop cardia cancer is 3.1 95% confidence interval, 1.4-7.3) times greater than for p53 Pro homozygous and p53 Arg/Pro heterozygous patients. Arginine 241-244 tumor protein p53 Homo sapiens 98-101 12796380-10 2003 CONCLUSIONS: These findings indicate that codon 72 Arg p53 may be associated with a prolonged survival for patients who have had gastric adenocarcinoma, especially non-cardia adenocarcinoma. Arginine 51-54 tumor protein p53 Homo sapiens 55-58 12684648-2 2003 A sequence polymorphism at codon 72 of the p53 gene results in either a proline or an arginine and may induce different functional activities. Arginine 86-94 tumor protein p53 Homo sapiens 43-46 12684648-4 2003 It has been reported that the p53 Arg homozygous genotype could be a potential genetic risk factor for cancer. Arginine 34-37 tumor protein p53 Homo sapiens 30-33 12684648-8 2003 A significantly higher prevalence of homozygosity for the p53 Arg allele was observed in the patients as compared to the controls. Arginine 62-65 tumor protein p53 Homo sapiens 58-61 12679912-6 2003 RESULTS: We found in exon 7 of p53 gene G-T transversion at the third base of codon 249 resulting 249(Arg) - 249(Ser) mutation in 10/25 (40 %) hepatocellular carcinoma cases, 4/20 (20 %) cirrhotics, and 2/30 (7 %) healthy controls. Arginine 102-105 tumor protein p53 Homo sapiens 31-34 12726864-3 2003 A polymorphism encoding either arginine (72R) or proline (72P) at codon 72 of p53 influences inhibition of p73 by a range of p53 mutants identified in squamous cancers. Arginine 31-39 tumor protein p53 Homo sapiens 78-81 12726864-3 2003 A polymorphism encoding either arginine (72R) or proline (72P) at codon 72 of p53 influences inhibition of p73 by a range of p53 mutants identified in squamous cancers. Arginine 31-39 tumor protein p53 Homo sapiens 125-128 12628849-2 2003 A common polymorphism at codon 72 of exon 4 encoding either arginine (Arg) or proline (Pro) has been shown to affect HPV-mediated degradation of p53 in vitro, and may represent a risk factor for HPV-induced carcinogenesis. Arginine 60-68 tumor protein p53 Homo sapiens 145-148 12628849-2 2003 A common polymorphism at codon 72 of exon 4 encoding either arginine (Arg) or proline (Pro) has been shown to affect HPV-mediated degradation of p53 in vitro, and may represent a risk factor for HPV-induced carcinogenesis. Arginine 70-73 tumor protein p53 Homo sapiens 145-148 12628849-7 2003 Among the TP53 amplified samples, the rate of Arg homozygosity in penile SCC was 61% compared with 68% in BL (non-significant (NS)). Arginine 46-49 tumor protein p53 Homo sapiens 10-14 12635827-4 2003 The genotype of p53 codon 72 (Arg/Arg, Arg/Pro, or Pro/Pro) was determined for all subjects by polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP). Arginine 30-33 tumor protein p53 Homo sapiens 16-19 14513722-2 2003 (1998) implicated the proline/argine polymorphism of the codon 72 of the tumor-suppressor gene p53 in the development of cervical cancer (CC) with the observation that the p53 protein is more efficiently inactivated by the E6 oncoprotein of human papillomavirus in p53 arginine as compared with its proline isoform. Arginine 269-277 tumor protein p53 Homo sapiens 95-98 14513722-2 2003 (1998) implicated the proline/argine polymorphism of the codon 72 of the tumor-suppressor gene p53 in the development of cervical cancer (CC) with the observation that the p53 protein is more efficiently inactivated by the E6 oncoprotein of human papillomavirus in p53 arginine as compared with its proline isoform. Arginine 269-277 tumor protein p53 Homo sapiens 172-175 14513722-2 2003 (1998) implicated the proline/argine polymorphism of the codon 72 of the tumor-suppressor gene p53 in the development of cervical cancer (CC) with the observation that the p53 protein is more efficiently inactivated by the E6 oncoprotein of human papillomavirus in p53 arginine as compared with its proline isoform. Arginine 269-277 tumor protein p53 Homo sapiens 172-175 12567188-1 2003 The gene TP53, encoding p53, has a common sequence polymorphism that results in either proline or arginine at amino-acid position 72. Arginine 98-106 tumor protein p53 Homo sapiens 9-13 12567188-1 2003 The gene TP53, encoding p53, has a common sequence polymorphism that results in either proline or arginine at amino-acid position 72. Arginine 98-106 tumor protein p53 Homo sapiens 24-27 12708345-1 2003 In codon 72 of the p53 antioncogene there are two alleles, arginine and proline; the arg/arg genotype has recently been identified as a risk factor for developing of cervicouterine cancer (CuCa) associated to human papillomavirus (HVP) infection. Arginine 59-67 tumor protein p53 Homo sapiens 19-22 12708345-1 2003 In codon 72 of the p53 antioncogene there are two alleles, arginine and proline; the arg/arg genotype has recently been identified as a risk factor for developing of cervicouterine cancer (CuCa) associated to human papillomavirus (HVP) infection. Arginine 59-62 tumor protein p53 Homo sapiens 19-22 12708345-1 2003 In codon 72 of the p53 antioncogene there are two alleles, arginine and proline; the arg/arg genotype has recently been identified as a risk factor for developing of cervicouterine cancer (CuCa) associated to human papillomavirus (HVP) infection. Arginine 85-88 tumor protein p53 Homo sapiens 19-22 12708345-5 2003 From 102 analyzed samples, p53-arginine allele corresponded to 67.64% and p53-proline allele corresponded to 32.36%; 47 women (46.10%) were arg/arg homocygotes, 11 women (10.77%) were pro/pro homocygotes, 44 women (43.13%) were arg/pro heterocigotes; the genotype distribution was within the Hardy-Weinberg equilibrium. Arginine 31-39 tumor protein p53 Homo sapiens 27-30 12708345-5 2003 From 102 analyzed samples, p53-arginine allele corresponded to 67.64% and p53-proline allele corresponded to 32.36%; 47 women (46.10%) were arg/arg homocygotes, 11 women (10.77%) were pro/pro homocygotes, 44 women (43.13%) were arg/pro heterocigotes; the genotype distribution was within the Hardy-Weinberg equilibrium. Arginine 31-34 tumor protein p53 Homo sapiens 27-30 12767266-5 2003 RESULTS: G-->T transversion at the third base of 249 codon resulting in 249(Arg)-->249(Ser) mutation in exon 7 of p53 gene were found in 11/25(44%) hepatocellular carcinoma cases, 4/20 (20%) cirrhotics, and 2/30 (7%) healthy controls (p<0.01). Arginine 79-82 tumor protein p53 Homo sapiens 120-123 12635827-4 2003 The genotype of p53 codon 72 (Arg/Arg, Arg/Pro, or Pro/Pro) was determined for all subjects by polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP). Arginine 34-37 tumor protein p53 Homo sapiens 16-19 12635827-4 2003 The genotype of p53 codon 72 (Arg/Arg, Arg/Pro, or Pro/Pro) was determined for all subjects by polymerase chain reaction-restricted fragment length polymorphism (PCR-RFLP). Arginine 34-37 tumor protein p53 Homo sapiens 16-19 12530090-2 2002 The human tumor suppressor gene TP53 contains single nucleotide polymorphism that encodes either arginin (Arg) or proline (Pro) at amino acid codon 72 of the p53 protein. Arginine 97-104 tumor protein p53 Homo sapiens 32-36 12459171-2 2002 In this report, we addressed the question whether the natural variability at p53 locus (the proline-arginine substitution at codon 72) affects the capacity of peripheral-blood mononuclear cells from healthy subjects to undergo in vitro apoptosis in response to the cytotoxic drug cytosine arabinoside. Arginine 100-108 tumor protein p53 Homo sapiens 77-80 12496062-1 2002 An Arg/Pro polymorphism in codon 72 of the TP53 gene was analyzed in blood samples from 390 breast and 162 colorectal cancer patients previously investigated for TP53 mutations in their tumors. Arginine 3-6 tumor protein p53 Homo sapiens 43-47 12530090-2 2002 The human tumor suppressor gene TP53 contains single nucleotide polymorphism that encodes either arginin (Arg) or proline (Pro) at amino acid codon 72 of the p53 protein. Arginine 97-104 tumor protein p53 Homo sapiens 158-161 12530090-2 2002 The human tumor suppressor gene TP53 contains single nucleotide polymorphism that encodes either arginin (Arg) or proline (Pro) at amino acid codon 72 of the p53 protein. Arginine 106-109 tumor protein p53 Homo sapiens 32-36 12530090-2 2002 The human tumor suppressor gene TP53 contains single nucleotide polymorphism that encodes either arginin (Arg) or proline (Pro) at amino acid codon 72 of the p53 protein. Arginine 106-109 tumor protein p53 Homo sapiens 158-161 12445252-1 2002 Recently it has been found that the presence of homozygous arginine polymorphism at codon 72 of p53, represents a significant risk factor in the development of HPV-associated cervical cancer. Arginine 59-67 tumor protein p53 Homo sapiens 96-99 12445252-4 2002 The aim of the present study was to assess the frequency distribution of the p53 homozygous arginine polymorphism in cervical cancer patients and in a population sample of healthy Israeli Jewish women in order to determine whether the incidence pattern among them is genetically based. Arginine 92-100 tumor protein p53 Homo sapiens 77-80 12445252-12 2002 It may be assumed that the low incidence of cervical cancer in Israeli Jewish women and the differences between the ethnic groups may be related to the frequency pattern of the homozygous arginine p53 polymorphism Arginine 188-196 tumor protein p53 Homo sapiens 197-200 12142377-7 2002 The p53 codon 72 arginine allele showed a suggestive negative association with cervical cancer (HET, OR = 0.49; 95% CI, 0.14-1.63; homozygotes, OR = 0.35; 95% CI, 0.11-1.17). Arginine 17-25 tumor protein p53 Homo sapiens 4-7 12434294-0 2002 Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Arginine 72-75 tumor protein p53 Homo sapiens 15-18 12434294-0 2002 Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Arginine 132-135 tumor protein p53 Homo sapiens 15-18 12434294-5 2002 p53 Arg/Arg genotype was significantly increased in lung cancer patients compared to normal controls (50% vs 24.2%, P<0.002). Arginine 4-7 tumor protein p53 Homo sapiens 0-3 12434294-5 2002 p53 Arg/Arg genotype was significantly increased in lung cancer patients compared to normal controls (50% vs 24.2%, P<0.002). Arginine 8-11 tumor protein p53 Homo sapiens 0-3 12434294-7 2002 Loss of heterozygosity at the TP53 locus was found in 14 out of 27 Arg/Pro patients (51.85%). Arginine 67-70 tumor protein p53 Homo sapiens 30-34 12434294-9 2002 Our results suggest that p53 codon 72 Arg homozygosity is associated with advanced lung cancer, and that the Arg allele is preferentially retained in patients heterozygous for this polymorphism. Arginine 38-41 tumor protein p53 Homo sapiens 25-28 26680888-8 2002 The women who had p53 (Arg/Arg), IRF-1 (T/T) and had experience of first sexual intercourse before the age of 22-years showed a 5.5 fold increased risk of cervical cancer than those women who had p53 (~Pro), IRF-1 (~C) and had experience of first sexual intercourse after the age of 26-years. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 12065086-3 2002 The p53 codon 72 Arg/Pro polymorphism has been suggested to be associated with susceptibility to tobacco-related cancers, but this association remains controversial. Arginine 17-20 tumor protein p53 Homo sapiens 4-7 12458344-2 2002 Previous studies have reported that a common polymorphism of the wild type p53 gene at codon 72 of exon 4 (Arg/Arg) is associated with a sevenfold increased risk of HPV-associated cancer compared to Arg/Pro and Pro/Pro polymorphisms. Arginine 107-110 tumor protein p53 Homo sapiens 75-78 12458344-2 2002 Previous studies have reported that a common polymorphism of the wild type p53 gene at codon 72 of exon 4 (Arg/Arg) is associated with a sevenfold increased risk of HPV-associated cancer compared to Arg/Pro and Pro/Pro polymorphisms. Arginine 111-114 tumor protein p53 Homo sapiens 75-78 12458344-2 2002 Previous studies have reported that a common polymorphism of the wild type p53 gene at codon 72 of exon 4 (Arg/Arg) is associated with a sevenfold increased risk of HPV-associated cancer compared to Arg/Pro and Pro/Pro polymorphisms. Arginine 111-114 tumor protein p53 Homo sapiens 75-78 26680888-6 2002 The women who had p53 (Arg/Arg), IRF-1 (T/T) and an education of less than 6 years showed a 14.7 fold increased risk of cervical cancer than those women who had p53 (~Pro), IRF-1 (~C) and an education of more than 15 years. Arginine 23-26 tumor protein p53 Homo sapiens 18-21 26680888-6 2002 The women who had p53 (Arg/Arg), IRF-1 (T/T) and an education of less than 6 years showed a 14.7 fold increased risk of cervical cancer than those women who had p53 (~Pro), IRF-1 (~C) and an education of more than 15 years. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 26680888-7 2002 The women who had p53 (Arg/Arg), p21 (Ser/Ser) and more than 3 children showed a 6.4 fold increased risk of cervical cancer than those women who had p53 (~Pro), p21 (~Arg) and had borne no child. Arginine 23-26 tumor protein p53 Homo sapiens 18-21 26680888-7 2002 The women who had p53 (Arg/Arg), p21 (Ser/Ser) and more than 3 children showed a 6.4 fold increased risk of cervical cancer than those women who had p53 (~Pro), p21 (~Arg) and had borne no child. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 26680888-7 2002 The women who had p53 (Arg/Arg), p21 (Ser/Ser) and more than 3 children showed a 6.4 fold increased risk of cervical cancer than those women who had p53 (~Pro), p21 (~Arg) and had borne no child. Arginine 27-30 tumor protein p53 Homo sapiens 18-21 26680888-8 2002 The women who had p53 (Arg/Arg), IRF-1 (T/T) and had experience of first sexual intercourse before the age of 22-years showed a 5.5 fold increased risk of cervical cancer than those women who had p53 (~Pro), IRF-1 (~C) and had experience of first sexual intercourse after the age of 26-years. Arginine 23-26 tumor protein p53 Homo sapiens 18-21 12144822-2 2002 A common polymorphism of p53 in exon 4 codon 72, resulting in either proline (Pro) or arginine (Arg), affects HPV16/18 E6-mediated degradation of p53 protein in vivo. Arginine 86-94 tumor protein p53 Homo sapiens 25-28 12144822-2 2002 A common polymorphism of p53 in exon 4 codon 72, resulting in either proline (Pro) or arginine (Arg), affects HPV16/18 E6-mediated degradation of p53 protein in vivo. Arginine 86-94 tumor protein p53 Homo sapiens 146-149 12144822-7 2002 The frequency of distribution of the three genotypes of p53 codon 72 in a subgroup of the HPV16/18-positive cervical cancer patients was Pro/Pro 0.18 and Arg/Arg 0.26, with the heterozygous Pro/Arg 0.56, differing significantly from the genotype frequency in the normal healthy women (chi(2) = 6.928, df = 2, P < 0.05). Arginine 158-161 tumor protein p53 Homo sapiens 56-59 12144822-2 2002 A common polymorphism of p53 in exon 4 codon 72, resulting in either proline (Pro) or arginine (Arg), affects HPV16/18 E6-mediated degradation of p53 protein in vivo. Arginine 96-99 tumor protein p53 Homo sapiens 25-28 12144822-10 2002 The p53 genotype distribution indicated that women homozygous for Arg genotype were at a 2.4-fold higher risk for developing HPV16/18-associated cervical carcinomas, compared to those showing heterozygous Pro/Arg genotype (odds ratio 2.4, 95% confidence interval 1.89 to 3.04). Arginine 66-69 tumor protein p53 Homo sapiens 4-7 12144822-2 2002 A common polymorphism of p53 in exon 4 codon 72, resulting in either proline (Pro) or arginine (Arg), affects HPV16/18 E6-mediated degradation of p53 protein in vivo. Arginine 96-99 tumor protein p53 Homo sapiens 146-149 12144822-7 2002 The frequency of distribution of the three genotypes of p53 codon 72 in a subgroup of the HPV16/18-positive cervical cancer patients was Pro/Pro 0.18 and Arg/Arg 0.26, with the heterozygous Pro/Arg 0.56, differing significantly from the genotype frequency in the normal healthy women (chi(2) = 6.928, df = 2, P < 0.05). Arginine 154-157 tumor protein p53 Homo sapiens 56-59 12144822-7 2002 The frequency of distribution of the three genotypes of p53 codon 72 in a subgroup of the HPV16/18-positive cervical cancer patients was Pro/Pro 0.18 and Arg/Arg 0.26, with the heterozygous Pro/Arg 0.56, differing significantly from the genotype frequency in the normal healthy women (chi(2) = 6.928, df = 2, P < 0.05). Arginine 158-161 tumor protein p53 Homo sapiens 56-59 12144687-1 2002 The usefulness of the arginine (Arg) residue at codon 72 of the p53 tumor suppressor gene as a marker for the risk of cervical cancer remains unclear. Arginine 22-30 tumor protein p53 Homo sapiens 64-67 12200603-8 2002 RESULTS: A G:C to A:T mutation at codon 175 of p53 resulting in an arginine --> histidine substitution was detected, confirming the clinical diagnosis of LFS. Arginine 67-75 tumor protein p53 Homo sapiens 47-50 12115545-1 2002 p53 codon 72, which produces variant proteins with an arginine (Arg) or proline (Pro), has been reported to be associated with cancers of the lung, esophagus and cervix. Arginine 54-62 tumor protein p53 Homo sapiens 0-3 12115545-1 2002 p53 codon 72, which produces variant proteins with an arginine (Arg) or proline (Pro), has been reported to be associated with cancers of the lung, esophagus and cervix. Arginine 64-67 tumor protein p53 Homo sapiens 0-3 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 181-184 tumor protein p53 Homo sapiens 34-37 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 181-184 tumor protein p53 Homo sapiens 177-180 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 181-184 tumor protein p53 Homo sapiens 177-180 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 181-184 tumor protein p53 Homo sapiens 177-180 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 243-246 tumor protein p53 Homo sapiens 34-37 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 243-246 tumor protein p53 Homo sapiens 177-180 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 243-246 tumor protein p53 Homo sapiens 177-180 12221910-1 2002 A polymorphism at codon 72 in the p53 gen has been reported as a potential risk factor to cervical cancer (CC) because human papillomavirus (HPV) is more effective at degrading p53 Arg-72 than p53 Pro-72, making individuals homozygous for p53 Arg-72 seven times more likely to develop HPV-associated CC. Arginine 243-246 tumor protein p53 Homo sapiens 177-180 12221910-6 2002 Among cases with CC the proportions of the p53 genotypes at codon 72 were 0.05 to proline homozygous, 0.5 to heterozygous, and 0.45 to arginine-homozygous. Arginine 135-143 tumor protein p53 Homo sapiens 43-46 12221910-9 2002 We conclude than In our population, as other worldwide countries, the homozygous for arginine at codon 72 of the p53 gene is not a risk factor to cervical cancer. Arginine 85-93 tumor protein p53 Homo sapiens 113-116 12144687-1 2002 The usefulness of the arginine (Arg) residue at codon 72 of the p53 tumor suppressor gene as a marker for the risk of cervical cancer remains unclear. Arginine 32-35 tumor protein p53 Homo sapiens 64-67 12144687-9 2002 It would appear that, in the absence of HPV 16/18 infections, the Arg allele at codon 72 of the p53 tumor suppressor gene may constitute a risk factor for carcinogenesis of the cervix. Arginine 66-69 tumor protein p53 Homo sapiens 96-99 11888672-1 2002 p53 codon 72 Arg homozygosity has been associated with increased risk of developing cervical cancer. Arginine 13-16 tumor protein p53 Homo sapiens 0-3 12164929-1 2002 Upregulation of p53 protein induces either growth arrest or apoptosis in response to cellular injury This is signaled from a highly conserved p53 domain between codons 64 and 92, where a functional polymorphism results in either a proline (p53-72P) or an arginine (p53-72R) at codon 72. Arginine 255-263 tumor protein p53 Homo sapiens 16-19 12164929-1 2002 Upregulation of p53 protein induces either growth arrest or apoptosis in response to cellular injury This is signaled from a highly conserved p53 domain between codons 64 and 92, where a functional polymorphism results in either a proline (p53-72P) or an arginine (p53-72R) at codon 72. Arginine 255-263 tumor protein p53 Homo sapiens 142-145 12164929-1 2002 Upregulation of p53 protein induces either growth arrest or apoptosis in response to cellular injury This is signaled from a highly conserved p53 domain between codons 64 and 92, where a functional polymorphism results in either a proline (p53-72P) or an arginine (p53-72R) at codon 72. Arginine 255-263 tumor protein p53 Homo sapiens 142-145 12164929-1 2002 Upregulation of p53 protein induces either growth arrest or apoptosis in response to cellular injury This is signaled from a highly conserved p53 domain between codons 64 and 92, where a functional polymorphism results in either a proline (p53-72P) or an arginine (p53-72R) at codon 72. Arginine 255-263 tumor protein p53 Homo sapiens 142-145 12060398-10 2002 Our results suggest that TP53 arginine/arginine genotype could represent a potential risk factor for the development of squamous cell carcinoma in renal transplant recipients compared to immunocompetent patients. Arginine 30-38 tumor protein p53 Homo sapiens 25-29 12060398-10 2002 Our results suggest that TP53 arginine/arginine genotype could represent a potential risk factor for the development of squamous cell carcinoma in renal transplant recipients compared to immunocompetent patients. Arginine 39-47 tumor protein p53 Homo sapiens 25-29 12011992-10 2002 The KOSCC-11 cell line contained a frameshift mutation and the other cell lines harbored an identical p53 mutation at codon 175 from CGC (Arg) to CTC (Leu). Arginine 138-141 tumor protein p53 Homo sapiens 102-105 11888672-6 2002 The distribution of p53 alleles in bladder cancer patients and in controls was statistically significant (P<0.002; odds ratio, 2.67; 95% confidence interval, 1.38-5.20), and homozygosity for arginine at residue 72 was associated with an increased risk for bladder cancer (P<0.00002; odds ratio, 4.69; 95% confidence interval, 2.13-10.41). Arginine 194-202 tumor protein p53 Homo sapiens 20-23 11888672-9 2002 Our results provide evidence that this p53 polymorphism is implicated in bladder carcinogenesis and that individuals harboring the Arg/Arg genotype have an increased risk of developing bladder cancer. Arginine 131-134 tumor protein p53 Homo sapiens 39-42 11888672-9 2002 Our results provide evidence that this p53 polymorphism is implicated in bladder carcinogenesis and that individuals harboring the Arg/Arg genotype have an increased risk of developing bladder cancer. Arginine 135-138 tumor protein p53 Homo sapiens 39-42 12575207-1 2002 OBJECTIVE: A polymorphism at codon 72 of the human tumor-suppressor gene, p53, results in translation to either arginine or proline. Arginine 112-120 tumor protein p53 Homo sapiens 74-77 12019159-8 2002 Indicator variables were created to evaluate the risk for individuals with the following DVs: GSTP1 GG + GSTM1-null and GSTP1 GG + p53 Arg/Pro or Pro/Pro. Arginine 135-138 tumor protein p53 Homo sapiens 131-134 12168882-5 2002 The amino acid residue at this position is either arginine (p53-Arg) or proline (p53-Pro). Arginine 50-58 tumor protein p53 Homo sapiens 60-63 12168882-5 2002 The amino acid residue at this position is either arginine (p53-Arg) or proline (p53-Pro). Arginine 64-67 tumor protein p53 Homo sapiens 60-63 12006537-1 2002 PURPOSE: It is known that a common p53 polymorphism, encodingeither proline (Pro) or arginine (Arg) at residue 72, produces marked change in the structure of p53. Arginine 85-93 tumor protein p53 Homo sapiens 35-38 12006537-1 2002 PURPOSE: It is known that a common p53 polymorphism, encodingeither proline (Pro) or arginine (Arg) at residue 72, produces marked change in the structure of p53. Arginine 85-93 tumor protein p53 Homo sapiens 158-161 12006537-1 2002 PURPOSE: It is known that a common p53 polymorphism, encodingeither proline (Pro) or arginine (Arg) at residue 72, produces marked change in the structure of p53. Arginine 95-98 tumor protein p53 Homo sapiens 35-38 12006537-1 2002 PURPOSE: It is known that a common p53 polymorphism, encodingeither proline (Pro) or arginine (Arg) at residue 72, produces marked change in the structure of p53. Arginine 95-98 tumor protein p53 Homo sapiens 158-161 12006537-7 2002 RESULTS: There was a bias to mutate and express the Arg allele in the p53 -mutated TCCs arising in individuals with heterozygosity (Pro/Arg). Arginine 52-55 tumor protein p53 Homo sapiens 70-73 12006537-7 2002 RESULTS: There was a bias to mutate and express the Arg allele in the p53 -mutated TCCs arising in individuals with heterozygosity (Pro/Arg). Arginine 136-139 tumor protein p53 Homo sapiens 70-73 12575207-8 2002 CONCLUSION: In this population, individuals homozygous for the arginine variant of codon 72 of the p53 gene were at increased risk of cervical cancer. Arginine 63-71 tumor protein p53 Homo sapiens 99-102 11856771-3 2002 During a survey of risk factors for renal and cardiovascular disease in one such community, an association between a common polymorphism at codon 72 (Arg/Pro) of the p53 gene and markers of renal disease was sought. Arginine 150-153 tumor protein p53 Homo sapiens 166-169 11807792-3 2002 A common polymorphism of p53, encoding either proline (Pro) or arginine (Arg) at position 72, affects the susceptibility of p53 to E6 mediated degradation in vivo. Arginine 63-71 tumor protein p53 Homo sapiens 25-28 11807792-3 2002 A common polymorphism of p53, encoding either proline (Pro) or arginine (Arg) at position 72, affects the susceptibility of p53 to E6 mediated degradation in vivo. Arginine 63-71 tumor protein p53 Homo sapiens 124-127 11807792-3 2002 A common polymorphism of p53, encoding either proline (Pro) or arginine (Arg) at position 72, affects the susceptibility of p53 to E6 mediated degradation in vivo. Arginine 73-76 tumor protein p53 Homo sapiens 25-28 11807792-3 2002 A common polymorphism of p53, encoding either proline (Pro) or arginine (Arg) at position 72, affects the susceptibility of p53 to E6 mediated degradation in vivo. Arginine 73-76 tumor protein p53 Homo sapiens 124-127 11807792-8 2002 Our results also indicate that the p53 codon 72 genotype frequencies in Indian Oral Cancer patients are 0.55 (Arg) and 0.45 (Pro) as per Hardy-Weinberg equilibrium. Arginine 110-113 tumor protein p53 Homo sapiens 35-38 11710828-10 2001 The results indicate that women homozygotic for arg/arg in codon 72 of the p53 gene are at an increased risk for the development of cervical adenocarcinomas. Arginine 48-51 tumor protein p53 Homo sapiens 75-78 11836677-4 2002 Subjects homozygous for the p53 Pro allele had a more than 2-fold increased risk of developing ESCC (OR=2.18; 95%CI=1.10-4.35, adjusted for age, sex, and smoking), whereas the Arg/Pro genotype was not associated with elevated risk of the cancer (adjusted OR=0.84; 95%CI=0.42-1.68). Arginine 176-179 tumor protein p53 Homo sapiens 28-31 11782367-7 2002 Transient expression of dominant-negative p53 ((175)Arg-->His) counteracted the detrimental effects of BPDE on BRCA-1 promoter activity and protein levels. Arginine 52-55 tumor protein p53 Homo sapiens 42-45 11779589-6 2002 MAIN OUTCOME MEASURE(S): Polymerase chain reaction was used to detect p53 codon 72 polymorphisms (arginine homozygosity, heterozygosity, and proline homozygosity). Arginine 98-106 tumor protein p53 Homo sapiens 70-73 11779589-11 2002 p53 arginine homozygotes have lower risk for endometriosis. Arginine 4-12 tumor protein p53 Homo sapiens 0-3 11713288-6 2001 The extreme C terminus of p53 harbors several lysine residues whose ubiquitination by MDM2 appears to be the initial event in p53 nuclear export, as evidenced by the impaired nucleocytoplasmic shuttling of p53 mutants bearing simultaneous substitutions of lysines 370, 372, 373, 381, 382, and 386 to arginines (6KR) or alanines (6KA). Arginine 300-309 tumor protein p53 Homo sapiens 26-29 11713288-6 2001 The extreme C terminus of p53 harbors several lysine residues whose ubiquitination by MDM2 appears to be the initial event in p53 nuclear export, as evidenced by the impaired nucleocytoplasmic shuttling of p53 mutants bearing simultaneous substitutions of lysines 370, 372, 373, 381, 382, and 386 to arginines (6KR) or alanines (6KA). Arginine 300-309 tumor protein p53 Homo sapiens 126-129 11713288-6 2001 The extreme C terminus of p53 harbors several lysine residues whose ubiquitination by MDM2 appears to be the initial event in p53 nuclear export, as evidenced by the impaired nucleocytoplasmic shuttling of p53 mutants bearing simultaneous substitutions of lysines 370, 372, 373, 381, 382, and 386 to arginines (6KR) or alanines (6KA). Arginine 300-309 tumor protein p53 Homo sapiens 126-129 11983027-10 2001 The supposedly anti-apoptotic homozygous Arg 72-p53 genotype may increase susceptibility of some cancers. Arginine 41-44 tumor protein p53 Homo sapiens 48-51 11710828-10 2001 The results indicate that women homozygotic for arg/arg in codon 72 of the p53 gene are at an increased risk for the development of cervical adenocarcinomas. Arginine 52-55 tumor protein p53 Homo sapiens 75-78 11527429-6 2001 S100A4 had a greater affinity for wild-type or mutant arg-175-his p53 than for non-muscle myosin. Arginine 54-57 tumor protein p53 Homo sapiens 66-69 11564578-1 2001 The p53 codon 72 polymorphism, resulting in either an arginine or a proline residue has been proposed to affect the susceptibility of p53 protein to human papilloma virus (HPV) E6-mediated degradation in vitro. Arginine 54-62 tumor protein p53 Homo sapiens 4-7 11564578-1 2001 The p53 codon 72 polymorphism, resulting in either an arginine or a proline residue has been proposed to affect the susceptibility of p53 protein to human papilloma virus (HPV) E6-mediated degradation in vitro. Arginine 54-62 tumor protein p53 Homo sapiens 134-137 11429426-2 2001 A recent report suggests that a polymorphism of the p53 tumour suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in HPV associated malignancies. Arginine 141-149 tumor protein p53 Homo sapiens 52-55 11429426-2 2001 A recent report suggests that a polymorphism of the p53 tumour suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in HPV associated malignancies. Arginine 141-149 tumor protein p53 Homo sapiens 180-183 11429426-7 2001 RESULTS: The proportions of p53 codon 72 genotypes found were 78% arginine homozygous, 2% proline homozygous, and 20% heterozygous among patients with skin cancer and 79% arginine homozygous, 3.5% proline homozygous, and 17.5% heterozygous among the control population. Arginine 66-74 tumor protein p53 Homo sapiens 28-31 11429426-7 2001 RESULTS: The proportions of p53 codon 72 genotypes found were 78% arginine homozygous, 2% proline homozygous, and 20% heterozygous among patients with skin cancer and 79% arginine homozygous, 3.5% proline homozygous, and 17.5% heterozygous among the control population. Arginine 171-179 tumor protein p53 Homo sapiens 28-31 11273008-3 2001 The first tumor contained 2 p53 mutations, in codon 213 (CGA-->TGA, Arg-->stop) and codon 306 (CGA-->TGA, Arg-->stop), further, 1 missense PTEN mutation (codon 257, TTC-->TTA, Phe-->Leu) and a silent PTEN mutation (codon 154, TTC-->TTT, Phe-->Phe). Arginine 71-74 tumor protein p53 Homo sapiens 28-31 26680792-9 2001 CONCLUSION: These findings suggest that Arg/Arg homozygocity of the p53 codon 72 would be a protective factor against the development of cervical adenocarcinoma. Arginine 40-43 tumor protein p53 Homo sapiens 68-71 26680792-9 2001 CONCLUSION: These findings suggest that Arg/Arg homozygocity of the p53 codon 72 would be a protective factor against the development of cervical adenocarcinoma. Arginine 44-47 tumor protein p53 Homo sapiens 68-71 11259085-2 2001 A p53 Pro/Arg polymorphism at exon 4 codon 72, has been suggested to be involved in susceptibility to cancers as well. Arginine 10-13 tumor protein p53 Homo sapiens 2-5 11518751-3 2001 PCR/direct sequencing analysis revealed the presence of a nucleotide substitution, AGC (Ser) to AGG (Arg), at codon 106 of the p53 gene in DNA from non-cancerous breast tissue. Arginine 101-104 tumor protein p53 Homo sapiens 127-130 21044462-9 2001 The different biological effect between 172Leu and 172His shows that some p53 variants such as 172 Arg->Leu may act as wild-type p53. Arginine 99-102 tumor protein p53 Homo sapiens 74-77 21044462-9 2001 The different biological effect between 172Leu and 172His shows that some p53 variants such as 172 Arg->Leu may act as wild-type p53. Arginine 99-102 tumor protein p53 Homo sapiens 132-135 11273008-4 2001 The second glioblastoma also contained multiple, but different mutations: p53 mutations in codons 158 (CGC-->CAC, Arg-->His) and 273 (CGT-->TGT, Arg-->Cys), and a PTEN mutation in codon 233 (CGA-->TGA, Arg-->Stop). Arginine 117-120 tumor protein p53 Homo sapiens 74-77 11273008-4 2001 The second glioblastoma also contained multiple, but different mutations: p53 mutations in codons 158 (CGC-->CAC, Arg-->His) and 273 (CGT-->TGT, Arg-->Cys), and a PTEN mutation in codon 233 (CGA-->TGA, Arg-->Stop). Arginine 154-157 tumor protein p53 Homo sapiens 74-77 11273008-4 2001 The second glioblastoma also contained multiple, but different mutations: p53 mutations in codons 158 (CGC-->CAC, Arg-->His) and 273 (CGT-->TGT, Arg-->Cys), and a PTEN mutation in codon 233 (CGA-->TGA, Arg-->Stop). Arginine 154-157 tumor protein p53 Homo sapiens 74-77 11669337-10 2001 A common polymorphism in p53 at codon 72 (arginine/proline) was found in 6/8 of the patients. Arginine 42-50 tumor protein p53 Homo sapiens 25-28 11212257-2 2001 It was suggested that HPV 16 E6 variants and the p53 codon 72 arginine polymorphism could be progression markers. Arginine 62-70 tumor protein p53 Homo sapiens 49-52 11212257-3 2001 Indeed, it has been demonstrated that specific E6 variants and p53 arginine were both enriched in cancer. Arginine 67-75 tumor protein p53 Homo sapiens 63-66 11212257-5 2001 Our aim was thus to investigate whether p53 arginine is important for cervical carcinogenesis by scaling up samples of the two European cohorts, the initial results of which were reported previously. Arginine 44-52 tumor protein p53 Homo sapiens 40-43 11212257-7 2001 We found p53 arginine to be increased in cancer of both cohorts, consistent with our previous concept. Arginine 13-21 tumor protein p53 Homo sapiens 9-12 11212257-8 2001 Although specific E6 genotypes increased gradually with the severity of the lesion, p53 arginine was enriched in cancer only. Arginine 88-96 tumor protein p53 Homo sapiens 84-87 11212257-10 2001 It is concluded that p53 arginine is a risk factor for cervical cancer but probably acts independently of E6 variants. Arginine 25-33 tumor protein p53 Homo sapiens 21-24 11174479-1 2001 OBJECTIVE: It has recently been suggested that white women who are homozygous for the allele of the gene for wild-type p53 protein (TP53) that encodes arginine at position 72 are more susceptible to human papillomavirus-associated cervical carcinoma than are women who are heterozygous for this polymorphism and women who are homozygous for the allele that encodes proline at that position. Arginine 151-159 tumor protein p53 Homo sapiens 119-122 11174479-1 2001 OBJECTIVE: It has recently been suggested that white women who are homozygous for the allele of the gene for wild-type p53 protein (TP53) that encodes arginine at position 72 are more susceptible to human papillomavirus-associated cervical carcinoma than are women who are heterozygous for this polymorphism and women who are homozygous for the allele that encodes proline at that position. Arginine 151-159 tumor protein p53 Homo sapiens 132-136 21340840-7 2001 We have identified a missense mutation in the p53 gene in the 2774 ovarian cancer cell line that converts an arginine residue in the DNA binding region of the protein to a histidine residue (6). Arginine 109-117 tumor protein p53 Homo sapiens 46-49 11046142-6 2000 Simultaneous mutation of lysine residues 370, 372, 373, 381, 382, and 386 to arginine residues (6KR p53 mutant) generates a p53 molecule with potent transcriptional activity that is resistant to Mdm2-induced degradation and is refractory to Mdm2-mediated ubiquitination. Arginine 77-85 tumor protein p53 Homo sapiens 100-103 11156383-0 2000 Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Arginine 35-43 tumor protein p53 Homo sapiens 44-47 11255264-4 2001 We set out a case-control study to determine the risk of squamous cell carcinoma of the skin in individuals with the p53 codon 72 arginine genotype in order to establish the possible need for screening. Arginine 130-138 tumor protein p53 Homo sapiens 117-120 11046142-6 2000 Simultaneous mutation of lysine residues 370, 372, 373, 381, 382, and 386 to arginine residues (6KR p53 mutant) generates a p53 molecule with potent transcriptional activity that is resistant to Mdm2-induced degradation and is refractory to Mdm2-mediated ubiquitination. Arginine 77-85 tumor protein p53 Homo sapiens 124-127 11126384-4 2000 Aflatoxin B1 exposure leads to mutations in the p53 tumor suppressor gene, most commonly a transversion in codon 249 that leads to a substitution of serine for arginine in the p53 protein. Arginine 160-168 tumor protein p53 Homo sapiens 48-51 11042688-2 2000 Although all cell lines contain the same p53 mutations at codons 175 (Arg-->His) and 248 (Arg-->Gln), the constitutive levels of p53 were progressively increased with the resistance of the cells to teniposide. Arginine 93-96 tumor protein p53 Homo sapiens 135-138 11072671-2 2000 In invasive cervical cancer, the arginine form of the p53 gene is estimated to be more susceptible to degradation mediated by tumour-associated human papilloma viruses (HPV) than the proline form. Arginine 33-41 tumor protein p53 Homo sapiens 54-57 11008209-4 2000 The codon 72 p53 Pro allele was more frequently found in ESCC patients [odds ratio (OR) 1.86, 95% confidence interval (CI) 1.04-3.35 for Arg/Pro genotype and OR 2.56, 95% CI 1.29-5.08 for Pro/Pro genotype]. Arginine 137-140 tumor protein p53 Homo sapiens 13-16 11045785-13 2000 In conclusion, the codon 72 germ-line polymorphism (Arg/Pro) of the common tumor suppressor gene p53 contributes to heritable susceptibility for smoke-induced lung adenocarcinoma. Arginine 52-55 tumor protein p53 Homo sapiens 97-100 10994962-3 2000 PCR products of the proline [5"-x(G17)-x(C38)x-3"] and arginine variants [(5"-x(Gl7)-x(G38)x-3"] of the p53 gene are distinguished by an SNP (cytosine or guanine) and were discriminated using both quadrupole and quadrupole ion trap MS analysis. Arginine 55-63 tumor protein p53 Homo sapiens 104-107 11240705-1 2000 Recent analysis of the codon-72 polymorphism of the p53 gene, the allele encoding proline or arginine, suggested that the homozygous Arg/Arg genotype is a significant risk factor for cervical cancer associated with human papillomavirus (HPV). Arginine 93-101 tumor protein p53 Homo sapiens 52-55 11240705-1 2000 Recent analysis of the codon-72 polymorphism of the p53 gene, the allele encoding proline or arginine, suggested that the homozygous Arg/Arg genotype is a significant risk factor for cervical cancer associated with human papillomavirus (HPV). Arginine 133-136 tumor protein p53 Homo sapiens 52-55 11240705-1 2000 Recent analysis of the codon-72 polymorphism of the p53 gene, the allele encoding proline or arginine, suggested that the homozygous Arg/Arg genotype is a significant risk factor for cervical cancer associated with human papillomavirus (HPV). Arginine 137-140 tumor protein p53 Homo sapiens 52-55 11126384-4 2000 Aflatoxin B1 exposure leads to mutations in the p53 tumor suppressor gene, most commonly a transversion in codon 249 that leads to a substitution of serine for arginine in the p53 protein. Arginine 160-168 tumor protein p53 Homo sapiens 176-179 10918193-12 2000 Homozygous codon-72 p53-Arg apparently confers a higher susceptibility to HPV-associated cervical tumorigenesis. Arginine 24-27 tumor protein p53 Homo sapiens 20-23 10850407-2 2000 The arginine allele at codon 72 of p53 was found to be more susceptible to degradation by HPV E6 protein than is the proline allele in vivo, thus resulting in a high frequency of cervical SCC in individuals homozygous for arginine at the codon. Arginine 4-12 tumor protein p53 Homo sapiens 35-38 10850407-2 2000 The arginine allele at codon 72 of p53 was found to be more susceptible to degradation by HPV E6 protein than is the proline allele in vivo, thus resulting in a high frequency of cervical SCC in individuals homozygous for arginine at the codon. Arginine 222-230 tumor protein p53 Homo sapiens 35-38 10813720-3 2000 RESULTS: Among these polymorphisms, the individuals carrying arginine/proline genotypes of p53 showed a 9.5-fold increase of cervical carcinoma risk (95% confidence interval [CI], 4.9-18.6) compared with those individuals carrying arginine/arginine genotypes. Arginine 61-69 tumor protein p53 Homo sapiens 91-94 11032762-3 2000 The purpose of this study was to examine whether p53 Arg at the polymorphic position 72 could represent a risk factor for women with breast lesions. Arginine 53-56 tumor protein p53 Homo sapiens 49-52 11032762-7 2000 The allele frequency of p53 Arg/Arg was much higher than that of the normal samples (61% versus 20%). Arginine 28-31 tumor protein p53 Homo sapiens 24-27 11032762-7 2000 The allele frequency of p53 Arg/Arg was much higher than that of the normal samples (61% versus 20%). Arginine 32-35 tumor protein p53 Homo sapiens 24-27 11032762-8 2000 Based on the findings of this study, it is suggested that p53 Arg homozygosity could represent a risk factor for the tumorigenesis of the breast. Arginine 62-65 tumor protein p53 Homo sapiens 58-61 10928171-6 2000 There was a trend towards an association between disease recurrence and the presence of the p53 codon 72 arginine homozygous genotype (OR = 3.41, p = 0.23). Arginine 105-113 tumor protein p53 Homo sapiens 92-95 10813720-3 2000 RESULTS: Among these polymorphisms, the individuals carrying arginine/proline genotypes of p53 showed a 9.5-fold increase of cervical carcinoma risk (95% confidence interval [CI], 4.9-18.6) compared with those individuals carrying arginine/arginine genotypes. Arginine 231-239 tumor protein p53 Homo sapiens 91-94 10813720-3 2000 RESULTS: Among these polymorphisms, the individuals carrying arginine/proline genotypes of p53 showed a 9.5-fold increase of cervical carcinoma risk (95% confidence interval [CI], 4.9-18.6) compared with those individuals carrying arginine/arginine genotypes. Arginine 231-239 tumor protein p53 Homo sapiens 91-94 10813720-6 2000 The individuals carrying both the arginine/proline genotype of p53 and the null genotype of GSTT1 showed a 3.5-fold increase of cervical carcinoma risk (95% CI, 1.8-7.1) compared with those individuals carrying both the arginine/arginine genotype of p53 and the GSTT1 positive genotype. Arginine 34-42 tumor protein p53 Homo sapiens 63-66 10813720-6 2000 The individuals carrying both the arginine/proline genotype of p53 and the null genotype of GSTT1 showed a 3.5-fold increase of cervical carcinoma risk (95% CI, 1.8-7.1) compared with those individuals carrying both the arginine/arginine genotype of p53 and the GSTT1 positive genotype. Arginine 34-42 tumor protein p53 Homo sapiens 250-253 10813720-6 2000 The individuals carrying both the arginine/proline genotype of p53 and the null genotype of GSTT1 showed a 3.5-fold increase of cervical carcinoma risk (95% CI, 1.8-7.1) compared with those individuals carrying both the arginine/arginine genotype of p53 and the GSTT1 positive genotype. Arginine 220-228 tumor protein p53 Homo sapiens 63-66 10813720-6 2000 The individuals carrying both the arginine/proline genotype of p53 and the null genotype of GSTT1 showed a 3.5-fold increase of cervical carcinoma risk (95% CI, 1.8-7.1) compared with those individuals carrying both the arginine/arginine genotype of p53 and the GSTT1 positive genotype. Arginine 220-228 tumor protein p53 Homo sapiens 63-66 10813720-9 2000 CONCLUSIONS: The results of the current study suggested that the arginine/proline genotype of p53, independently or in conjunction with the GSTT1 null genotype, could affect the genetic susceptibility for cervical carcinoma, and HPV positive women carrying both null genotypes of GSTT1 and GSTM1 have an increased risk of cervical carcinoma developing before age 40 years. Arginine 65-73 tumor protein p53 Homo sapiens 94-97 10802655-3 2000 The binding of such mutants is influenced by whether TP53 (encoding p53) codon 72, by virtue of a common polymorphism in the human population, encodes Arg or Pro. Arginine 151-154 tumor protein p53 Homo sapiens 53-57 10802655-3 2000 The binding of such mutants is influenced by whether TP53 (encoding p53) codon 72, by virtue of a common polymorphism in the human population, encodes Arg or Pro. Arginine 151-154 tumor protein p53 Homo sapiens 68-71 10802655-4 2000 The ability of mutant p53 to bind p73, neutralize p73-induced apoptosis and transform cells in cooperation with EJ-Ras was enhanced when codon 72 encoded Arg. Arginine 154-157 tumor protein p53 Homo sapiens 22-25 10719058-4 2000 It was revealed that the arginine form of p53 is more susceptible to degradation by the HPV E6 protein than the proline form and that patients with the arginine form have a higher risk of developing cancer than those with the proline form. Arginine 25-33 tumor protein p53 Homo sapiens 42-45 10794489-1 2000 A case-control study was performed to investigate the risk of cervical cancer associated with p53 polymorphism at codon 72, encoding either arginine or proline. Arginine 140-148 tumor protein p53 Homo sapiens 94-97 10754463-0 2000 Homozygous arginine at codon 72 of p53 has no prognostic significance in cervical cancer. Arginine 11-19 tumor protein p53 Homo sapiens 35-38 10754463-2 2000 The findings of increased susceptibility to degradation of p53 by E6 protein of HPV16/18 in cervical cancer with homozygous arginine at codon 72 (HA72) of p53 led to this study on whether cervical cancers with HA72 were more aggressive with the increase in the rate of loss of p53 function. Arginine 124-132 tumor protein p53 Homo sapiens 59-62 10754463-2 2000 The findings of increased susceptibility to degradation of p53 by E6 protein of HPV16/18 in cervical cancer with homozygous arginine at codon 72 (HA72) of p53 led to this study on whether cervical cancers with HA72 were more aggressive with the increase in the rate of loss of p53 function. Arginine 124-132 tumor protein p53 Homo sapiens 155-158 10754463-2 2000 The findings of increased susceptibility to degradation of p53 by E6 protein of HPV16/18 in cervical cancer with homozygous arginine at codon 72 (HA72) of p53 led to this study on whether cervical cancers with HA72 were more aggressive with the increase in the rate of loss of p53 function. Arginine 124-132 tumor protein p53 Homo sapiens 155-158 10738214-2 2000 The most frequent mutation of the p53 gene in HCC is an AGG(Arg) to AGT(Ser) missense mutation at codon 249 of exon 7. Arginine 60-63 tumor protein p53 Homo sapiens 34-37 10830578-1 2000 In 1998, Storey and co-workers suggested that individuals homozygous for arginine (Arg) at codon 72 of the p53 gene are about seven times more susceptible to human papillomavirus (HPV)-related carcinogenesis than heterozygotes. Arginine 73-81 tumor protein p53 Homo sapiens 107-110 10830578-1 2000 In 1998, Storey and co-workers suggested that individuals homozygous for arginine (Arg) at codon 72 of the p53 gene are about seven times more susceptible to human papillomavirus (HPV)-related carcinogenesis than heterozygotes. Arginine 83-86 tumor protein p53 Homo sapiens 107-110 10830578-8 2000 p53 Arg homozygosity (Arg/Arg) alone was associated with four-, six- or eight-fold increased risks for LGCIN, HGCIN or invasive cancer, respectively. Arginine 4-7 tumor protein p53 Homo sapiens 0-3 10830578-8 2000 p53 Arg homozygosity (Arg/Arg) alone was associated with four-, six- or eight-fold increased risks for LGCIN, HGCIN or invasive cancer, respectively. Arginine 22-25 tumor protein p53 Homo sapiens 0-3 10830578-8 2000 p53 Arg homozygosity (Arg/Arg) alone was associated with four-, six- or eight-fold increased risks for LGCIN, HGCIN or invasive cancer, respectively. Arginine 22-25 tumor protein p53 Homo sapiens 0-3 10830578-18 2000 Our present small study results, which suggest a biologically relevant association, provide strong evidence that homozygous arginine at codon 72 of p53 may confer a higher susceptibility to HPV-associated intra-epithelial and invasive cervical neoplasia. Arginine 124-132 tumor protein p53 Homo sapiens 148-151 10719058-9 2000 There was a difference in the distribution of p53 genotypes between high risk HPV-skin lesions and the controls, and the allele frequency of p53 Arg/Arg was much higher than the controls (65.5% versus 20%). Arginine 149-152 tumor protein p53 Homo sapiens 141-144 10719058-10 2000 Therefore, it is suggested that p53 Arg homozygosity could represent a potential risk factor for tumorigenesis of the skin. Arginine 36-39 tumor protein p53 Homo sapiens 32-35 10719058-4 2000 It was revealed that the arginine form of p53 is more susceptible to degradation by the HPV E6 protein than the proline form and that patients with the arginine form have a higher risk of developing cancer than those with the proline form. Arginine 152-160 tumor protein p53 Homo sapiens 42-45 10719058-5 2000 The purpose of this study was to examine whether p53 Arg at the polymorphic position 72 could represent a risk factor for patients with high risk HPV-associated malignant skin lesions. Arginine 53-56 tumor protein p53 Homo sapiens 49-52 10719058-9 2000 There was a difference in the distribution of p53 genotypes between high risk HPV-skin lesions and the controls, and the allele frequency of p53 Arg/Arg was much higher than the controls (65.5% versus 20%). Arginine 145-148 tumor protein p53 Homo sapiens 141-144 11023067-7 2000 Mutations of p53 were present in 3 of 38 HPV-positive samples: one with an ATG-->TTG transversion (Met-->Leu) in codon 237 of exon 7; and the others with a TGC-->TGG transversion (Cys-->Trp) in codon 242 of exon 7, and a CGT-->CCT transversion (Arg-->Pro) in codon 273 of exon 8, respectively. Arginine 260-263 tumor protein p53 Homo sapiens 13-16 10698487-3 2000 ), 393: 229-234, 1998)] reported a 7-fold increased risk of cervical cancer associated with having an Arg/Arg polymorphism at codon 72 of p53 compared with the Pro/Arg heterozygotes (odds ratio, 7.4; 95% confidence interval, 2.1-29.4). Arginine 102-105 tumor protein p53 Homo sapiens 138-141 10680816-2 2000 Sequencing of the p53 gene, exon 4, showed heterozygosity (Arg-Pro) at codon 72 in five of six PML patients. Arginine 59-62 tumor protein p53 Homo sapiens 18-21 10698487-3 2000 ), 393: 229-234, 1998)] reported a 7-fold increased risk of cervical cancer associated with having an Arg/Arg polymorphism at codon 72 of p53 compared with the Pro/Arg heterozygotes (odds ratio, 7.4; 95% confidence interval, 2.1-29.4). Arginine 106-109 tumor protein p53 Homo sapiens 138-141 10698487-3 2000 ), 393: 229-234, 1998)] reported a 7-fold increased risk of cervical cancer associated with having an Arg/Arg polymorphism at codon 72 of p53 compared with the Pro/Arg heterozygotes (odds ratio, 7.4; 95% confidence interval, 2.1-29.4). Arginine 106-109 tumor protein p53 Homo sapiens 138-141 10775508-4 2000 The purpose of this study was to examine whether p53 Arg at the polymorphic position 72 could represent a risk factor for women with high-risk HPV-associated premalignant and malignant cervical lesions. Arginine 53-56 tumor protein p53 Homo sapiens 49-52 10732740-1 2000 An initial report suggested that patients homozygous for the arginine allele at codon 72 of P53 were at increased risk for human papillomavirus (HPV)-related cervical cancer, but other groups have not confirmed this finding. Arginine 61-69 tumor protein p53 Homo sapiens 92-95 10719811-1 2000 A common polymorphism of the wild type p53 is known at codon 72 of exon 4, with 2 alleles encoding either arginine (CGC, p53Arg) or proline (CCC, p53Pro). Arginine 106-114 tumor protein p53 Homo sapiens 39-42 10775508-10 2000 Based on the findings of this study, it is suggested that p53 Arg homozygosity could possibly represent a potential risk factor for the tumorigenesis of the cervix. Arginine 62-65 tumor protein p53 Homo sapiens 58-61 10732742-3 2000 DNA sequencing confirmed the presence of a G to T base substitution within the Haelll site spanning codons 249 and 250 of the p53 gene that results in replacement of arginine (wild-type) by methionine at residue 249. Arginine 166-174 tumor protein p53 Homo sapiens 126-129 10644829-6 2000 However, HPV-16 350T variants were significantly over-represented in p53 Arg homozygous women with cervical cancer. Arginine 73-76 tumor protein p53 Homo sapiens 69-72 10644829-7 2000 This suggests that, in p53 Arg/Arg women, infection with HPV-16 350T variants confers a higher risk of cervical cancer. Arginine 27-30 tumor protein p53 Homo sapiens 23-26 10644829-7 2000 This suggests that, in p53 Arg/Arg women, infection with HPV-16 350T variants confers a higher risk of cervical cancer. Arginine 31-34 tumor protein p53 Homo sapiens 23-26 10775508-9 2000 The allele frequency of p53 Arg/Arg was much higher than the normal samples (46.5% versus 20.5% in HPV-negative normal smears and 20% in blood samples). Arginine 28-31 tumor protein p53 Homo sapiens 24-27 10775508-9 2000 The allele frequency of p53 Arg/Arg was much higher than the normal samples (46.5% versus 20.5% in HPV-negative normal smears and 20% in blood samples). Arginine 32-35 tumor protein p53 Homo sapiens 24-27 11996107-1 2000 A polymorphism at codon 72 of gene p53 results in the presence of either arginine or proline at this position. Arginine 73-81 tumor protein p53 Homo sapiens 35-38 10647890-2 1999 A common p53 polymorphism at codon-72 of exon 4 results in translation to either arginine or proline. Arginine 81-89 tumor protein p53 Homo sapiens 9-12 10895031-3 2000 The homozygous p53 arginine allele (Arg/Arg) was detected in 22 (31%), the homozygous p53 proline allele (Pro/Pro) in 14 (19%) and the heterozygous allele (Arg/Pro) in 36 (50%) cases, respectively. Arginine 19-27 tumor protein p53 Homo sapiens 15-18 9825943-3 1998 This report presents clinical, neuropathological and molecular genetic data from 2 families in France with an identical p53 germline mutation in codon 248 (CGG->TGG; Arg->Trp) and a clustering of CNS tumors. Arginine 169-172 tumor protein p53 Homo sapiens 120-123 10567656-12 1999 There was no difference in the distribution of p53 proline and arginine alleles between HPV-16-positive cervical carcinoma patients and local controls, and no influence on clinical outcome; however, there was a trend for an increased frequency of p53 arginine homozygotes among the 350T carcinoma patients. Arginine 251-259 tumor protein p53 Homo sapiens 247-250 10551826-4 1999 To characterize further the function of these two domains, we demonstrate in this report that the previously described major nuclear localization signal works together with Lys(305)-Arg(306) to form a bipartite and functional nuclear localization sequence (NLS) for p53 nuclear import. Arginine 182-185 tumor protein p53 Homo sapiens 266-269 10425273-2 1999 A polymorphism at codon 72 of p53 results in translation to either arginine (p53Arg) or proline (p53Pro), and recent study showed that Caucasian women with arginine form of p53 are more susceptible to HPV-associated carcinoma of the cervix. Arginine 67-75 tumor protein p53 Homo sapiens 30-33 10425273-2 1999 A polymorphism at codon 72 of p53 results in translation to either arginine (p53Arg) or proline (p53Pro), and recent study showed that Caucasian women with arginine form of p53 are more susceptible to HPV-associated carcinoma of the cervix. Arginine 67-75 tumor protein p53 Homo sapiens 77-80 10425273-2 1999 A polymorphism at codon 72 of p53 results in translation to either arginine (p53Arg) or proline (p53Pro), and recent study showed that Caucasian women with arginine form of p53 are more susceptible to HPV-associated carcinoma of the cervix. Arginine 156-164 tumor protein p53 Homo sapiens 30-33 10425273-2 1999 A polymorphism at codon 72 of p53 results in translation to either arginine (p53Arg) or proline (p53Pro), and recent study showed that Caucasian women with arginine form of p53 are more susceptible to HPV-associated carcinoma of the cervix. Arginine 156-164 tumor protein p53 Homo sapiens 77-80 10487521-0 1999 Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax. Arginine 40-43 tumor protein p53 Homo sapiens 30-33 10487521-2 1999 We have previously reported that a mutation at codon 273, p53-273L (Arg --> Leu), suppresses cell growth despite its having no p53-specific transactivation activity. Arginine 68-71 tumor protein p53 Homo sapiens 58-61 10465111-5 1999 Furthermore, three missense mutations (V92M) and two silent mutations (CGA (Arg) to CGG (Arg), codon 213, exon 6) were found in the MC1R and p53 genes, respectively. Arginine 76-79 tumor protein p53 Homo sapiens 141-144 10465111-5 1999 Furthermore, three missense mutations (V92M) and two silent mutations (CGA (Arg) to CGG (Arg), codon 213, exon 6) were found in the MC1R and p53 genes, respectively. Arginine 89-92 tumor protein p53 Homo sapiens 141-144 10321742-3 1999 It was found that a single mutation of Arg-306 resulted in the defect of p53 nuclear import. Arginine 39-42 tumor protein p53 Homo sapiens 73-76 10051470-10 1999 Significantly increased risk associated with the p53 genotype was observed only among smokers who were glutathione S-transferase-null (Pro/Pro vs. Arg/Arg: odds ratio = 6.46; 95% CI = 1.55-26.94). Arginine 147-150 tumor protein p53 Homo sapiens 49-52 10051470-10 1999 Significantly increased risk associated with the p53 genotype was observed only among smokers who were glutathione S-transferase-null (Pro/Pro vs. Arg/Arg: odds ratio = 6.46; 95% CI = 1.55-26.94). Arginine 151-154 tumor protein p53 Homo sapiens 49-52 9891044-1 1999 The wild-type p53 protein exhibits a common polymorphism at amino acid 72, resulting in either a proline residue (p53Pro) or an arginine residue (p53Arg) at this position. Arginine 128-136 tumor protein p53 Homo sapiens 14-17 11601009-4 1999 The latter p53 gene encoding protein contained an Arg-->His substitution at the same position, and pBLuscript plasmid was used as control. Arginine 50-53 tumor protein p53 Homo sapiens 11-14 11601009-10 1999 CONCLUSION: Codon 172 mutant (Arg-->Leu) p53 genomic DNA exhibited a strong suppressive transfecting effects on carcinoma cell, so it is a possible candidate to be used in cancer gene therapy. Arginine 30-33 tumor protein p53 Homo sapiens 44-47 10449610-0 1999 p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. Arginine 13-16 tumor protein p53 Homo sapiens 0-3 10449610-1 1999 A polymorphism at codon 72 of the p53 gene, resulting in either an arginine or a proline residue in the protein, has been reported to affect the susceptibility of p53 to human papillomavirus (HPV) E6-mediated degradation in cultured cells. Arginine 67-75 tumor protein p53 Homo sapiens 34-37 10449610-1 1999 A polymorphism at codon 72 of the p53 gene, resulting in either an arginine or a proline residue in the protein, has been reported to affect the susceptibility of p53 to human papillomavirus (HPV) E6-mediated degradation in cultured cells. Arginine 67-75 tumor protein p53 Homo sapiens 163-166 10469618-5 1999 It has recently been reported that the extent of p53 dysfunction caused by HPVs depends on the status of a polymorphism at codon 72 of p53, Pro or Arg. Arginine 147-150 tumor protein p53 Homo sapiens 49-52 10468305-1 1999 Homozygous arginine at codon 72 (HA72) of p53 was found in 22% of normal cervices and 30.0% of cervical cancers and no significant difference was detected between normal and cervical cancer with or without HPV 16/18. Arginine 11-19 tumor protein p53 Homo sapiens 42-45 10405166-5 1999 Apoptosis induced by PTP-S2 in MCF7 cells was inhibited by cotransfection with mutant p53 (Arg-273 --> His) but not by wild type p53. Arginine 91-94 tumor protein p53 Homo sapiens 86-89 10334492-7 1999 A p53 mutation in codon 273 (CGT-->TGT, Arg-->Cys) was identified in the first biopsy and persisted throughout the course of the disease. Arginine 43-46 tumor protein p53 Homo sapiens 2-5 10226945-4 1999 The other tumor (case 33) had a point mutation at codon 266, changing GGA to AGA and causing a substitution of glycine to arginine in the p53 protein. Arginine 122-130 tumor protein p53 Homo sapiens 138-141 10023783-2 1999 Most recently, p53 protein containing an arginine residue in codon 72 was shown to be more effectively degraded by the E6 oncoprotein of human papillomavirus (HPV) than the corresponding proline isoform in cervical carcinoma cells. Arginine 41-49 tumor protein p53 Homo sapiens 15-18 9848359-0 1998 Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Arginine 11-19 tumor protein p53 Homo sapiens 36-39 11245004-1 1998 OBJECTIVE: To establish a tetracycline-regulated expression model and to determine and verify whether a specific point mutant type p53 minigene, containing an Arg-->Leu substitution at amino acid 172, possesses a suppressing effect on human lung cancer. Arginine 159-162 tumor protein p53 Homo sapiens 131-134 9788606-2 1998 A common polymorphism of p53, encoding either proline or arginine at position 72, affects the susceptibility of p53 to E6-mediated degradation in vivo; Caucasian women homozygous for arginine 72 reportedly are about seven times more susceptible to HPV-associated carcinoma of the cervix than heterozygotes. Arginine 57-65 tumor protein p53 Homo sapiens 25-28 9788606-2 1998 A common polymorphism of p53, encoding either proline or arginine at position 72, affects the susceptibility of p53 to E6-mediated degradation in vivo; Caucasian women homozygous for arginine 72 reportedly are about seven times more susceptible to HPV-associated carcinoma of the cervix than heterozygotes. Arginine 57-65 tumor protein p53 Homo sapiens 112-115 9788606-2 1998 A common polymorphism of p53, encoding either proline or arginine at position 72, affects the susceptibility of p53 to E6-mediated degradation in vivo; Caucasian women homozygous for arginine 72 reportedly are about seven times more susceptible to HPV-associated carcinoma of the cervix than heterozygotes. Arginine 183-191 tumor protein p53 Homo sapiens 25-28 9788606-2 1998 A common polymorphism of p53, encoding either proline or arginine at position 72, affects the susceptibility of p53 to E6-mediated degradation in vivo; Caucasian women homozygous for arginine 72 reportedly are about seven times more susceptible to HPV-associated carcinoma of the cervix than heterozygotes. Arginine 183-191 tumor protein p53 Homo sapiens 112-115 9607760-2 1998 A common polymorphism that occurs in the p53 amino-acid sequence results in the presence of either a proline or an arginine at position 72. Arginine 115-123 tumor protein p53 Homo sapiens 41-44 9742979-1 1998 BACKGROUND: A polymorphism at codon 72 of the human tumour-suppressor gene, p53, results in translation to either arginine or proline. Arginine 114-122 tumor protein p53 Homo sapiens 76-79 9742979-8 1998 INTERPRETATION: In the population studied, individuals homozygous for the arginine variant of codon 72 of the p53 gene were not at increased risk of cervical cancer. Arginine 74-82 tumor protein p53 Homo sapiens 110-113 9652798-1 1998 The prognostic value of the mutation of the p53 tumor suppressor gene in non-small cell lung carcinomas (NSCLC) is controversial and a polymorphism of the p53 gene at codon 72 consisting of two alleles, arginine (Arg) and proline (Pro), has been reported to be associated with the incidence of smoking-related NSCLC. Arginine 203-211 tumor protein p53 Homo sapiens 155-158 9652798-1 1998 The prognostic value of the mutation of the p53 tumor suppressor gene in non-small cell lung carcinomas (NSCLC) is controversial and a polymorphism of the p53 gene at codon 72 consisting of two alleles, arginine (Arg) and proline (Pro), has been reported to be associated with the incidence of smoking-related NSCLC. Arginine 213-216 tumor protein p53 Homo sapiens 155-158 9607760-3 1998 The effect of this polymorphism on the susceptibility of p53 to E6-mediated degradation has been investigated and the arginine form of p53 was found to be significantly more susceptible than the proline form. Arginine 118-126 tumor protein p53 Homo sapiens 57-60 9607760-3 1998 The effect of this polymorphism on the susceptibility of p53 to E6-mediated degradation has been investigated and the arginine form of p53 was found to be significantly more susceptible than the proline form. Arginine 118-126 tumor protein p53 Homo sapiens 135-138 9607760-4 1998 Moreover, allelic analysis of patients with HPV-associated tumours revealed a striking overrepresentation of homozygous arginine-72 p53 compared with the normal population, which indicated that individuals homozygous for arginine 72 are about seven times more susceptible to HPV-associated tumorigenesis than heterozygotes. Arginine 120-128 tumor protein p53 Homo sapiens 132-135 9607760-4 1998 Moreover, allelic analysis of patients with HPV-associated tumours revealed a striking overrepresentation of homozygous arginine-72 p53 compared with the normal population, which indicated that individuals homozygous for arginine 72 are about seven times more susceptible to HPV-associated tumorigenesis than heterozygotes. Arginine 221-229 tumor protein p53 Homo sapiens 132-135 9472095-1 1998 The polymorphism of p53 gene at codon 72 consisting of either arginine (Arg)- or proline (Pro)-encoded allele is suggested to be associated with the susceptibility of tobacco-related lung cancer. Arginine 62-70 tumor protein p53 Homo sapiens 20-23 9546285-10 1998 Only one PCNSL showed a mutation of the TP53 gene, i.e., a missense mutation at codon 248 (CGG to TGG:Arg to Trp). Arginine 102-105 tumor protein p53 Homo sapiens 40-44 9472095-1 1998 The polymorphism of p53 gene at codon 72 consisting of either arginine (Arg)- or proline (Pro)-encoded allele is suggested to be associated with the susceptibility of tobacco-related lung cancer. Arginine 72-75 tumor protein p53 Homo sapiens 20-23 9740272-3 1998 One case harbored a p53 gene mutation in codon 282 in exon 8, CGG (arginine) to TGG (tryptophan), but the mutation was not found in other patient"s tissues with similar histological features. Arginine 67-75 tumor protein p53 Homo sapiens 20-23 9253509-2 1997 Codon 72 of the p53 gene is highly polymorphic with a reported arginine/proline allelotype frequency of 0.65/0.35 for Caucasians and a reversal of this ratio in African-Americans. Arginine 63-71 tumor protein p53 Homo sapiens 16-19 9446323-5 1997 The p53 Arg/Pro polymorphism study revealed the elevated frequency of Arg allele in lung and stomach cancer groups. Arginine 8-11 tumor protein p53 Homo sapiens 4-7 9446323-5 1997 The p53 Arg/Pro polymorphism study revealed the elevated frequency of Arg allele in lung and stomach cancer groups. Arginine 70-73 tumor protein p53 Homo sapiens 4-7 9530523-8 1998 The results of these experiments demonstrate that: (1) there were mutations in p53 exon 5 and 8 in 35% (14 out of 40 samples) of human renal cancer tissues as revealed by PCR-SSCP analysis; (2) DNA sequencing of samples showing frame-shift have hot spot of p53 mutation on exon 8 at codon 244 (GGC-->TGC) and exon 5 at codon 132 [AAG (Lys)-->AGG (Arg)]. Arginine 353-356 tumor protein p53 Homo sapiens 79-82 10069444-5 1998 In one case, p53 codon 282 mutation (CGG-->TGG; arg-->trp) were observed in initial diagnosis. Arginine 51-54 tumor protein p53 Homo sapiens 13-16 9041254-6 1997 Furthermore, a CGC-->CAC transition in the p53 gene of the adenoma resulted in an Arg-->His missense mutation in codon 175. Arginine 85-88 tumor protein p53 Homo sapiens 46-49 9187098-5 1997 Among p53 mutations at various sites, mutation at codon 242 (C TGC --> C CGC; Cys --> Arg) was specifically observed in both skin cancers and actinic keratoses. Arginine 92-95 tumor protein p53 Homo sapiens 6-9 9070661-4 1997 In these cells, wild type for the p53 gene, we have overexpressed the mutant p53(175(Arg>His)) protein leading to a p53 mutant phenotype, as verified by the absence of a G1 arrest after gamma-irradiation. Arginine 85-88 tumor protein p53 Homo sapiens 34-37 9070661-4 1997 In these cells, wild type for the p53 gene, we have overexpressed the mutant p53(175(Arg>His)) protein leading to a p53 mutant phenotype, as verified by the absence of a G1 arrest after gamma-irradiation. Arginine 85-88 tumor protein p53 Homo sapiens 77-80 9070661-4 1997 In these cells, wild type for the p53 gene, we have overexpressed the mutant p53(175(Arg>His)) protein leading to a p53 mutant phenotype, as verified by the absence of a G1 arrest after gamma-irradiation. Arginine 85-88 tumor protein p53 Homo sapiens 77-80 9053847-6 1997 Moreover, detection of ThaI polymorphism of codon 72 showed that MCF-7 cells predominantly express wild-type p53 with proline, while mutated p53 in MCF-7/Adr cells contains an arginine residue at codon 72. Arginine 176-184 tumor protein p53 Homo sapiens 141-144 8824527-12 1996 At this passage, mutation of the p53 gene was detected at codon 273 of exon 8, with G to T conversion (Arg to Leu). Arginine 103-106 tumor protein p53 Homo sapiens 33-36 9020384-5 1997 A novel germline p53 mutation was identified at codon 133 (ATG-->AGG) in exon 5, resulting in the substitution of arginine for methionine, in all four cancer-affected individuals and in three apparently healthy individuals. Arginine 114-122 tumor protein p53 Homo sapiens 17-20 8910896-0 1996 A nonsense mutation (Arg-196-Term) in exon 6 of the human TP53 gene identified in small cell lung carcinoma. Arginine 21-24 tumor protein p53 Homo sapiens 58-62 8810317-1 1996 We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 --> Ala, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). Arginine 135-138 tumor protein p53 Homo sapiens 101-104 8810317-1 1996 We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 --> Ala, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). Arginine 155-158 tumor protein p53 Homo sapiens 101-104 8810317-1 1996 We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 --> Ala, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). Arginine 155-158 tumor protein p53 Homo sapiens 101-104 8810317-1 1996 We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 --> Ala, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). Arginine 155-158 tumor protein p53 Homo sapiens 101-104 8649776-2 1996 By using recombination PCR in vitro mutagenesis, we introduced point mutations into the codon 273 of wild-type (wt) p53 (pC53-SN3) from Arg to His (pC53-273H [273H]), Asp (273D), Pro (273P), Lys (273K), Leu (273L) or Thr (273T), and compared their biological and biochemical activities with wt p53 and cancer-derived 175H, 248W and 273H/309S. Arginine 136-139 tumor protein p53 Homo sapiens 116-119 7627952-4 1995 Here we show that mAb PAb421 when microinjected into human SW480 colorectal carcinoma cells restores the transcription activation function to the resident mutant p53 (arg to his 273, pro to ser 309). Arginine 167-170 tumor protein p53 Homo sapiens 162-165 9162298-3 1996 A germline polymorphism of p53 with a single-base change at codon 72 that causes an amino acid replacement of arginine (Arg; CGC) by proline (PRO; CCC) has also been reported to be associated with cancer susceptibility in a Japanese population. Arginine 110-118 tumor protein p53 Homo sapiens 27-30 9162298-3 1996 A germline polymorphism of p53 with a single-base change at codon 72 that causes an amino acid replacement of arginine (Arg; CGC) by proline (PRO; CCC) has also been reported to be associated with cancer susceptibility in a Japanese population. Arginine 120-123 tumor protein p53 Homo sapiens 27-30 9162298-8 1996 The study of the p53 polymorphism in the healthy population showed allele frequencies of 0.79 (Arg) and 0.21 (Pro). Arginine 95-98 tumor protein p53 Homo sapiens 17-20 8819013-3 1996 These mutations result in an Arg-->Trp amino acid substitution at residue 249 and an Ile-->Phe amino acid substitution at residue 255 in a highly conserved region in the DNA-binding core domain of the p53 protein. Arginine 29-32 tumor protein p53 Homo sapiens 207-210 8625447-1 1996 The p53 tumor suppressor gene is often mutated in various human cancers and a common polymorphism is known at codon 72 of exon 4, with two alleles encoding either arginine (CGC) or proline (CCC). Arginine 163-171 tumor protein p53 Homo sapiens 4-7 7594817-2 1995 A-7 was found to contain a mutant p53 gene in which the arginine codon at position 175 was substituted by a histidine codon. Arginine 56-64 tumor protein p53 Homo sapiens 34-37 7559095-2 1995 The wild-type p53 gene has a polymorphism at codon 72 that presents the arginine (CGC) or proline (CCC) genotype, which recently has been reported to be associated with genetically determined susceptibility to smoking-related lung cancers. Arginine 72-80 tumor protein p53 Homo sapiens 14-17 7605578-3 1995 This p53 mutation resulted in the same change, an Arg-->Ser substitution, as in the human p53 gene at position 249. Arginine 50-53 tumor protein p53 Homo sapiens 93-96 8207805-9 1994 In the ACH-2 cell line, which is now demonstrated to contain an endogenous mutant form of p53 (amino acid 248, Arg to Gln), additional mutant p53 proteins did not alter HIV-1 replication. Arginine 111-114 tumor protein p53 Homo sapiens 90-93 7605578-1 1995 A mutation in the tumor suppressor p53 gene resulting in an Arg-->Ser substitution in position 249 is found frequently in human hepatocellular carcinomas associated with hepatitis B infection and with aflatoxin exposure. Arginine 60-63 tumor protein p53 Homo sapiens 35-38 7605578-3 1995 This p53 mutation resulted in the same change, an Arg-->Ser substitution, as in the human p53 gene at position 249. Arginine 50-53 tumor protein p53 Homo sapiens 5-8 7622024-1 1995 The effect of the expression of the exogenous human mutant p53 (Arg-->His in codon 273) on the amplification rate of the gene dhfr in permissive Rat-1 and LIM1215 cells was studied. Arginine 64-67 tumor protein p53 Homo sapiens 59-62 21556589-4 1995 Sequencing of p53 cDNA revealed a mutation CGC(Arg)-->CAC(His) at codon 175 of the gene encoding for an abundant nuclear protein. Arginine 47-50 tumor protein p53 Homo sapiens 14-17 8084608-0 1994 A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Arginine 50-53 tumor protein p53 Homo sapiens 114-117 8174105-4 1994 We report here that p53-deficient hepatoma cells (Hep3B) transfected with mutant p53-249ser (codon 249 Arg-->Ser) acquire a new phenotype with an increased in vitro survival and mitotic activity. Arginine 103-106 tumor protein p53 Homo sapiens 20-23 8187062-2 1994 The cells carry only a mutated form of the p53 gene, the G-->A mutation at codon 273 which results in an arginine to histidine substitution (mp53). Arginine 108-116 tumor protein p53 Homo sapiens 43-46 8174105-4 1994 We report here that p53-deficient hepatoma cells (Hep3B) transfected with mutant p53-249ser (codon 249 Arg-->Ser) acquire a new phenotype with an increased in vitro survival and mitotic activity. Arginine 103-106 tumor protein p53 Homo sapiens 81-84 8382111-3 1993 All of the nine mutations in the p53 gene detected in HCC from Qi-Dong were clustered at the third base of codon 249, i.e. G:C to T:A, leading to an arginine to serine change. Arginine 149-157 tumor protein p53 Homo sapiens 33-36 8221663-2 1993 Mutations of the p53 gene were found in six of seven ES cell lines: a missense mutation of TGC (Cys)-->TAC (Try) at codon 141 in one, a missense mutation of CGT (Arg)-->TGT (Cys) at codon 273 in one, a missense mutation of TGC (Cys)-->TTC (Phe) at codon 176 in three, and one base deletion of CGC-->CG at codon 283 in one. Arginine 165-168 tumor protein p53 Homo sapiens 17-20 21573446-8 1993 The point mutation of p53 gene was found at codon 181 contained C to T transversions (Amino acid switch: Arg --> Cys) in ES-4 esophageal cancer. Arginine 105-108 tumor protein p53 Homo sapiens 22-25 8361764-4 1993 A third mutant 175 (Arg-->His) bound to the p53CON but did not activate transcription. Arginine 20-23 tumor protein p53 Homo sapiens 47-50 8389669-2 1993 The wild-type of p53 protein exists as at least two forms of variants among human populations, ascribed to amino acid replacement at codon 72 of Arg by Pro. Arginine 145-148 tumor protein p53 Homo sapiens 17-20 8389669-3 1993 In this study, we show that this germ line Arg-Pro polymorphism at codon 72 of the p53 gene is associated with genetically determined susceptibility to smoking-induced lung cancer; a susceptible genotype Pro/Pro has a 1.7-fold higher risk of this cancer compared with other genotypes. Arginine 43-46 tumor protein p53 Homo sapiens 83-86 8389256-6 1993 The p53 point mutations in the three HCC cell lines from Japan resulted in the amino acid changes of cysteine for tyrosine in cell line HuH 7 at codon 220 (A:T-->G:C), alanine for glycine in cell line HLF at codon 244 (G:C-->C:G), and serine for arginine in cell line HLE at codon 249 (G:C-->C:G). Arginine 252-260 tumor protein p53 Homo sapiens 4-7 7908608-10 1994 The p53 arginine allele was found to be more common in Caucasians (0.71) than African-Americans (0.50). Arginine 8-16 tumor protein p53 Homo sapiens 4-7 8110876-4 1994 p53 mutations were restricted to one case of myeloid blast crisis, showing a CGC-->TGC (Arg-->Cys) mutation at codon 283; two additional cases displayed LOH at 17p13 in the absence of p53 mutations. Arginine 91-94 tumor protein p53 Homo sapiens 0-3 8476653-1 1993 p53 gene which is known as a tumor suppressor gene locates in chromosome 17p and has a polymorphism at codon 72 (Arginine CGC-->Proline CCC). Arginine 113-121 tumor protein p53 Homo sapiens 0-3 8380785-5 1993 Sequencing analysis revealed a single-base mutation at codon 273 from CGT to CAT(Arg-->His) and immunocytochemical studies provided evidence that the p53 protein was overexpressed in this cell line. Arginine 81-84 tumor protein p53 Homo sapiens 153-156 1644930-6 1992 The other nonhereditary p53 mutation was a transition at codon 248 (CGG to CAG, arginine to glutamine) found in the lymphoblasts of a patient with a preleukemic syndrome and acute lymphoblastic leukemia (ALL) whose brother is a long-term survivor of ALL. Arginine 80-88 tumor protein p53 Homo sapiens 24-27 1486864-9 1992 The p53 gene is a tumor-suppressor gene that can encode either a proline or an arginine in the 72nd residue. Arginine 79-87 tumor protein p53 Homo sapiens 4-7 1559227-6 1992 The p53 mutations in cell lines included a codon 248 C to T transition (arginine to tryptophan) in RD and a codon 280 A to T transversion (arginine to serine) in RH30. Arginine 72-80 tumor protein p53 Homo sapiens 4-7 1559227-6 1992 The p53 mutations in cell lines included a codon 248 C to T transition (arginine to tryptophan) in RD and a codon 280 A to T transversion (arginine to serine) in RH30. Arginine 139-147 tumor protein p53 Homo sapiens 4-7 1737852-7 1992 The other two nonhereditary p53 mutations included a T to G transversion at codon 270 (phenylalanine to cysteine) and a G to C transversion at codon 248 (arginine to proline). Arginine 154-162 tumor protein p53 Homo sapiens 28-31 1549103-4 1992 A new dominant mutation of p53, resulting in the change of a cysteine to an arginine at amino acid residue 141, was identified. Arginine 76-84 tumor protein p53 Homo sapiens 27-30 34817806-5 2022 Next to TP53 and PTEN, FBXW7 was reported with the highest percentage of arginine substitution among mutations related to cancer. Arginine 73-81 tumor protein p53 Homo sapiens 8-12 1999338-1 1991 We describe a simple method for characterizing a frequent polymorphism (that substitutes an arginine for a proline) in the coding sequence of the Tp53 gene in patients with colonic cancer and in a control population. Arginine 92-100 tumor protein p53 Homo sapiens 146-150 34783301-6 2021 The development of AIC was significantly related to Arg/Arg of p53 protein gene (OR = 2.972; p = 0.001), T/T of NOS3 gene (OR = 3.059, p = 0.018), T/T of NADPH oxidase gene (OR = 2.753, p = 0.008), and C/C of GPX1 (OR = 2.345; p = 0.007). Arginine 52-55 tumor protein p53 Homo sapiens 63-66 34783301-6 2021 The development of AIC was significantly related to Arg/Arg of p53 protein gene (OR = 2.972; p = 0.001), T/T of NOS3 gene (OR = 3.059, p = 0.018), T/T of NADPH oxidase gene (OR = 2.753, p = 0.008), and C/C of GPX1 (OR = 2.345; p = 0.007). Arginine 56-59 tumor protein p53 Homo sapiens 63-66 34393505-5 2021 Results: The distribution of TP53 Pro72Arg differed in T2DM patients from the controls, with a moderately increased proportion of TP53 Arg72 variant carriers (Pro/Arg and Arg/Arg genotypes) (88.3% vs 81.2%, p=0.022; OR=1.089, 95% CI=1.018-1.164). Arginine 163-166 tumor protein p53 Homo sapiens 29-33 34393505-5 2021 Results: The distribution of TP53 Pro72Arg differed in T2DM patients from the controls, with a moderately increased proportion of TP53 Arg72 variant carriers (Pro/Arg and Arg/Arg genotypes) (88.3% vs 81.2%, p=0.022; OR=1.089, 95% CI=1.018-1.164). Arginine 163-166 tumor protein p53 Homo sapiens 130-134 34393505-5 2021 Results: The distribution of TP53 Pro72Arg differed in T2DM patients from the controls, with a moderately increased proportion of TP53 Arg72 variant carriers (Pro/Arg and Arg/Arg genotypes) (88.3% vs 81.2%, p=0.022; OR=1.089, 95% CI=1.018-1.164). Arginine 171-174 tumor protein p53 Homo sapiens 29-33 34393505-5 2021 Results: The distribution of TP53 Pro72Arg differed in T2DM patients from the controls, with a moderately increased proportion of TP53 Arg72 variant carriers (Pro/Arg and Arg/Arg genotypes) (88.3% vs 81.2%, p=0.022; OR=1.089, 95% CI=1.018-1.164). Arginine 171-174 tumor protein p53 Homo sapiens 130-134 34393505-5 2021 Results: The distribution of TP53 Pro72Arg differed in T2DM patients from the controls, with a moderately increased proportion of TP53 Arg72 variant carriers (Pro/Arg and Arg/Arg genotypes) (88.3% vs 81.2%, p=0.022; OR=1.089, 95% CI=1.018-1.164). Arginine 175-178 tumor protein p53 Homo sapiens 29-33 34393505-5 2021 Results: The distribution of TP53 Pro72Arg differed in T2DM patients from the controls, with a moderately increased proportion of TP53 Arg72 variant carriers (Pro/Arg and Arg/Arg genotypes) (88.3% vs 81.2%, p=0.022; OR=1.089, 95% CI=1.018-1.164). Arginine 175-178 tumor protein p53 Homo sapiens 130-134 34393505-8 2021 Conclusion: There was a significant association of the TP53 Pro72Arg polymorphism with susceptibility to T2DM, and the homozygous Arg/Arg genotype of this gene locus might be a protective factor for diabetic complications. Arginine 130-133 tumor protein p53 Homo sapiens 55-59 34393505-8 2021 Conclusion: There was a significant association of the TP53 Pro72Arg polymorphism with susceptibility to T2DM, and the homozygous Arg/Arg genotype of this gene locus might be a protective factor for diabetic complications. Arginine 134-137 tumor protein p53 Homo sapiens 55-59 35072516-6 2022 The role of a gene variant in Tp53 that modifies proline to arginine was examined using nasal brushings from study participants in the Lovelace Smokers Cohort, primary human AECs, and mice with a modified Tp53 gene. Arginine 60-68 tumor protein p53 Homo sapiens 30-34 35072516-8 2022 Study participants who were homozygous for p53 arginine compared with the proline variant showed higher mucin 5AC (MUC5AC) mRNA levels in nasal brushings if they reported WS exposure. Arginine 47-55 tumor protein p53 Homo sapiens 43-46